var title_f26_7_26736="Sling and swathe splint";
var content_f26_7_26736=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F78370&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F78370&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Sling and swathe splint",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 276px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A: A powdered pad is placed in the axilla prior to application of the swathe to prevent maceration. B: The swathe component is essential to minimize motion of the shoulder region.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_7_26736=[""].join("\n");
var outline_f26_7_26736=null;
var title_f26_7_26737="Combined proximal forearm fracture";
var content_f26_7_26737=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F73062&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F73062&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 561px\">",
"   <div class=\"ttl\">",
"    Olecranon fracture associated with a displaced radial neck fracture",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 541px; height: 382px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAF+Ah0DASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5UooooAKK9V/4Z8+J/wD0LP8A5P2v/wAcrA8a/C3xj4I0qLUvE+j/AGGylmFukn2qGXMhVmAwjk9FbnGOKAOJooooAKKKKACiiigAooooAKKKKACiiigAooooAKKK3/C+kx6jK3noWU8KMkcjrQBgUV7t4e+HWg3ph86xZgRlv30g/ka7S1+EXg58B9JY+/2qb/4qgD5Vor67Hwa8Dn/mDtx/09zf/F0x/g54IX/mDN/4Fzf/ABdAHyPRX2v4c+BPgG7tGmutEZwWwo+2TjgfR6v3PwG+HCHC6A4/7frj/wCLoA+GaK+4774FfDez0yS4fw+xZVyP9OuOvb/lpXJD4PeCMc6O3/gXN/8AF0AfJNFfWc3wh8EIm7+x2/8AAub/AOLrLuPhd4MRGI0lhgf8/M3/AMVQB8wUV7vqngbwtb7mj03aoztX7RLz7n5uleU+LbbT7O5WGwg8okkn52bjt1NAHPUUUUAFFd/8KdC0vWm1H+1dOm1GRZLaC3ghl2M0k0vlqAd6jlmXliAK9/0f4OeH4rFF1T4Va/Pc87nj1W3A68f8vo/lQB8g0V9m6d8Jfh9c67DpOofD/V9JuJ7aW6ha71EOjpG0auAYrlyCDMnUDv6Vvf8ACgvhx38Pt/4HXH/xygD4Uor7kuvgN8OkiZl0Bgf+v24/+Lr5p8T+DtMi1nU4NPgkggS4dIcOzbVBwOpOelAHmNFbWpaDcWRJxuX1HQ/4VkMpRirqQfQ0AMoqQbeOKQgAkY5oAZRTgM0oA70AMop2KMfnQA2in4HrRgbenP1oAZRTwBgcUgA55oAbRTuKMUANopaKAEopaKAEop4AJowOOMe9ADKKftpSAOoIoAjop4AOaUgdhQBHRTmGMYptABRRRQAUUUUAfZX7RkOoePPF+n+BtEtr28Gn2M2q3Udo0akSlSlvuMjquAxyeSdr8CuU+N/ilvGH7MnhHVJ2Y3w1WK3uw33hPHBOr59yRu/4FWB/w1X44/6BXhv/AMB5/wD49XH/ABQ+NfiP4j6Bb6RrllpEFtBdLdq1nFIrl1R1AJaRhjDnt6UAeX0UUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFepfD6wxawEjDA5J9M815zpNt9qv4o8ZGcn6CvbvCFmYhswATQB6L4ZtVSMORjcOldpZRgDdWBo8QSCNQOMCumgXantQBNwF9zUTgtIFXkk4FPfPJFWtBtzc6rFnlU+c0AddaRC10+GHoQAKjz510gPTvT76TaT7DApulruLufpQBk+NbrbFBaqfvne30HT9a5UdPatHxHcfadXuD1WP92v4f/XzWcDjqP1oAp6hIQuK5nWLnyoG9fT1rY1Gb525wBXEa5ecuwPzHhBjoPWgDmvE9+sVvI8hB9/8APavDNTumvb6adifnbj6dq7X4g6oSPs6N975fw71wFABRRRQB61+z+P8AibOfTVtH/wDS6OvRPjHbWFx8S/iZ9tvdFtblNOspLVb2APczSLGp2Wr7wUkOAMhX6jiuM/Zs0S51qfXBYXMdtd2s1hdwvLEZU3xT+YAyhlJBKAcMOtfWip45I513w2P+4HP/APJlAGZps8134j8Bz3VtPa3Evhq8eSC4bdJGxfTyVYnqwPBziuzI689K56x0fXJPFFprGvatpt39ls7i0ihstOe2/wBa8LMzM08mceQAAAOprpCAaAKGpsI7OVz0VSf0r5budOeaV5tpPmOznj1Oa+nPE7+VoN846iJh+leLJZbVUbQQKAPObvR0lBDKDnggjrXE+I/BpfMln+7f+4R8v59q91udMWTJRQG9xWNfacRlXQZx3NAHzNeWk9nMYrmNo3HY9/pUBr3TxB4chu4iksKsp/T6V5Zr/he505mkgDSwDr/eX/GgDnhjvSj3plLmgBwxjk0DrTRSigBxGc4pGxnjpSHI60UAHbrRRRQAUv1pKKACiiigAoxxmkooAcVOOhpMUZ4PNFAD+g/DpTaSigBeRRnn1+tJRmgAam0ppKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiipIY2mlSNPvMcCgDsPAemecrXOMndj8BXt/h3Tlk2Oi/vExlfX3rhfAdgLZIwFwhAB/CvXNDtdjCSMAE9qAN3TYud2Dj0Nba9ABVayTJyvGOo96vDI69aAIJDx14rp/CdsI7aS5Ycv0PsK53YZZViQfMxAHFdzAi21kiAcKAKAM7UH3SBR3OTVyJxa6dJKeNqlqov8AvZhhRzTvE8v2fRGQdXAWgDid5kZnOcsSTUVzJthZgOccVYjGF6VQ1J+x4A5oA53VZdqHPU8Y9a878U36wRyFW+Y9zXXa9d4du/YV4z491QqkgVvmb5VH1oA4bWrs3moSyZyoO1fpVCiigAooooA+g/2QS39va4q/xLb5/N6+wB0FfIv7G0e/xDr7f3YoT+r19ddqACiiigDnPG0uzQZ07yFU/WvOliAHSvSfF1kb2yjiRtp37vXoDXCXVlcWp/eoSv8AeHIoAotAGBOKp3VosgIZcjscVqoMemKVkBUdMmgDjL6w29Rketc3q2lLLGQFPPtXpdxbhgeBisPUtPIBMS7h6UAeB+KPCILNNaARydxjCt/ga4OeGS3kMcyMjjqCK+kdQsFlBBADY5rgvEvhyO6UhkAI6MOooA8mpRV/VdKuNNkIlXdHnhx0P+FZ9ADqKSloAMcUdqKKACiiigApKWkoABRRRQAopKWigApKWigAoxRRQAhpKU0lABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABW94SsjcXwkK5C8CsNFLMFXqTgV6h4I0ry0jA5z396APQPC9kBEgIwvevRtGhZUXA61z+kWXlwIoH1Ndfp8J2LzgCgDSt0IXPep2fqc8dKao2jNIQWIRRuZuAKANfw9befeGYj5V4H1rotQcKoXnioNGthaWa9MgdfeoL2UtLjPFADrRd0w574rN8ZzbmhhB4zkitWyGCoHY81zPiWYvqWOuBQBnEhUrnNXuf3ch/vVr3k+2Nua43XLwLwpxgZOaAOS8UXvlRtzg9zmvC/Et8bzUW+bKpxn3716J471Ty4ZDu5AOPr2ryViWJJOSeSaAEooooAKKKKAPoz9jUH+2vEjDtDB/N6+tlORmvkv9jX/AJC3iY/9Mrf+clfWUfK0APoopCQOTQBha9My3USqSMLmq8M0cy7ZlGcdan1Bo5tQcbwGUAEGq7QhWHG3+VAFK/0CKYGS2Oxj6dD+Fc7d2k1oxE0ePRh0Ndj5jxHCkj69KeXhuFKTqvIx6igDgjhhVeaMH8K6nUvD45ksiB/sZ4P0rnZY3icpIhVh1BoAw7+wScE42v6iuZ1LTChJkUlf7wrvGUMaqXECupBwaAPINY0WOZHBRSp4IxkGvM9e8MS2rNJaKzIOsZ6j6etfReoaSDkxfKT1HauS1TSc7ldB680AfPZBBIIwR1FFej+JfCyTlpYxsl/vL3+vrXA31jPYy+XcIVPY9j9DQBWpaSigBaKTNLQAlFFFABRRRQAUUUUAFLSZooAWikpaAENJSmkoAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAoopQMnA60AbHhmy+1XysRlVP617n4M00BVcqeBivPfA2lEBFK5Y9eK9s0W3ENuiIuDigDYtY8OqqRgH866a1T92DisnTrYR7S2MjmtqDL4VASewAoAlyO54FbWhaeS/2mXgfw57e9Q6dpmG8274A5Cd62Fn8xlRB8o7CgC5LKuwKnA71lyEvJyPxFXyU2fdz6k1WQLkkKc9iDQBLEdikA544rkNbb/TiQe1dRLIFDbScgc1yeunbMG9jQBzuo3CgupzkVwHiC7wkjg5H8q6XWLgrHK3evM/FN95cT5OOKAPNfG18Z7wQg8D5j/SuYqzqE5ubyWU9zx9KrUAFFFFABRRRQB9G/sbf8hXxN/1yt/5yV9Zw/dr5M/Y2H/E28Tf9crf+clfWcQ+WgB9RzfdP0qSq94wjhdz0AzQB5Lf6rdQ69eywSZTzmGw9MDj+ldJoviOK4AjuD5b9NrdDXDJKJZHkzy7FvzNTKuQAO1AHqBiSVd0JyP7p/pVSWJg3y5z3U9a5LS9XubMgZMkYPKk9PpXX2GqW2oJgnD+h4IoAjhneJuDg9wakuba11GPbMoD9j0/I1NPa5GR8w9R2qqymP1IoA5zVNFuLIllBki9QOR9ayTkjpnivQYLgAbZPmQ/mKz9V8Pw3QM1kQjnkgdD9aAOFkUNwQKz7yySQEFQRit28s5rWQxzxlW9ex+lU2U45FAHDalpJ52LlfTFcVruhR3ETI8YIxyDXs0sKuDxWNqOkxzgkqN3qKAPmrWvDtxZOzQq0kf8Adx8w/wAawjX0JrGhMMjYWHYivPPEPhVJS0kQ8uXuQOD9RQB57S5qe8s57OXy7hCp7HsfpVegBaSiigAooooAKWkooAKWkpaACikooAU0lFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFanh6zN3foCPlXk/WsuvRvh1pZLROVyXIY/0oA9F8I6WsKKWXbtxk16LpsGEDEe4GKx9HswsaLgbQeldTZYE8W7hdwP60Aa1rpzBQZCBjqP6Vt2EWxAFAGeDgcj2pFGGbB6mrVqRvVTjGe/FAE5XgjPXFCMke7J9iaiu3dSQeGXjHpVFpnBJJJ470AawuAWAAKjr9KmEg5IIPasaKY5GD8xGOKtW7fu2JPTvnvQASvtdieQQcVy3iZsW+8f3sfnXQXcp8kKWGfX0Nc94hG6yYE5IGfyoA858QSlYmA557V4347vSkUoB5PA+pr1TxLLtBycEA14b46ufMuUQeuaAOVooooAKKKKACiiigD6J/Y6ONY8Rj1ig/m9fWsBytfIP7I7Oms6+yDOI4Mj15evre0kDxhh0oAuVjeLrn7J4fv5s4KQsf0rYDVxPxavRa+D7sZx5pWIfiwoA8ytZB5a49K0YXB4Nc7ZT7lGDnitu0fIAoA04+BzUgYqwZSQQeo7VAmSeTx/Kp1X3oA3tK12SIqtySy9Nw6/jXRxvDdxh4WByOmeDXCqm0mp7e4ltZA8TFfUdjQB1klvtY7ePUGmxO8TfK2Ki07WIrsCO4ASTt/wDWq7Pb8blOR6igBJUgvY/LukXnuelc3qvhySElrQ71/uH+hrc5Q8jj1qyshAAB3Ljp2oA83miZJCroVYdjxUTx5xx1Feg39nbXYIdBn9R+Nc1faJJGSYD5g9D1oA5a5tFZeRmud1XQ1mBKgA127xYO1lKsOxGKrz24NAHiviHw2jxlJogVP5V5nrvh+fT2aSMF4f1X/Gvp2/09ZEbcua4vXNADKdi/8BoA+eaK7LxJ4WeNnmtFwwPzR9j9PSuPZSrFWBDDgg9qAG0UUUAFFFFABRRRQAUUUUALSUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQBPZxGe6ijxkFufpXungWy2RREJyBn2rx7wvb+bfBvTive/CMQECjoTwKAO60yHEeSM1poOD9KqWa7YVUegq6D8vHFAHQ6bciaM7hl1AzVwbgm/wDhPfNY2iMP3+f4gK2ZN3lKBwgPBP8AKgBL24eeBZU5ePCyj+TVXJyAA/bsKvWkaxyFjsYNw4PcelWl0205KylV9CM4oAx3haKRQxPXPFXbcbkOM4HartylpBHuYyTY57AVm3N6D91Nq7u3egCrclgdzodpPc9awtUYGKXHQJj61q3bCWJmBwwI6VgatIFiYHlnyOPTFAHlHjGbYzc9BivDPEkxm1STn7oxivYfHcu24kGOnevEdQfzL2dvVjQBXooooAKKKKACiiigD6A/ZHQtq3iEqekcH83r6vtWKKCcZ9q+Vf2QRnVfEn/XKD+b19URDigC6JlI4PNeQ/HzVli0uwtM4MtznGeoVSf8K9HvpDEpKnFfMv7QHiHz/FGlWJOHiieUjPXJAH/oJoAuaVccJ6GuqsZdwFeXeHdWDFUmOM9+xr0DT7gYUg0AdVbtkYNWlUYzWTbzbgMNWlbS7hgnmgC3G3AyORUoVWGDnmoO+RUitjFACOjJ7itLTdcmtCqTEyRdPcVUyCMHv0qN4wO9AHaQtBfReZbOpJ7VA4a3LZBUe1chay3FpL5lu5Vu/ofrXV6TrUGoL5FwBHPjGD3+lAFxCsysGUHvuHGKq3cLxjPOMdcdakuoHtstEWGe4NJb6iANl0rMh4ZmOcUAY94kcygSxB+wxwRWLdac6gtbMZR3Q/e/+vXT6rAbaQbfmjcZRu1ZEjgsCf060AczIgJwykEdcjkVRurJZQcce47V1l3At2gZsCX+GQDr7GsSRSjFXGGHWgDhdc0QSKzAZPrivKPFvhfzC0sSbJx37N9a+hriEMcEde9c3rWjx3CN8ozQB8tyxvFI0cilXU4IPamV6T428MFt0sS4mXof73sa84ZSrFWBBBwQe1ADaKKKACiiigApaSigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiinxrvdV9TQB2fgy0wAxHJ5zXtfhqHy41BHOBXlPhOFgIgV6kE17JoyhVUcYPfvigDp7Y4UZ6VZz74qlA2Rip3YEe9AGzp1wltbtIWBZzgLWxDNFKEbht2MAGuORmJAUHmtPToHbe6feUDFAHUNII2CgAZOMiragg8kbu2DXMWc5jn/eHkcit23ullXrkfyNAEl0HCndg9xWUY1IIbAIOcnqfwq1qbEcH7zf5zVGKRojjh1HY0AR3iqkTCPnLZxXPXg3xSzkcDKr9K2tQcSpIIwQ+MkY7+lc/rVwqQC2jIyOXK+vpQB4h8Q5fLnnJ7ZrxpiWJJ6nmvUvidOCZz67hXllABRRRQAUUUUAFFFFAH0P+x//AMhTxJ/1yg/nJX1Oo+Wvlr9jz/kK+Jf+uUH85K+p+i0AY2tNthY57V8V/HW7M/xEuQGOYIo0HPTjd/7NX2b4hfbA5r4U+I939t8da1MDkfaGQf8AAfl/pQBL4f1sb0iuG2v0B7N/9evTtB1vy9qSNlex9K8IxXQaH4gktWWK5YmPoH7j60AfR+n3iyKGVs/jW5azA4wea8f8Pa7sCFJA6Hnrx+Feg6XqsdxGCjfNQB2cE27APWpyfl9vrWHb3J6549a1La43DB6UAX4G3DGc1IBnIPaqy5DcHg1bXoDxmgCN0wOAarSRAkcYPYitALyKjkjzylAF7SfELQgW2pgywHgSDqv1rWu7IFBcW8gkhYZDKePxrkJotyE4q5oOqy6a+w5a3b7yHt9KAOogYSaUYpVyEbHPbNYt7psifPENye/NdHFPaSRkjASUDB6iojH5MgC42nuDwaAObtojIWAG0YIK1l6nAC27HzLwcdx612zWStM0iKQwHUdzWHdwqrusmGAFAHKTR7eGHNPm0hbiNTBNjcMgMMg1pW9shnYEbueCeeKsSWnl/wDHrtKnnaDjmgDzHxPojgmO4j2sRwc8H8a8J8d6E9lcNcomFzhx/I19VeIJY7myWGVXFyj5AZcY9a8u8Z6QlzaSblB3Agj2oA+dqKs6jatZXs1u/VGwD6jtVagAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooqxY20l7ewW0QJeVwg/GgBFt2+zGdhiPOF5A3H29an0m2ae4Bx8q/zr0fxPoi6VpVtbxvFsMW4DZnHbqe+Qc1naLoUsWmQsYj+8+ckdMH/IoA3vCdqyushU4A9K9P0kYRecgDrXL+GdOMMWfU4yRz+ldnZQ45XnA9aAL0Dd91TFic/zqFFIHOQfpThnqRQBraLtkEgG3evOD3FdBp7sobdEqdsgVx+nzeRdo+eA2D9DXZpiIZGSrHOPagClfoCRIvBU847iooJi8qbeOM46VM0isWUggcc0um2RudSAx+7HLE/3R1oAS/vnFyryg+W33PUD1/GhLpHGVdfzpNVtmuDPcpk4JO30Uen0rGzgZoAsajd+XGyQN8z/AHmB6CuS1mcRRM2cHHWtycgZNcb4ruDHauR6GgDxP4iXQeUIDnJrh63fFtz5+pkZyFrCoAKKKKACiiigAooooA+iv2O/+Qn4m/65W/8AOSvqVuFFfLn7HH/IU8Tf9crf+clfUT8LQBy/iuUJZyseAAfwr4D1Of7VqV3cE582V5PzJNfcXxVvBZeE9VuN2PLtpGz/AMBNfClAC5pKSigDR0rVJ9PkGwlo+6E/yr0bw34kSYK8UmGHVc4I+teU1JBNJbyrJC5Rx0IoA+mNE1xJ9quw3foa6u0uBwQ2QfSvnHw34rCssd2fLk6Bux/wr1XQPEKlVDvkHo1AHqVrNvXBIrRiPykda5PT71XXcrflXQWdyCBz14oA0omyCD+FKV9KgQjduH1qwGyOlAEewHIIqpPEVPFXhSyJuUigBNKujEGhc/IRlc9j3rfsJiYGVecONo64rmCvluG7DritXS70QkDqnc56UAdEJNpw8nzH05xWHqg84l0XC/wn+9Wt5aTLuDfKRyR/Ks/WJEVOWCquOPSgDDslAuHOOFAqtcM63Bxkd8CrVtIN0khOM9PekkQSkbSNwGDxzQAlxD/aGnyowzLtypPXNef6vbh7dxj867/TpCkpVzyRxXK69AI7q4TtuJH0NAHzV8SNNNvercBcDOxv6VxVez/EjT/OspgoycEj6ivGKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACu0+EenDUvGlsrIWWJS+MZ54H9TXF17J+zpYB9Tvr5wSigR9PTk/04oA1fikyy628KKuVCxZHU9uo4PXvV2zsbcwRQhQMAKCMf+y49KxNWlOo+MN53nMzS9ycDp6H0rqbJWeeMMCR1+bJ9j1H1oA3tMsBFGmMA+/4f/Xrcjt2CfKAf8/8A1qr2YIUKBx6f5+taqAHaM8e9AEawHYAc/jUEkZXOe9ai/d6VTuxuPH5mgCpbpvZs/dHJrt7RhNpFtMerJj8q4wt5Y2jgdfrXX6YP+JBbA/3c0ARWtv57TOQQFUY/OtqxIh0+eVsBiBEOO3U1HYxiKwZm4MrAj6Cn37GPTEhjADO355NAFYHyZYnPKSH6j/OOK5vWbb7Hc/uzmF/mjPt6VsSX0X2hrYlSUXH/AALvis7UbuOe2eJscfMvqG74+tAGDeOGQc9etec+O7kJby5OO1d7fsFU4PNeT/EKUmI7Tjk5BoA8a1OTzb6Vs55xVWnyndIx9STTKACiiigAooooAKKKKAPo39jf/kJ+J/8Arlb/AM5K+oZfu18vfsbf8hPxP/1yt/5yV9QXH+rNAHjX7RF59l+HupkHmQLF/wB9MB/WvjevqX9qa98rwjbW4bm4u1GPYAn+gr5aoAKKKKAClFJRQAtbeheIbnTXVXLSwD+HPI+n+FYgpaAPdfCfiiOZFeGUMh6+o+temaVqSTp1/CvkfTr+40+4E1s+1u47MPQivYfBHilb2FPn2t90qTyh9PpQB7xaznIB5FaUZyuRXIaJfGaIBj869Qe4rpbSUMvBoAvLz2qQc5qFTzUgP0oAjlQEcVVxjIxg9jV9+nGKqSjBzigCSK4n2hIWccdmPFSm0klQmVixHJJParei2u85YAufWtS4gfATHydCBQBzbhIxgKwHTNOSMBAQe+OtaN1bBIyec54/GqDuDCEOMg0AQ3MJaQSISGXmua1yTzLjJ+9tANdTEwKhT95ciuU8QjZqUgAOCAw/GgDzrxjGr2snHY18+3ieVdzJjG1yP1r6M8UpugfAHQ5OK+ftfTZq9yAMDdn9KAM6iiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACvoL4PRjTfh7e3bEBpEbsOc9M/wCB/Cvn6vpXT4G0r4XQxD5WZVXoc/T/ADxQByuiRC4v7m44IXCDOPqev4V2Wix7rtz2XAJA7/h+Nc74UjZLHf8AN87MxPzdOn9BXW6CokBb+JyWPegDorVSP8/59a0EHzDA/L/61VbZSMZHOavLkYyPw/8A1+9AD1Pyn9KqTMDk9O1WW4XAyRmqNwRuAx70AMnzsB49K7rTYPMsLWHoCBuPoAK4QjcygHOSBXpWnL5dkCeygZoAbIyyTiNRhF4AHYUzUXWJHuZCCkCZA9T2p1qPMm3lSBms3xjN5dvDbLwZDvf6DoKAOTlZnJZmyzEkn3qFunzGpynGeaqXT7EY80AZOs3Jjicg4AHvXifjq/yLj1z1r1LxLeCK2kOSeOw/wrwjxhdeZNsySWOTQBzNFFFABRRRQAUUUUAFFFFAH0d+xr/yE/FH/XK3/nJX07dn90a+Y/2Nf+Ql4p/65W/85K+mr4gQnnH40AfKf7VN9vvNHsw2QDLKR/3yB/WvAq9Y/aTuzP8AEBIM8QWyj8SzH/CvKKAEooooAKKKKACiiigBa1/Ct41nrUB3YSQ7G/Hp+uKyR0NKjmORXU/MpyPrQB9Q+FroMqE9cDNdzZSYPXivIfBd75sELZ++ARXqekyCSEEnJAFAHQA7mBqdeMZFUoZOMdqshulAErEduaryNz2pxY9TkCoyMk8UAbUTlUAjUsGAIbsKvW16rBYpn+bHDH+RrGsJjvhhPBJxnNS3iElizHjtQBp6mc2bnb8wPNc3KduDxg1u6fMLi1eBzlwMZPcVm3NvtwCOD2oAqRcuPQGub8XqUvYpMcNH/I11qxYOMcYFY3jG13W0Eo6AkUAeX+IMNbPj6V4J4pXbrEnuAa991xGEciY4FeEeMlxrBPHKD+ZoAwaKWkoAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigC5pEH2jVLSH+/KoPOOM19IeN2W38MWdsMKdhbHHpjpXhfw0tftfjLT1JIVG3kgE4x9OR1617J8SZvMuYbdTn5VThlPX9aAK2lW/k6dCoU52eg9K67Q49sSYPQf561z9qdkYX7y5CDJ/HvXYaZEFhUqoU49CMf54oA1LY9j90/hVoDuCRxVVFKryOPWrCKc7gMfWgB7D92S3pWdK37wk844q7cS4UgnNUSQyk8E5oAfaDfcwj1cfzr0qMbdNdvUYrzjShnU4B/tZr0uYbdOiXu2CaAIbFMlcHPGc1yHiS7FxrE5BJCYQd+ldihFtZyzHgKhNebPIZJGZjyxLfnQBI8nB5BrJ1GcKrHtirdw+F9MVzGuXGyNhu4Iz1oA4zxnqS4Kge5rxrVZ/tF7I4OVHArrPGl+5aQBup2jnpXD0AFFFFABRRRQAUUUUAFFFFAH0f8Asa/8hLxT/wBcbf8AnJX0TqZ4GSfzr51/Y2/5CPin/rjb/wA5K+g9afbETzwKAPi346Xf2r4mapg8RCOL8kB/rXAV0HxAu/t3jbXLjOd13IAfYMQP5Vz9ABRRRQAUUUUAFFFFAEsKhiV7npSSDBxjFMBwcjrU7nzI93547UAep/D67zpVuV6pgflx/SvbPDwdvmAUg4OCa+efhrOWhmhz9xsgfWvorwzh7WB88Y28UAdHAjHgqKtKg4+Wkt0w3G6rYXP3t30oAqsvTBFN8skntV1ox12/maUoMdFFAFa1QrdQnn74rWvowDIOMnpiqUSjz4uvDDtWrqAAduM80AZsWUlRkG3GMkVbkjE0WRjIJNNXGAB0PXFV9In8wyxnqCWWgAmRQFwO1UPEESzaO7AZKMGrUvlwo9Kq3KmXSrhMA/KemaAPGvE0RWRyvCkfSvBfHA/4maH1U/zr37xWG2KQuRyOleCeNhnVIwRjgj9aAOZNJSnqaSgAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAPSvgXZfaPE0s2FJiQAEjJGfTkH8q7fxHMb7xeiht2JOMsei/UA1k/AG2CWl7dOBjecZxg4X0PH5GtDSlafxPJIytiNGbo2CScepoA3YEBnjRc9SSe3+FddYRhYhgAdq5uwjDXykY4HP+f8a660yUHHSgCymQAecVLneB6+vSmkfMPandFPAz2xQBXuxtUDI9fx+lVHGFz6irV2TwP58VVk6AEc/pQBf8NRmTVFIzwvH4mvRb7dviiHIXrj8q4zwLB5l8Xx/GB+Vdm26TUGIxjOAaAMzxbOLXQSmcNMwT8K4QICorofHt7u1CG1U/LEu4/U1zCyqPmODmgCK843ck4rhPGFykNuw3HJ4xmuu1W7REYkH/gJryDxtqilpSdxVBnDLj+RoA888RziS9Mak4Xk896yKfLIZZHdsbmJJxTKACiiigAooooAKKKKACiiigD6O/Y2/wCQj4p/642/85K998UyLDptxK5wEQsT9BXgP7HBxqHin/rlb/zkr2H4uX/2HwLrk4OCtrJj6lcD+dAHwvdTG4uppm+9I5c/ic1DTqbQAUUUUAFFFFABRRRQAVJFkkgNjPXnrUdLQB1Hgy4FrrKICRHMNn49Qa+kfBdz5mn8N0AP0r5Utp2ikjmByYyGHsRg/wCNfR3w2vfPtiFY7WUMv40AesWsm5FbjpVzeD0NY+mPujCntWkpwKAJ0bd24p5bjmoUBPtSkD1JNAEsJDXEWOfmFaepgmQ+x5rLtv8Aj5hH+0K19QxuYetAFOY+XaySegwPxrGs5jbXcUhHyjhvpWpqh26egHVnrHYDbg5oA6W/UeWH7HkVRhXckqe1WtPl+1aNycvGNpqrCQJivIyMUAeReModsUq8ZVyOcV89+NUP29DyfmYdK+k/H8Wya8GeM7sY9a+a/GMpaVTkEiRvSgDmmG1iD2ptTTYcCQcZ6j3qGgAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKcil3VV6scCgD6H+E1qdP+HUl02VMqMxbkDknHYjp6iq3heJJby+mHlnLBBgIfU9gK6G3jGmfDq2tkxuCLH8oycAf7JBFZfhdXTTmlfeRK7Oclue3f2FAG5oqmWeRhg/MRx0FdbbrjGABXNeGoswhj3Oef/wBVdREvy/LQBKoH6896JDhc5py5bjB9qiuCAvFAFOU5PA96jP6UpfJJz+NN5ZgvUk4oA7nwPbmO180jHylvzrdsQCXlbPygmq2jxC30o4HX5fyp9/MLXRZXJxuBNAHm2uzm71q5kySNxFUHXCnPam+YxYuTyxLHNNuZgsfzcAUAcv4quFggdieBznB/xrwvxTc722Bid7ZP4V6h41uQ7MoZWB5PTivGdWuFub6R0OUHyr9KAKdFFFABRRRQAUUUUAFFFFABRRRQB9F/sdHGoeKf+uVv/OSuz/aR1E23w+vogeZ3jiH4sCf0Briv2Pv+P7xT/wBcrf8AnJV39qq926LptqDzLc7yPZVP9SKAPmvtTaUnikoAKKKKACiiigAooooAKKKKALVt8ycjIBr2r4OagWt47fcd8eYyfp0rxi0miRVUr8xzk9a7z4VambTxCkQO1ZSBz69P8KAPpnTifM9jzxWwnQe3qa5zTpslWJPNbsbjABbnv/nNAFvIwMnn0FDNuBwef/rUxccEnNLkAe9AE1iCbyHjjd/Sta9zvbnvWXpfN/GAOma1rkfvWz1zQBm61/x7QfU1kEfLkCtjWQfs8H1NZTD5McflQBoeGX/fXNvnh49w+oqSRdlyDnvis7RZPJ1q3OeGJU/iK1tQXbcHIyAf8/yoA82+JcJWeRhkBo+/sa+XfFG77SqOCcOa+tfiNEXt4XUZyCMj6V8qeOIvJvAw7uaAOWds5AAC+gqOnyAByB0plABRRS0AJRS0lABRRRQAUUUUAFFFFABRRRQAUUUUAFafhq3N1r9hCBndMp79jnt9KzK6j4aQC48Z6crY2qxY5x6e5FAHvnjhlt/DtlbttOFJCsV4/Bhn8qz7WIWmkoMhQIv7o5OPy71Z+I7sot4AHCrGvADKOfzFOulP2AhF5wF6+px2+tAG54dQpbrx7cD29jW/GB3HTnPt+NY2kIfKUnIyO/4+v4VtRrgDp9OP8+tAEykBcNwQKq3bccdf51azgMPTgd6oXxGeRgUAVtwY8VZ0iPz9RhUjhTu5qiCwHHSt/wAIweZcSS+4Qf1oA7sIVsY4x1OB+J5rD8d3XkaWYlPUBAPrXRZwEJ6DL/4V534+uzJPBFnliXIoA5oEA59O1ZOtXoht3J7Cr8rYBwea4PxjqKqhjBznj3oA4nxdqbeVNJyrN8q158a1fEN59outiHKJ1+tZNABRRRQAUUUUAFFFFABRRRQAUUUUAfQ/7IRxfeKf+uNv/OSsn9qe88zxBpNqD/q4pJCPqQB/6Ca0/wBkY7b3xQf+mVv/ADkriP2h7v7T8SbmPOVggjj/ADy3/s1AHmZpKKKACiiigAooooAKKKKACiiigCa0jMsyhQDjnmuj0aUWeq2jlsSAjtweeOfrXMxyMh+U4zwa1IXJhjlJyEYjIHb9PegD6u0e5E9rFKpG1lDce/4V09q5ZQeea858B3f2vQrV88Yxjj/Gu9tHG1eR+lAGuhJHQ0kh3E+p9aiiJ9R+n+FPPfr+tAF7Reb9OMcGtW4b98fTNZOgj/TgD2U/zrTuMednPegCrrmBbx9PvVkc4Naeu4+yr9ayQf3eM9qAIo38u6gf0kB/Wuk1Q4mJ7HmuWkPzKR1zmunvWDwxNnqBQByfjaPfoyk9VNfLfxQg8u5VuxfrivqzxIhk0Scd1Gfp3r5i+LUWIYm9JMZ/D/61AHms4+YEdxmoqmm+4h9qhoAKWkooAKKKKACiiigAooooAKKKKACiiigAooooAK7/AOCkBl8ZK4BwkZyRkdx6Aj864CvV/wBn2083X7qbGdiqBgc9/fP5UAd98RCh1ONUAPKr8u32/ukVduWDW8Y6jcuSfQfXPpWZ4xkM/iWFWJwJgec5wPqCa13iU2+Bj1yOp/l/nFAHQaT9xQeoGCP/ANX41sJyBhuax9NU4Xkn0z35rYi7ZA/CgBzYwen+fwrNu2GCewGa0nG1OTj6Vl3x+Uhs0AUkOFzniu78KW/k2cW4fORn8TXD2sJmuYohyGYA/TvXpuhRbrmGIDhRmgDQ1V/IttoPzSEKPpXlXiifzdccA8RoB+Neh+ILkNqPlg/LBGWP1NeUXkxnv7mY5O5zz7UAUdTuBHE3IBwa8d8Y6id8zlg23IHvXo/iq88m2kOece4rxLxTclpRCCeTubOf8+tAGAxLEknJPJNJRRQAUUUUAFFFFABRRRQAUUUUAFFFFAH0B+yY2278Uf8AXGD+cleW/Fi8+2/EbXps5AuTGP8AgIC/0r0n9luYQyeKXOMCGAn83rxbW7r7drN/dE58+eSX/vpif60AUaKKKAClFJRQAppKKKACiiigAooooAK0rEB7aRB1xn8R+FZtXtLfbNg5wewz/jQB7j8I9R8zQxEW+aN9vf6/4167p75jBHFfOXwnuzBrM9oxwGXIz7H/AAr6C0py0KjnPtQBvxn1PH+fenuwPTFV4iQo4IzU+SFBzQBp+Hv+P1/92tKcAyE+9Zfh4j7c/wDu/wBa05v9YQBQBS1sZs4yf71Y4GF7CtjXP+PRFxzmsZcD1oAgn4Hv9K6JjusYT6cVzlwBz/OugtTmxXjIBz0oAydUTfY3aZHIz+lfNnxbg/4kpfH3ZlP0zkV9M3fKTrjqOK+ePitBu0G/AHKFW/Jh/iaAPFZh+6iPOMd6gqd2LWy5wcHHSoKACilooASiiigAooooAKKKKACiiigAooooAKKKKACvb/2d4h5OoSkjHmYIJGOF754714hX0J8BIDb+E7q5IILl2/iGR0/p2oAkvXE3iaHO0YZmBHb8q6fY32UgnPyjr+HrXGW0xl8Rox5wrHnnt713UJLWjsoz8o6f/WNAGhpg4X3Hb/61asRy3OM1k2A5wT19fr7itWA/IPQ0ASyjPB5HbNZd633a0ZGOOc5x/n+lZN3J82B0oA0/C0Hm3rSY4QYH1NeheHlCRXF03AGQCfSuO8ORGDSmmx878j8eBXWai32Hw0sS8NMdo+n+c0Actqt2RZ394x5kJI+navPQ4WIkkZ+o5rrvF0wjsYbccFyM/wA64bU5NlueeRQBxPjW7/5ZhhgZY49vxrx/UpfOvZWHTOB+Fd34sv8AEk7MeQOP849a87NACUUUUAFFFFABRRRQAUUUUAFFFFABRRRQB658Dbv7D4e8d3OceXYIwPuBJXkld34Gu/sngLx2c4MlvbRD/gUjD+tcIaAEooooAKKKKACiiigAooooAKKKKACprU4mHvUNPjba6n0NAHZ+ErgWviqxkJG2RgpPGPmGPT1NfR+iSlkAPcd6+VbS+KXVs/8Ay0RlY4JwOa+nfD8ilY2HcetAHX27KQDkZ+oqyD8uCOlU4CSO+e3WrSEEHjkUAafh8/6cQe61rTj/AEhgOOcViaCduojHOQR0rcuh/pZ7d6AM/Xf9QuM9jWOp+XHoOgrY17/VflWKvA5zigCC5HX1FbmnENbkE9hWLNzwM4rT0Zi0YXuVIoAZOvzsPUEf5/KvDPifBu0nVYx/dJ6e+a92nAL9Oc/5/nXj/wAQrfzF1NMfejagD5txmxPHRqq1bIItpRjo+KqUAFLSUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAKAScDrX0j4OSPSvh2UXYCUCgjack9Tx+NfP3h+2a71q0iUEkyAnAPQc9ue1e/a5K1p4ZtLUEgsuTyfT3JoAyfDkZm1mWdQxCLt4z1PJ6H2rv7dP8ARHDHJwBz+A7j2rkPB8MZtlZ9jPIxbnafQDqAe/rXbxbTZSEHBwOFz7+h+lAE2nNnBX7uM8H29j9K1kOB04H+FZdgnIB75zn8vT61qpj6/wD66AI5yAvI45H6VkspmuFjXqx2itC5bnjjAzj9aZoMBm1UHHEfP40Adfp9uC1rap0zk/QVf8TyiTUYbVfuQpz9TUnhuMPfzXDD5IvlB+nWsW7uPMku71j94nH0/wD1UAcZ4pn8/VSoPEY6VxPia5ENqzDhiM9elb95cmSeWVjjexIJrh/Gl0rLsz+IoA8t8VTliFzks2Sa5utHXZC98Vz90VnUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAbGm3vk+H9WtM4+0vAfwUsf8KyDRk4xmkoAKKKKACiiigAooooAKKKKACiiigAooooAswHG0jOehr6T8D3/2nSbKQAHMSn8cYP6g180wHIYenNe3/B2+E+jCJyd0LlDj3+YfzNAHtNq+5FOOCM9P/rVejbB4B/L/AOtWPp8mUAz0/WtIOMY3dRjtQBo6S+3U4s8E8fpXQXRH2vPfArmNPIF9bsD/ABc8V094CJVI7igCjrvEQ9cCsVRxgEVteIBiBT6CsNRyO/1oAZPxkd6t6K+JgPRqquMjk0ulNtvAPp0oA0rsYlIOeD/n+VeaeMoAb264+8h5/CvTr8f6Q/vyP8/jXCeMIs34PXK80AfKGoReXeahEDyHOB+NZFdF4ug+z+JbyI8BmPSuePWgBKKKKACiiigAooooAKKKKACiiigAooooAKKKKAOm+H8Al1vcQDtXAzjqT7g16l40nG6GABR5cSgjjj2xx6+tcH8LLcvqDOM8yKvBxnHPqPX3rpPEVwZdQuDzjcQByPT6igDsfCkrGyt0G8AKOof29yP/ANddaGxYnIBBIGcdsfT61yXhmERRdI9wGOij+QrrGVRZrsxjI4B/wP8AnFAFzTTyD+P860kOIieeBjj6VlacpB9M9ueK0ZGJXGMfUUAVrljhuua1PDEXlWk9yw5Y8Z9BWLdMSufeussbfZZ2lqnVyM/1oA3YSdP8KyyHiWb5R9T1rj/FFwbTRBGpw8nH512HiX71jYqeEG9q8x8d33maksKn5Ihz9aAObu5gkIAzx+teYeK7/MkrFspzgjPSu0168EVrMTjJX8a8h8U3mR5Snlzz9KAOduJDNM8jdWOajoooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAJbdgsyk9Dwa9B+E2oG11uezcgeYm5c+q//AFq86rb0a8fT9Rs75M742Bb3Hf8AMUAfU+lS7iOcqec10KnKA59/881xWgXYmtbeaNvkZQQfY9K661lDxDJyR1oAuW7hbiEns4/nXXXPOwn0riWfDggngg12kpDW8TeooAqa/wA2ak+gzWCpwR1re13B00HPQVz69KAHSj04wKht223a8n8frUznjA9KqrkXCHPU4/SgDob4Dfu9VFcV40X/AEiM9FIxXZ3Z+SFh0Kj+lcf42AEduxHPT/P5UAfMPxLhEXiWR9uMkGuOk4kb616L8WYcal5oByVBJPqD/wDXrzyb/WE+vNAEdFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHqHwhh4eXB4Zjnkdvy7e341cul8y+A55kA4B9faj4QQ506eT5eA3Jx7+388/hVi+hCXKE4zvHQL/n9KAO/0iJjbpw2R6bj15rfnVvspHPUdf/r/AFrJ0TabaEkKSy/7J6Z/HtW9cIq2ygd2A/n7+1ACWAGeQAKvOSF9agshn64qeZjjHX6//qoAr2sYn1G3jxxu3H6D/wCvXd6BD5+sEkfu4lx7Zrk9CQG5nuCPljTA+tdnof8Aomg3N4fvyA4z+VAFK/uBPf3t2T8qfKv0FeO6tcNdX8spP3yW69q9H8QTmz8PP8wEk3H515XfsEjdv4iMUAcf4puFWMqG98f56V5Nqs5nvXOeF+UV2/i27P72QHgDgfyrz080AJRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUooAK0bNvMtymeR0rPIxVrTWxPg9xQB7n8KdS+1aIbdm/eQnHXnFenadMcFcjI9/wD69fP3wvv/ALH4gSFj8k3yEdvavdbGTbOMAcj1/wDrUAbbMMZ4PpxXZ2r79Mhb2FcV1i6cj0rrdFYvo8eR0H8jQBJqvzaQeOgrm15A56V1F2u/SpgDngmuVQ4xnp70ASHlcg5NVGbbKnTIP9asFht6fhmqdw+Ow65oA6SU7rCA+2K5bxuAbGFhyd2Pzz/jXRo2dKjJz96sDxgobRQSDw2etAHz78UYt8iEcEgj8xXlkucIT6Yr134igeXEf7rAfpXklwCrFT2YgH8aAIaKKKACiiigAooooAKKKKACiiigAooooAKKKKAPbvg7A3/CPyNgnKuRyc9e3f8ALFR663lvwp4YHHJ/p/WtT4QRBPCDMRgFHOeg59T0/OsLxIy/aHBA+9jnb/j7elAHp3h4MLOBcOCqAfxeg9a27oAwx4J68Vi6MgKIF7hTnA7/AP1q1rnIMI5AAzxQBctMbCSevrmi4YBTjt7VHaMRHxjOabcDd8vfpQBsaVGV0tQOHuJOPpnFdjrKiDS7OyT+IgkewrE0W28zUbOH+CCMMR79q1tVlEmqsf4IEwM+tAHC+ObjfdRWy/djXcfr2rzHxBIFtyBgbvX3rt9Xn+1X08xOVZjj6DivOPFE+53IJG3tzigDzLxhP8uwHlzz9BXKVs+KJvMvwnZF/U1jUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABTlpKcMd6AENOhbZKre9KcdqYaAOk0u7a11KGdfvKwf8AI5r6MsLkTWlvcAZ3AHr6/jXzNDKPJhfuDg1714GvftPhqzBYlgm0j6HHrQB39uweL9f511/hpt2nOnoxrhNOkIVd2eR3z/Wuv8JyA+eg56H9KAN1fmtJl77fzrjwflNdhaYy6+x/nXGyjZLKn91mFACMzbMVSnc8kHFWJCBkgVWmPU/WgDdsn3aNnPRgayvFGX8PysexzxWhpjbtHnA/hOaqauC/h64A5IBoA8E+IIP2UEd2U8YryfUABcP/ALxP5gV7B49Tdp+VHK4OfTmvJtVXbIxI5IB/z+VAGbRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQB9DfCbjwgoXJPl44PPOP7ozWF4rtpLe7cBZMHnowzxn1p3w11FotBSItkBVHzc/wA8/wCFdX4z01ZtOguVUfdK52gA/wDjoH5UAbejMzRQOctujVh/3z9a1b5yLhRzwuOfrVbRU22tpyD+6U/oPb2NWrxd10/QnIXP0/8Ar0APtiQowxx/n+lPtgZb+FT0LZ4pqDaGAz+H0qXRwTqJOMlATQB3fhxNpubo8GSTy1+g4/xrL1+88jTrubPzyMVX+VbSJ9ktIIQfmSMu31NcP40ugv2e2B4Ub2oA5O8m8pJMEYAPNea+JLjeHJI57+ldjrN3mEx5HzHJHtXmXiq8EcUrA9Bkf0oA4HUZfOvpnzn5sD6Diq1LSUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFLSUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAKKcGx2plFAD9wwcd6aaSloAtwSfuQCflU17H8JLgy6XJCTnypCMdeCPp7V4tCflkU9xn8a9Q+DNyqahNAx4lTIB9uf8aAPabNdpxkDnnoP8K63wo+L1lzncmf5VxyyeTKABw/Q8+o9CRXReHZ9moQ5OAwxg/SgDtbf5bhlPU5rk9TQx6lOv+3n866jzNl5n1wa5rxAdurPj+NQeP8+1AGcdx5HIqBx6g84zUpfB64qKRxgc80Aauh/PY3S8E4qKUB9Fu1bshJ/L/wCtSaDJzdJ6oTU0ODFcx9AUPH4//XoA8P8AHCn+yn6424wfr7/SvItZT5s4/h7fWvaPGEQk0yRQCCFI/SvIdVRWiXHYH/P6UAc5RS0lABRRRQAUUUUAFdX4GgsPsnie/wBS0y21P+ztMW4gt7mSVI/Ma7tosnynRjhZX43YziuUrv8AwD4S0vXNIM2pNd/aLu7awtmglVEtmWFpfMkBUl1OAMArwGOelAE3gjU9B17xpoGkXfgfw+ltqGoW9pK0VxqAdUkkVSVJuiM4JxkGsX/hKNI/6ETw3/3/ANR/+SqqeANLsNc8a6JpOrPcx2d9dx2rtbbd4LsFXG7gckZPPGeDWLdxiG6miUkqjsoz1wDQB6Br+p6Dp2k+GrqDwP4faTUtPe7mD3GoEK4uriEBcXXA2wqec8k+wBoGp6DqOk+JbqfwP4fWTTdPS7hCXGoAM5ureEhs3XI2zMeMcge4ONrWj6Xa+BtK1FYb2z1a5l2rHPOrrdQhTumVAgMahwFGS275sH5TU/w00LSPEN5eWOrJd/aGhd7WSG6WL5lUnaEaNvMcnbhdyDG7npQBW/4SjSP+hE8N/wDf/Uf/AJKrb8b6noOg+NNf0iz8D+H3ttP1C4tImluNQLskcjKCxF0BnAGcAVyHhTRJfEfiKx0mCeC3e6fb507hEjUAlmJPoAeO/Qc1r/FLw1a+FPGE2mac872X2e3nhed0aRg8KMS2zgfMW49McnqQDo9V8T2Oh6N4an07wrpMR1LT3u5kW+1JVVxdXEICgXQwNsKnnPJP0FrRfGy6vo/iSe80CxY6Xp6XUC/2lqZUsbq3hwwN2eNszHjHIHuDheJfD2h2/gDT9V0TfcXa/Z01CVrwkwSyxu4QwmJeDsOGEjfd5HNO+GPgyw8TWWo3WoXCiSOeCws7U3Jt/PuJxJsBcRyY/wBWcAgAk8soHIA9PijcxgBNB09QBgAalqox/wCTlbfjnx4+h+NfEGk2uiWklvYahcWsTy6pqhdljkZQWIuwCcAZwBXlVoYIL+I38Mk1vHIPOijkEbOoPKhsMFJ9cH6Guj+I+m6RpGs2tno9tdWsy2sb3tvcXInME7ZYx7wiZKqUB44bcO1AHZ3nj6SLwXpWrrotqbm61C8tHU6pqmwJFHbOpA+15yTO+eew6c5XwZ4/l1TWLi3l0a2hVNPvrsNDquqKxeC1lmQZ+1ngtGoPtnGDzWJrHgzSrP4Z2usQS3La0I4Li4iMykJHMzqpMe0bVwseGDsTv5Ve2N8OdG0rW9XuLfWJgCsG62t/tkdn9pkLouzzpFZVIVmYAj5iuB1oA6FvjDqrEltMgJPUnV9W/wDkytHx947bSfG3iDSo9DtLiCw1C4tI3uNT1R3ZI5GVSx+1gE4AzgCuesvCOlf8LF8ReHLu7upYbBNQFrNBtBke3jkdd+egIjOcDr+dO1Xwlpdr4IF7E93/AGpDaWl9NM0qmGVbh2Xy1TaCGXA53HOH4HGADWvfFtqngvStY/4RnTWubvULy0kVr/UigSKO2ZSB9qzkmd889h05zW8La7pOv6pcWmoeDtFMSaffXY23eo5Lw2ssyA5ujwWjUH2z0PNMPg7QG8aNpUU+qfYptC/tS1ZvL8wyfYvtIEnGAvBGBk9BnvXOWGj6dcfD/VdYZ7v+0rLULa3KAqIjFKkpz3O7MR9AOOvYAl/4SjSP+hE8N/8Af/Uf/kqtrxvqeg6D401/SLTwP4fe20/ULi0iaW41AuyRyMoLEXQGcAZwBVpvCHhubxFb6cF1ewuJdHurx7GWeOaW2nijkkjWVwi43JGGKbdylgOO2JDoWkXXw0vNXhju01iymjSUG6VlZXYgN5XlgqmNoDb2JbIxjkAGjaanoM3gvVdXbwP4fFzaahZ2iKLjUNhSWO5ZiR9qzkGBMc9z14weCNT0HXvGmgaRd+B/D6W2oahb2krRXGoB1SSRVJUm6IzgnGQal0jwBp2tXXhQWV7PBa3+mSahfvcvGrL5c8kTrCCQCSUAUE98nAzivqfg3S7LWfiLp7yXom0APLYgMjK8a3KRfvCOp2yKcADnOcYxQBkf8JRpH/QieG/+/wDqP/yVW14v1PQdG1WC1tfA/h945NPsbsmS41AnfNaxTMOLocBpCB7YznrWvD4L8KXt/wCD4rKS8ksNRu7awvrqC7DSpcSxqTGYniXZh2PzBnG0evFZUPgewPgC61UT+fqz/aJYLc3Ji8uCGQK77fKYSHrkb0wMYDZoAbaanoM3gvVdXbwP4fFzaahZ2iKLjUNhSWO5ZiR9qzkGBMc9z14weCNT0HXvGmgaRd+B/D6W2oahb2krRXGoB1SSRVJUm6IzgnGQajtvDej/AGvwWLex1PVf7dsyz2wuktmFx58kJw2x8IDGTyCcckjpUMmheGr648ctpE+oNb6TbC505i6ssqieOJi7YBIPmZXAHHXHSgDP/wCEo0j/AKETw3/3/wBR/wDkqtrxfqeg6NqsFra+B/D7xyafY3ZMlxqBO+a1imYcXQ4DSED2xnPWt+f4ceHItV8JWj3Op4vr+HTdRMU0bvFLJHGygqVHltudhgGQbVzuJ4OFpPgzRdQ8Eavfx3pbVLKOed/9NiXyBGwCIYCu9w4P+sDAAlRjrkATQNT0HUdJ8S3U/gfw+smm6el3CEuNQAZzdW8JDZuuRtmY8Y5A9wU8EanoOveNNA0i78D+H0ttQ1C3tJWiuNQDqkkiqSpN0RnBOMg1Y8PeENA1HRdKub6LU7S7eK5untzdIXv4ILeWV3iXy8xAvGEUnfnLEfcIpH8JaBBqusxXUWqR6dHpkGoRXZuowLEzWwmSKVTH+9cuyoFUoSMnjnABz3/CUaR/0Inhv/v/AKj/APJVbev6noOnaT4auoPA/h9pNS097uYPcagQri6uIQFxdcDbCp5zyT7AZOq6FpdrF4MuLOPU7yPV7US3NupVZXkFxJEyRYVsZ8v5chjyOO1bknhfwwusa9bvHqcdnZ2SzSXQvYnj064MRJhdhHidvNAjAUpn5uu3dQBz3/CUaR/0Inhv/v8A6j/8lVh6zfW+oXYmtNLstLj2hfItGmZM8/NmWR2z+OOOldD4a8GR6vpdhd3eqpZNqN61hZxC3aUyOnllyxHCACVcZ689AM1peJfhzFpOg3Op2euxX3kQfaWi+zPETGLr7KxBJPIl6DuuTx0IBzvw90611fx94a03UI/NsrzU7a3nj3Fd8byqrDIwRkE8jmrf/CUaR/0Inhv/AL/6j/8AJVV/BGlWWp399JqqzyWdhZS3skEEgjkm2YwgcqwXkgk7TwDUPjbR4NB8VX+m2skj20LKYzIQXCsoYK2AAWAbB4HIPAoA6jxfqeg6NqsFra+B/D7xyafY3ZMlxqBO+a1imYcXQ4DSED2xnPWi01PQZvBeq6u3gfw+Lm01CztEUXGobCksdyzEj7VnIMCY57nrxjn/AB/o9homuQQaRJdSWU9jaXiG62+Z++gSQg7eB97pz9TVjwto+lX3hrXbzVYb2E2kTNDfLOqwibb+7h8soTIztnow2qC2CAaANjwRqeg69400DSLvwP4fS21DULe0laK41AOqSSKpKk3RGcE4yDWL/wAJRpH/AEInhv8A7/6j/wDJVZPhiKwn1y1j1eKWSxZsSCO4EG3PAZpCj7VBwSdp4zVrx5pFvoPi7U9MsTMbW3kAiMrBmKlQQdwADA5yDgZGDgdAAdPr+p6Dp2k+GrqDwP4faTUtPe7mD3GoEK4uriEBcXXA2wqec8k+wCWmp6DN4L1XV28D+Hxc2moWdoii41DYUljuWYkfas5BgTHPc9eMN+IngCLwh4U8PXouvtN9dyzRXrRyxvCjBInRY9pJOA7Bie47DBMXgvw9oer+ENVmn3z+IY/Pe2tfthtwYoofMZ1HkuHK8kqWTIHBoAn8IanoOs6rPa3Xgfw+kcen312DHcagDvhtZZlHN0eC0YB9s4x1rF/4SjSP+hE8N/8Af/Uf/kqpfhr4c03X7/UpdcvFtdN020+1S5lMW/MiRqpcJIVG6QZIRumMc5GF4i02TRvEWo6bcxGKSzuZIHj8wOV2sRjeAAenXAz6UAdl4v1PQdG1WC1tfA/h945NPsbsmS41AnfNaxTMOLocBpCB7YznrRd6noMPgvStXXwP4fNzd6heWjqbjUNgSKO2ZSB9qzkmd889h05zmeO9P0Gy0vQZtIsb2wvr2F7qa2ubwXOyFiBCciNMFgHbHPylD3409Y8GaVZ/DO11iCW5bWhHBcXERmUhI5mdVJj2jauFjwwdid/Kr2ADwhqeg6zqs9rdeB/D6Rx6ffXYMdxqAO+G1lmUc3R4LRgH2zjHWsX/AISjSP8AoRPDf/f/AFH/AOSqX4c6NpWt6vcW+sTAFYN1tb/bI7P7TIXRdnnSKyqQrMwBHzFcDrWjZeEdK/4WL4i8OXd3dSw2CagLWaDaDI9vHI6789ARGc4HX86ALHjfU9B0Hxpr+kWngfw+9tp+oXFpE0txqBdkjkZQWIugM4AzgClu9T0GHwXpWrr4H8Pm5utQvLR1NxqGwJFHbMpA+1ZyTO+eew6c5g1Xwlpdr4IF7E93/akNpaX00zSqYZVuHZfLVNoIZcDncc4fgcYtHwdoDeNG0qKfVPsU2hf2pas3l+YZPsX2kCTjAXgjAyegz3oAZ4f1TQtQ0rxLdS+B9AWTTdPS7hCXGoAM5ureEhv9K5G2ZjxjkD3BsfDzxDpmo+OPD+l/8Iho1pDf6hb2kklreajHIqSSKrFT9q4OCexrBh0LS28KeHNVjj1O7urzVJrG7toSql9ghZVh+VjuIlAyQee3rq6l4V8PCbxbHZTX63GlabDexwedHMkMpkiSaF5QBv2NLgFQOh545AIm+JkrsGbw7prMO51HVCf/AEsrf1zx9JpWl+Gbu00W1Euo6e93LnVNUwri6uIQFxdjA2wqec8k/Qc1qeheH4vB2ha1EmoRGS7FrqCC5SdlwuWO0onlsfmKrlwV5JB69PZfCezudZ8cRi9k+x6M97bWMXnRiaaaKJ3UyZxhBtAJA5LDoASACXQPiTealpfiS7n02MS6Zp6XcO3V9VwXN1bw4bN302zMeMcge4LPBvxDuPEnjbw/pWo6TAYL/ULe0kddW1XeqSSKpKk3ZAOCcZB5rl9B8O+HrjR/Ceo6ldX0UN7q81jqbcBY40ELbo8An7svJPcHjjnQ1jwhoiDxI9sLmIWmkQ6np5hvBcwzI00cbMzmKNv+WnC7ARg5PTIBCfipdnrodif+4nqv/wAmVta/49fTtJ8NXMGi2rPqenvdTB9U1QhWF1cQgLi74G2FTznkn2AyPHfgvSfDNvpTx3Et1Ck6W+p3EM+51do1cqsTRqF43bTvcHjJHSrK+F/DWneK/Gel6pZ6nNp+iPORfJepGY0Q7I1KeUQ7u5VRyo59ATQBoWHxAlbwZq2sDR7ZLq2v7S0RV1XVAjJNHcs2f9LznMCY57ng8YXwP8Qp9d8aaDpF3pEEdtqOoW9pM0WraoHCSSKrEE3ZGcHuDWVovgzQbubw3cSz3w0+70afUr1pZViCyRSyR43hXKRl0UZ2ueRwM8VNQ8H6Ta6j48sxNqHmaLbLdWBYoVkjM0SZcjrlZVIwBnqcdKAIZfiKJVKy+GNJdT1DX+pkH/ybq94x1rR9I1W3tLfwZockT6fY3Z8261AnfNaxTOOLocBpGA9sZz1rZPw+8O/ZtHvLEXeqWlxKbeRrfVYAJAIlkedj5Z+zrGC25HBIG3kck5Or+DPD8Hhi9u9OuL+5ljsn1WC9Z1WCSAX5tFiKbciQrh87uvy470AQXep6DD4L0rWF8D+Hzc3eoXlo6m41DYEijtmUgfas5JnfPPYdOcp4Q1PQdZ1We1uvA/h9I49PvrsGO41AHfDayzKObo8FowD7ZxjrVpvCHhubxFb6cF1ewuJdHurx7GWeOaW2nijkkjWVwi43JGGKbdylgOO3OaHpOk3PgrWNR1KC/gubZgLa8FwghmlJTECxFNzNtLsWDYUBSRzggCf8JRpH/QieG/8Av/qP/wAlVz2pXMV3fSz29lb2MTnK29u0hjj46AyMze/LHrXZa74SsrjxT4d0XQI7qx1DUxHHNZahcLK9pI8hVN7qi4JTa5Tbld2OvAvaR8N9N1a2a5tPFC/Zy8yRtJp8iljDCZpMjPGFVvXJAHrgA81orY8WaI3h7XJdPNwlyqxxTRzKpXfHLEsqEg9DtdcjnBzyetY9ABWhputapplre22m6jeWlvep5dzFBMyLMvPDgHDDkjn1Pqaz6KALuj6rf6LqEd9pF5PZXseQk8DlHXIIOCPUEio9QvbrUr2e81C4lubudi8s0rlmdj3JPWq1FAGzqHijXdS0a20m/wBXvrnTLbb5NrLMzRx7V2rtUnAwDgegqHTdf1jS7G7stN1S+tLO7G24hgnZElGMYYA4PHHPbIrMooAKnvLu4vZ/OvJ5Z5diR75GLHaqhVGT2CqAPYCoKKANPUNf1fUdNs9P1DU725sLMYt7eaZnjiGMDapOBxx9OKbo+t6ropuDpGpXlibiPypvs0zR+Yn91sHkVnUUAPhkeGZJYXZJUYMrKcFSOQQaddXE13cy3F1K81xM5kkkkYszsTkkk9ST3qKigDRn1vVZ9Gg0mbUryTS4HMkVo8zGJGOeQmcA8n8z6mm6Pq+o6Jdm60e/urG5KGMy20pjfaeoyDmqFFAGpoXiDV9AvJLvRNSu7C5kQxvLbylGZSQSCR1GQD+FJc6/rF1pkWnXOq301hDKZ47aS4Zo0kJJLBScA5JOfc+prMooA6c+P/Fx1IagfEurfbhEYBP9qfeIyQxXOemQDj2qlaeKtfs9NuNPtdZ1CGyuJfOlhjuGVXkyDuIB5OVHPtWLRQB1J+IPi86gt8fEurm8WIwCb7U+4Rkglc56ZAP4Vl33iLWtQ0uHTb7Vr+50+FzJHbTXDvGrHPIUnGeT+Z9ayqKANbUvEmtapZWNpqOq3t1a2IC20UszMsIAAG0E8YAA/CpbLxX4gsW1JrPWtQgbUyWvWjnZTcE5yXOfmJ3NyfU1iUUAdAPGniYXNhcf8JBqpnsEMdq5unJgUjaQnPGRxx24qC58Ua9dWl9a3OtajLbX0vn3UL3LlJ5OPmdc4J4HX0HoKxqKAN2fxd4iuILKGfW9ReKyjaG2RrhiIUZPLKrzwCny/Tiq+j+ItZ0W2vLfSNUvLKC8XbcJbzMglGCMNjrwx/OsqigDeh8YeJIZtPlj17VFk05DHZt9qf8A0dSNpCc/KCOOO2B2qG+8Ta7qFncWl9rGoXFrczm5mhkuGZJJTj52GcE8Dk+lY9FAHQ/8Jr4n+yWFqPEGqC3sGRrSMXLgQFFKqU54wCQMdqS18aeJrV797fX9Uja/bddFbp8znGMtzyccVz9FAG9J4w8RyDTA+uakRpmPsWbhv9HwABs544AHHarR8f8Ai4yXTnxLq5e6UJOftT/vAAQAeeeCRXL0UAauleIta0i0mtdK1a/sraZleSK3uGjV2HQkA8ngVHLrWqTWz28uo3bwPGYmjaZirIZPNKkZ5HmfP/vc9azqKALelale6RfxX2lXdxZ3kRJjngkKOuRg4I55BI/Gorm5nuruS6uZ5ZrmVzJJNI5Z3YnJYseSSec1DRQBq6/4h1jxFcRT67qd5qE0S7Ee5laQquc4GenNSaZ4o13StJudM03V7610663edbQzMscm5drZUHByoAPsKxqKAL2jatqOiXyXuj31zY3aAhZreUxuAeoyO1V7u5nvLqW5u5pZ7iVi8ksrlndjySSeST61DRQBO93cSWcNpJPK1rC7yRxFiVRmChiB0BO1c+u0Vcstf1ex0i60uz1O9g026OZ7WOdlilOAPmUHB4A/IVmUUAXtG1fUdEvlvNHvrmxu1UqJraUxuAeoyO1VJpZJpnlmdpJZGLO7nJYnkknuaZRQBYvry5v7lri+uJbi4YKGklcsxAAUDJ9AAB7CrM+t6rPo0GkzaleSaXA5kitHmYxIxzyEzgHk/mfU1nUUAX9H1fUdEuzdaPf3VjclDGZbaUxvtPUZBzUuheINX0C8ku9E1K7sLmRDG8tvKUZlJBIJHUZAP4Vl0UAadzr+sXWmRadc6rfTWEMpnjtpLhmjSQkksFJwDkk59z6mtQ+P/Fx1IagfEurfbhEYBP8Aan3iMkMVznpkA49q5iigDoIPGfiaCztbWHX9UjtraXz4Y1uXCxyZJ3AZ65Zj+JqVvHfit5b2VvEWqmS9jWK5b7U+ZUAICsc8gBm/M1zVFAG1c+KtfupdOluda1KaTTSDZtJcuxtyMYKZPy9B09B6VFfeItZ1DU5tRvdUvZ7+aJoJLiSZi7RspQoTn7pUkEehrKooA3bbxd4itdNtLC11zUobK0k823hjuXVYnyTuUA8HLE/jUieNfE6TajMviDVBLqKhbt/tT7pwAQAxzyACQPQVz1FAGvJ4m1yQ6YZdY1BzpePsO+4c/ZsYx5eT8uMDp6D0FJqviPWtXe5bVNVvbtrkxmczTM/mGMEJuyedu5semTWTRQB0I8a+JwdO2+INUX+zl22e26ceQNu3Cc8DaMfTiobLxX4gsTqJs9a1GFtRybxkuGBuCc5LnOWPzNyfU1iUUAdDa+NvFFrc29xb+IdVjmt7f7JC63Tgxw8fu154X5V49hUFx4q1+5tpLe41rUpLeS4N28bXLlTMTnzMZ+9nnPrWLRQB1J+IPi86gt8fEurm8WIwCb7U+4Rkglc56ZAP4VTtPF3iK00yXTrXXNShsZXMjwJcuEZickkZ6kjNYVFAGzrXifXdcu7a61fV7+9ubb/UyzTszRc5+Uk8c88U++8W+Ir+fz73XNTuJsMN8t07H5kMbdT3QlT7EisOigCe8u7i9n868nlnl2JHvkYsdqqFUZPYKoA9gKgoooA//9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Anteroposterior (A) and lateral (B) views of the left elbow in a 13-year-old boy who fell off a fence.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paula Schweich, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_7_26737=[""].join("\n");
var outline_f26_7_26737=null;
var title_f26_7_26738="Junctional EB Herlitz 6";
var content_f26_7_26738=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F87697&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F87697&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Junctional epidermolysis bullosa Herlitz",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 337px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Two-year-old girl with Herlitz-type junctional EB. Note the characteristic exuberant granulation tissue.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission of: Informa Healthcare, from Mallory SB, Bree AF, Chern P. Bullous diseases. In: Illustrated Manual of Pediatric Dermatology: Diagnosis and Management, Taylor &amp; Francis, United Kingdom 2005; permission conveyed through Copyright Clearance Center, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_7_26738=[""].join("\n");
var outline_f26_7_26738=null;
var title_f26_7_26739="Slit lamp";
var content_f26_7_26739=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F66058&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F66058&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 473px\">",
"   <div class=\"ttl\">",
"    Slit lamp",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 453px; height: 493px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A basic slit lamp with typical features is illustrated.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_7_26739=[""].join("\n");
var outline_f26_7_26739=null;
var title_f26_7_26740="Ciprofloxacin (ophthalmic): Drug information";
var content_f26_7_26740=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Ciprofloxacin (ophthalmic): Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?35/39/36468?source=see_link\">",
"    see \"Ciprofloxacin (ophthalmic): Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?6/50/6947?source=see_link\">",
"    see \"Ciprofloxacin (ophthalmic): Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F9611239\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Ciloxan&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F9611240\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Ciloxan&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F9660656\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antibiotic, Ophthalmic;",
"     </li>",
"     <li>",
"      Antibiotic, Quinolone",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F9611431\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Bacterial conjunctivitis:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Ophthalmic solution:",
"     </i>",
"     Instill 1-2 drops into the conjunctival sac every 2 hours while awake for 2 days and 1-2 drops every 4 hours while awake for the next 5 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Ophthalmic ointment:",
"     </i>",
"     Apply a",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     inch ribbon into the conjunctival sac 3 times/day for the first 2 days, followed by a",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     inch ribbon applied twice daily for the next 5 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Corneal ulcer:",
"     </b>",
"     <i>",
"      Ophthalmic solution:",
"     </i>",
"     Instill 2 drops into affected eye every 15 minutes for the first 6 hours, then 2 drops into the affected eye every 30 minutes for the remainder of the first day. On day 2, instill 2 drops into the affected eye hourly. On days 3-14, instill 2 drops into affected eye every 4 hours. Treatment may continue after day 14 if re-epithelialization has not occurred.",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F9611430\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?6/50/6947?source=see_link\">",
"      see \"Ciprofloxacin (ophthalmic): Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Bacterial conjunctivitis:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Ophthalmic solution:",
"     </i>",
"     Children &ge;1 year: Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Ophthalmic ointment:",
"     </i>",
"     Children &ge;2 years: Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Corneal ulcer:",
"     </b>",
"     <i>",
"      Ophthalmic solution:",
"     </i>",
"     Children &ge;1 year: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F9611432\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F15682661\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15682662\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F9611527\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ointment, ophthalmic, as hydrochloride:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ciloxan&reg;: 3.33 mg/g (3.5 g) [equivalent to ciprofloxacin base 0.3%]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, ophthalmic, as hydrochloride [drops]: 3.5 mg/mL (2.5 mL, 5 mL, 10 mL) [equivalent to ciprofloxacin base 0.3%]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ciloxan&reg;: 3.5 mg/mL (5 mL) [contains benzalkonium chloride; equivalent to ciprofloxacin base 0.3%]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F9611242\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Excludes ointment",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F9611462\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">",
"     For topical ophthalmic use only; avoid touching tip of applicator to eye or other surfaces.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F9611264\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">",
"     Treatment of superficial ocular infections (corneal ulcers, conjunctivitis) due to susceptible strains",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F3198568\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Ciprofloxacin may be confused with cephalexin",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Ciloxan&reg; may be confused with Cytoxan",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F13854754\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &gt;10%: Ocular: White crystalline precipitate (solution:17%; in superficial portion of corneal defect in those with corneal ulcer; reversible after completion of therapy)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Unpleasant taste (immediately after instillation)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Ocular: Keratopathy (ointment: 2%), conjunctival hyperemia, crystal formation, burning, discomfort, foreign body sensation, itching, lid margin crusting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &lt;1% (Limited to important or life-threatening): Allergic reactions, blurred vision, corneal infiltrates, corneal staining, dermatitis, dry eyes, epitheliopathy, eye pain, hypersensitivity reactions, irritation, keratoconjunctivitis, keratitis, lid edema, nausea, photophobia, tearing, vision decreased",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F9611310\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to ciprofloxacin, any component of the formulation, or other quinolones",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F9611311\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Delayed healing: Corneal healing may be delayed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypersensitivity reactions: Severe hypersensitivity reactions, including anaphylaxis, have occurred with quinolone therapy (primarily with systemic use). Prompt discontinuation of drug should occur if skin rash or other symptoms arise.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Superinfection: Prolonged use may result in fungal or bacterial superinfection. If superinfection is suspected, institute appropriate alternative therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Contact lens wearers: Some products contain benzalkonium chloride which may be absorbed by soft contact lenses; contact lenses should not be worn during treatment of ophthalmologic infections.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Ophthalmic use: For ophthalmic use only. Not for subconjunctival  injection or for introduction into the anterior chamber of the eye. To avoid contamination, do not touch tip of container to any surface.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299045\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F9611335\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F9611268\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F9611269\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events have been observed in some animal reproduction studies. When administered orally or I.V., ciprofloxacin crosses the placenta. Refer to the Ciprofloxacin (Systemic) monograph for details. The amount of ciprofloxacin available systemically following topical application of the ophthalmic drops is significantly less in comparison to oral or I.V. doses.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F9611272\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use caution (AAP rates \"compatible\"; AAP 2001 update pending)",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F9611309\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     When administered orally or I.V., ciprofloxacin enters breast milk. Refer to the Ciprofloxacin (Systemic) monograph for details. The amount of ciprofloxacin available systemically following topical application of the ophthalmic drops is significantly less in comparison to oral or I.V. doses. The manufacturer recommends that caution be exercised when administering ciprofloxacin eye drops to nursing women.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F9611529\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Ointment",
"     </b>",
"     (Ciloxan Ophthalmic)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.3% (3.5 g): $136.68",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Ciloxan Ophthalmic)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.3% (5 mL): $99.96",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Ciprofloxacin HCl Ophthalmic)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.3% (2.5 mL): $24.75",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F10961928\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Alcon Cilox (CO, ID);",
"     </li>",
"     <li>",
"      Aprocin (HK);",
"     </li>",
"     <li>",
"      Baquinor (ID);",
"     </li>",
"     <li>",
"      Ceflox (IN);",
"     </li>",
"     <li>",
"      Cifloptic (PE);",
"     </li>",
"     <li>",
"      Cifran DPS (IN);",
"     </li>",
"     <li>",
"      Cilobact (CO);",
"     </li>",
"     <li>",
"      CiloQuin (AU);",
"     </li>",
"     <li>",
"      Cilox (NO);",
"     </li>",
"     <li>",
"      Ciloxan (AR, AT, AU, BE, BG, BR, CH, CN, CZ, DE, DK, EE, FR, GB, GR, HK, IE, IL, MY, NL, NZ, PH, PK, PL, PY, SE, TH, TR, TW, UY, VE, ZA);",
"     </li>",
"     <li>",
"      Cipcin (TW);",
"     </li>",
"     <li>",
"      Ciplus (KP);",
"     </li>",
"     <li>",
"      Ciprodar (HK);",
"     </li>",
"     <li>",
"      Ciprolak (PE);",
"     </li>",
"     <li>",
"      Ciprotal (PH);",
"     </li>",
"     <li>",
"      Ciroxin (TW);",
"     </li>",
"     <li>",
"      Ifloxin (PH);",
"     </li>",
"     <li>",
"      Interflox (ID);",
"     </li>",
"     <li>",
"      Novaflox (SG);",
"     </li>",
"     <li>",
"      Oftacilox (PT);",
"     </li>",
"     <li>",
"      Optal-Pro (TH);",
"     </li>",
"     <li>",
"      Qiu Lu (CL);",
"     </li>",
"     <li>",
"      Sophixin Ofteno (CR, DO, GT, HN, NI, PA, SV, VE);",
"     </li>",
"     <li>",
"      Vistaflox (PH)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F9611376\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Inhibits DNA-gyrase in susceptible organisms; inhibits relaxation of supercoiled DNA and promotes breakage of double-stranded DNA",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F9611379\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">",
"     Absorption: Only small amounts are absorbed systemically after ophthalmic instillation",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics Committee on Drugs, \"Transfer of Drugs and Other Chemicals Into Human Milk,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2001, 108(3):776-89.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/7/26740/abstract-text/11533352/pubmed\" id=\"11533352\" target=\"_blank\">",
"        11533352",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9049 Version 41.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-61.234.146.186-9089A68DA0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_7_26740=[""].join("\n");
var outline_f26_7_26740=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9611239\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9611240\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9660656\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9611431\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9611430\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9611432\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15682661\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15682662\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9611527\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9611242\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9611462\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9611264\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3198568\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13854754\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9611310\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9611311\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299045\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9611335\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9611268\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9611269\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9611272\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9611309\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9611529\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10961928\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9611376\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9611379\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9049\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9049|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?35/39/36468?source=related_link\">",
"      Ciprofloxacin (ophthalmic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?6/50/6947?source=related_link\">",
"      Ciprofloxacin (ophthalmic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?27/20/27971?source=related_link\">",
"      Ciprofloxacin (otic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?15/21/15700?source=related_link\">",
"      Ciprofloxacin (otic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/48/38658?source=related_link\">",
"      Ciprofloxacin (otic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?20/5/20570?source=related_link\">",
"      Ciprofloxacin (systemic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?17/11/17590?source=related_link\">",
"      Ciprofloxacin (systemic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?43/11/44216?source=related_link\">",
"      Ciprofloxacin (systemic): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_7_26741="Hyoscyamine: Pediatric drug information";
var content_f26_7_26741=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Hyoscyamine: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?29/9/29846?source=see_link\">",
"    see \"Hyoscyamine: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?38/60/39877?source=see_link\">",
"    see \"Hyoscyamine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F181212\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Anaspaz&reg;;",
"     </li>",
"     <li>",
"      ED-SPAZ;",
"     </li>",
"     <li>",
"      HyoMax&reg; -SR;",
"     </li>",
"     <li>",
"      HyoMax&reg;-SL;",
"     </li>",
"     <li>",
"      HyoMax&trade;-DT;",
"     </li>",
"     <li>",
"      HyoMax&trade;-FT;",
"     </li>",
"     <li>",
"      Hyosyne;",
"     </li>",
"     <li>",
"      Levbid&reg;;",
"     </li>",
"     <li>",
"      Levsin&reg;;",
"     </li>",
"     <li>",
"      Levsin&reg;/SL;",
"     </li>",
"     <li>",
"      NuLev&reg;;",
"     </li>",
"     <li>",
"      Oscimin;",
"     </li>",
"     <li>",
"      Symax&reg; DuoTab;",
"     </li>",
"     <li>",
"      Symax&reg; FasTab;",
"     </li>",
"     <li>",
"      Symax&reg; SL;",
"     </li>",
"     <li>",
"      Symax&reg; SR",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F181213\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Levsin&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1059345\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Anticholinergic Agent",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antispasmodic Agent, Gastrointestinal",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1059339\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?29/9/29846?source=see_link\">",
"      see \"Hyoscyamine: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     GI tract disorders:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Infants and Children &lt;2 years: Oral: The following table lists the hyoscyamine dosage using the drop formulation; hyoscyamine drops are dosed every 4 hours as needed",
"    </p>",
"    <table border=\"1\" frame=\"border\" rules=\"all\">",
"     <caption style=\"text-align:center;\">",
"      Hyoscyamine Drops Dosage",
"     </caption>",
"     <col align=\"center\" width=\"100\">",
"     </col>",
"     <col align=\"center\" width=\"100\">",
"     </col>",
"     <col align=\"center\" width=\"140\">",
"     </col>",
"     <thead valign=\"middle\">",
"      <tr>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Weight",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         (kg)",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Dose",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         (drops)",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Maximum Daily Dose",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         (drops)",
"        </p>",
"       </th>",
"      </tr>",
"     </thead>",
"     <tbody valign=\"top\">",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         2.3",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         3",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         18",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         3.4",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         4",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         24",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         5",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         5",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         30",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         7",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         6",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         36",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         10",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         8",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         48",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         15",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         11",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         66",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral, S.L.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children 2-12 years: 0.0625-0.125 mg every 4 hours as needed; maximum daily dosage 0.75 mg",
"     <b>",
"      or",
"     </b>",
"     timed release 0.375 mg every 12 hours; maximum daily dosage 0.75 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children &gt;12 years to Adults: 0.125-0.25 mg every 4 hours as needed; maximum daily dosage 1.5 mg",
"     <b>",
"      or",
"     </b>",
"     timed release 0.375-0.75 mg every 12 hours; maximum daily dosage 1.5 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.V., I.M., SubQ: Children &gt;12 years to Adults: 0.25-0.5 mg at 4-hour intervals for 1-4 doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adjunct to anesthesia: I.M., I.V., SubQ: Children &gt;2 years to Adults: 5 mcg/kg given 30-60 minutes prior to induction of anesthesia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hypermotility of lower urinary tract: Oral, S.L.: Adults: 0.15-0.3 mg four times daily; timed release: 0.375 mg every 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Reversal of neuromuscular blockage: I.V., I.M., SubQ: 0.2 mg for every 1 mg neostigmine",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F181189\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elixir, oral, as sulfate: 0.125 mg/5 mL (473 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hyosyne: 0.125 mg/5 mL (473 mL) [contains ethanol 20%, sodium benzoate; orange-lemon flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution, as sulfate:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Levsin&reg;: 0.5 mg/mL (1 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, oral, as sulfate [drops]: 0.125 mg/mL (15 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hyosyne: 0.125 mg/mL (15 mL) [contains ethanol 5%, sodium benzoate; orange-lemon flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as sulfate: 0.125 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Levsin&reg;: 0.125 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, sublingual, as sulfate: 0.125 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     HyoMax&reg;-SL: 0.125 mg [peppermint flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Levsin&reg;/SL: 0.125 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oscimin: 0.125 mg [peppermint flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Symax&reg; SL: 0.125 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, chewable/disintegrating, oral, as sulfate:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     HyoMax&trade;-FT: 0.125 mg [mint flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     NuLev&reg;: 0.125 mg [peppermint flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oscimin: 0.125 mg [peppermint flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Symax&reg; FasTab: 0.125 mg [mint flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, dispersible, oral, as sulfate:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oscimin: 0.125 mg [peppermint flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, extended release, oral, as sulfate: 0.375 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Levbid&reg;: 0.375 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oscimin: 0.375 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, orally disintegrating, oral, as sulfate: 0.125 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Anaspaz&reg;: 0.125 mg [scored]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     ED-SPAZ: 0.125 mg [scored]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, sustained release, oral, as sulfate: 0.375 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     HyoMax&reg; -SR: 0.375 mg [scored]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Symax&reg; SR: 0.375 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, variable release, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     HyoMax&trade;-DT: Hyoscyamine sulfate 0.125 mg [immediate release] and  hyoscyamine sulfate 0.25 mg [sustained release]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Symax&reg; DuoTab: Hyoscyamine sulfate 0.125 mg [immediate release] and  hyoscyamine sulfate 0.25 mg [sustained release]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F181175\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Excludes chewable/disintegrating, dispersible, and variable release tablets, and injection",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1059348\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral: Administer before meals; timed release tablets are scored and may be cut for easier dosage titration; S.L.: Place under the tongue",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Parenteral: May be administered I.M., I.V., and SubQ; no information is available for I.V. administration rate or dilution",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1059347\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of GI tract disorders caused by spasm; adjunctive therapy for peptic ulcers and hypermotility disorders of lower urinary tract; infant colic",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F181246\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Anaspaz&reg; may be confused with Anaprox&reg;, Antispas&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Levbid&reg; may be confused with Enbrel&reg;, Lithobid&reg;, Lopid&reg;, Lorabid&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Levsinex&reg; may be confused with Lanoxin&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Levsin/SL&reg; maybe confused with Levaquin&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      BEERS Criteria medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This drug may be potentially inappropriate for use in geriatric patients (Quality of evidence - moderate; Strength of recommendation - strong).",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F181244\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Palpitation, tachycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Ataxia, dizziness, drowsiness, headache, insomnia, mental confusion/excitement, nervousness, speech disorder",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Lactation suppression",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Bloating, constipation, dry mouth, loss of taste, nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Impotence, urinary hesitancy, urinary retention",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Blurred vision, cycloplegia, increased ocular tension, mydriasis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Allergic reactions, decreased diaphoresis",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1059352\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to hyoscyamine or any component; narrow-angle glaucoma, GI and GU obstruction, paralytic ileus, severe ulcerative colitis, myasthenia gravis",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1059338\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with hyperthyroidism, CHF, cardiac arrhythmias, prostatic hypertrophy, autonomic neuropathy, chronic lung disease, biliary tract disease, children with spastic paralysis. Disintegrating tablet (NuLev&trade;) contains aspartame which is metabolized to phenylalanine and must be used with caution in patients with phenylketonuria.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1059337\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Low doses may cause a paradoxical decrease in heart rate; heat prostration may occur in hot weather. Some oral liquids contain sodium benzoate; benzoic acid (benzoate) is a metabolite of benzyl alcohol; large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (&ldquo;gasping syndrome&rdquo;) in neonates;",
"     <i>",
"      in vitro",
"     </i>",
"     and animal studies have shown that benzoate displaces bilirubin from protein binding sites; avoid using products containing sodium benzoate in neonates",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299495\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F181184\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AbobotulinumtoxinA: Anticholinergic Agents may enhance the anticholinergic effect of AbobotulinumtoxinA.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetylcholinesterase Inhibitors (Central): Anticholinergics may diminish the therapeutic effect of Acetylcholinesterase Inhibitors (Central). Acetylcholinesterase Inhibitors (Central) may diminish the therapeutic effect of Anticholinergics. If the anticholinergic action is a side effect of the agent, the result may be beneficial.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aclidinium: May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticholinergics: May enhance the adverse/toxic effect of other Anticholinergics.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cannabinoids: Anticholinergic Agents may enhance the tachycardic effect of Cannabinoids.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ipratropium (Oral Inhalation): May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirabegron: Anticholinergic Agents may enhance the therapeutic effect of Mirabegron. This may result in acute urinary retention.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     OnabotulinumtoxinA: Anticholinergic Agents may enhance the anticholinergic effect of OnabotulinumtoxinA.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Potassium Chloride: Anticholinergic Agents may enhance the ulcerogenic effect of Potassium Chloride.  Management: Patients on drugs with substantial anticholinergic effects should avoid using any solid oral dosage form of potassium chloride.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramlintide: May enhance the anticholinergic effect of Anticholinergics. These effects are specific to the GI tract.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RimabotulinumtoxinB: Anticholinergic Agents may enhance the anticholinergic effect of RimabotulinumtoxinB.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Secretin: Anticholinergic Agents may diminish the therapeutic effect of Secretin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tiotropium: Anticholinergics may enhance the anticholinergic effect of Tiotropium.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Topiramate: Anticholinergic Agents may enhance the adverse/toxic effect of Topiramate. Specifically, the risk of oligohidrosis and hyperthermia may be enhanced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F181186\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F181198\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Crosses the placenta, effects to the fetus not known; use during pregnancy only if clearly needed.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1059344\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Pulse, anticholinergic effects, urine output, GI symptoms",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1059336\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Blocks the action of acetylcholine at parasympathetic sites in smooth muscle, secretory glands, and the CNS; specific anticholinergic responses are dose-related; increases cardiac output, dries secretions, antagonizes histamine and serotonin",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F1059350\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral: 20-30 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Sublingual: 5-20 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.V.: 2-3 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: 4-6 hours",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1059351\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Well absorbed from the GI tract",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Crosses the placenta; small amounts appear in breast milk",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 50%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: In the liver",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life: 3.5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: 30% to 50% eliminated unchanged in urine within 12 hours",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1059343\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?38/60/39877?source=see_link\">",
"      see \"Hyoscyamine: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May cause dry mouth; maintain good oral hygiene habits, because lack of saliva may increase chance of cavities; notify physician if skin rash, flushing or eye pain occurs, or if difficulty in urinating, constipation, or sensitivity to light becomes severe or persists; may cause dizziness or blurred vision; may cause drowsiness and impair ability to perform activities requiring mental alertness or physical coordination. May rarely cause photosensitivity reactions (eg, exposure to sunlight may cause severe sunburn, skin rash, redness, or itching); avoid direct exposure to sunlight",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13369 Version 41.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-115.25.216.6-41F16B85B6-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_7_26741=[""].join("\n");
var outline_f26_7_26741=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181212\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181213\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059345\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059339\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181189\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181175\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059348\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059347\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181246\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181244\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059352\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059338\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059337\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299495\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181184\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181186\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181198\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059344\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059336\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059350\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059351\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059343\">",
"      Patient Information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13369\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13369|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?29/9/29846?source=related_link\">",
"      Hyoscyamine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?38/60/39877?source=related_link\">",
"      Hyoscyamine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_7_26742="Mechanism of normal labor and delivery";
var content_f26_7_26742=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Mechanism of normal labor and delivery",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/7/26742/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/7/26742/contributors\">",
"     Edmund F Funai, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/7/26742/contributors\">",
"     Errol R Norwitz, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/7/26742/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/7/26742/contributors\">",
"     Charles J Lockwood, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/7/26742/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/7/26742/contributors\">",
"     Vanessa A Barss, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?26/7/26742/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 12, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Labor is the physiological process by which a fetus is expelled from the uterus to the outside world. This topic will discuss the process of normal labor and delivery. Management of labor and delivery is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/21/33114?source=see_link\">",
"     \"Management of normal labor and delivery\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Labor is a physiological event involving a sequential, integrated set of changes within the myometrium, decidua, and uterine cervix that occurs sometimes gradually over a period of days to weeks and sometimes rapidly over minutes to hours and culminates in delivery of the fetus. Biochemical connective tissue changes in the uterine cervix appear to precede uterine contractions and cervical dilation, and all of these events usually occur before rupture of the fetal membranes. These physiological changes are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/0/6153?source=see_link\">",
"     \"Physiology of parturition\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     MECHANICS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Uterine contractions during active labor have two major functions: to dilate the cervix and to push the fetus through the birth canal. However, the fetus is not merely the passive recipient of these forces, rather, its ability to successfully negotiate the pelvis is dependent upon the complex interaction of three mechanical variables, known as the \"three Ps\": the powers, the passenger, and the passage.",
"   </p>",
"   <p>",
"    The effect of maternal obesity on labor is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/11/29882?source=see_link\">",
"     \"The impact of obesity on fertility and pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Powers (uterine contractions)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Powers refer to the force generated by the uterine musculature during contractions. It is generally believed that the more optimal the powers, the more likely a successful outcome; however, there are no data to support this statement.",
"   </p>",
"   <p>",
"    Uterine activity can be assessed qualitatively by simple observation of the mother and palpation of the fundus of the uterus through the abdomen or by external tocodynamometry. Both methods provide information about the frequency (number of contractions in an average 10 minute window), intensity, and duration of the contractions. It can also be measured quantitatively by direct measurement of intrauterine pressure via internal manometry or pressure transducers. There is no evidence that one method is significantly better than another [",
"    <a class=\"abstract\" href=\"UTD.htm?26/7/26742/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Despite technological improvements, the criteria for adequate uterine activity during labor are unclear. Classically, the occurrence of three to five contractions in 10 minutes has been used to define adequate labor, and is observed in about 95 percent of women in spontaneous labor at term. The advent of intrauterine pressure transducers has enabled objective measurement of uterine activity, which is quantitated using Montevideo units (Montevideo units are calculated by multiplying the average peak strength of contractions in mm Hg by the number of contractions in 10 minutes). Using this method, adequate labor is usually observed with 200 to 250 Montevideo units [",
"    <a class=\"abstract\" href=\"UTD.htm?26/7/26742/abstract/2\">",
"     2",
"    </a>",
"    ]. These criteria are supported by a retrospective series in which 91 percent of women in spontaneous active labor achieved contractile activity greater than 200 Montevideo units and 40 percent reached 300 Montevideo units [",
"    <a class=\"abstract\" href=\"UTD.htm?26/7/26742/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Passenger (fetus)",
"    </span>",
"    &nbsp;&mdash;&nbsp;The passenger is the fetus. There are several fetal variables that can affect the course of labor, including:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Fetal size",
"     </li>",
"     <li>",
"      Lie (the long axis of the fetus relative to the longitudinal axis of the uterus). Fetal lie can be longitudinal, transverse, or oblique",
"     </li>",
"     <li>",
"      Presentation (the fetal part that directly overlies the pelvic inlet). Presentation is usually vertex or breech; shoulder, compound (eg, vertex and hand), and funic (umbilical cord) presentations are other possibilities",
"     </li>",
"     <li>",
"      Attitude (degree of",
"      <span class=\"nowrap\">",
"       flexion/extension",
"      </span>",
"      of the fetal head). The fetal head is in flexion when the chin approaches the chest and in extension when the occiput nears the back",
"     </li>",
"     <li>",
"      Position (relationship of a nominated site of the presenting part to a denominating location on the maternal pelvis, eg, right occiput anterior). Asynclitism refers to lateral deflection of the fetal head such that the sagittal suture is deflected anteriorly toward the symphysis or posteriorly toward the sacrum.",
"     </li>",
"     <li>",
"      Station (degree of descent of the leading edge of the presenting part of the fetus, typically measured as distance in centimeters between the leading bony edge of the fetus and the ischial spines)",
"     </li>",
"     <li>",
"      Number of fetuses",
"     </li>",
"     <li>",
"      Presence of fetal anomalies (eg, sacrococcygeal teratoma)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A small fetus in longitudinal lie, with vertex presentation, a flexed head in anterior position that has passed through the pelvic inlet is the ideal candidate for negotiating the maternal pelvis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Passage (pelvis)",
"    </span>",
"    &nbsp;&mdash;&nbsp;The passage consists of the bony pelvis (",
"    <a class=\"graphic graphic_figure graphicRef60078 graphicRef50612 \" href=\"UTD.htm?9/14/9448\">",
"     figure 1A-B",
"    </a>",
"    ) and the soft tissues of the birth canal (cervix, pelvic floor musculature), both of which offer varying degrees of resistance to fetal expulsion. The bony pelvis is assessed by pelvimetry (ie, quantitative measurement of pelvic capacity), which can be performed clinically or via imaging studies (x-ray, computed tomography, magnetic resonance imaging (",
"    <a class=\"graphic graphic_figure graphicRef72077 graphicRef51127 \" href=\"UTD.htm?34/45/35545\">",
"     figure 2A-B",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?26/7/26742/abstract/4-6\">",
"     4-6",
"    </a>",
"    ]). Average and critical limit values for the various parameters of the bony pelvis have been established; however, such measurements are of limited clinical value as they are not able to consistently predict women at risk for cephalopelvic disproportion [",
"    <a class=\"abstract\" href=\"UTD.htm?26/7/26742/abstract/7\">",
"     7",
"    </a>",
"    ]. Pelvimetry has been replaced, in large part, by clinical trial of the pelvis (a \"trial of labor\").",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     STAGES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although labor is a continuous process, it has traditionally been divided into three stages to facilitate study and to assist in clinical management.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     First stage",
"    </span>",
"    &nbsp;&mdash;&nbsp;The first stage refers to the interval between the onset of labor and full cervical dilatation. It has been subdivided [",
"    <a class=\"abstract\" href=\"UTD.htm?26/7/26742/abstract/8,9\">",
"     8,9",
"    </a>",
"    ] into three phases according to the rate of cervical dilatation (",
"    <a class=\"graphic graphic_figure graphicRef53413 \" href=\"UTD.htm?40/54/41837\">",
"     figure 3",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Latent phase &mdash; The period between the onset of labor and the point at which a change in the slope of the rate of cervical dilatation is noted [",
"      <a class=\"abstract\" href=\"UTD.htm?26/7/26742/abstract/8,9\">",
"       8,9",
"      </a>",
"      ]. It is characterized by slow cervical dilatation, and is of variable duration.",
"     </li>",
"     <li>",
"      Active phase &mdash; This phase is associated with a faster rate of cervical dilatation and usually begins by 2 to 4 cm of cervical dilatation [",
"      <a class=\"abstract\" href=\"UTD.htm?26/7/26742/abstract/8-10\">",
"       8-10",
"      </a>",
"      ]. The active phase is broken down further into an acceleration phase, a phase of maximum slope, and a deceleration phase, but these subdivisions are rarely employed today.",
"     </li>",
"     <li>",
"      Descent phase &mdash; Descent of the fetus usually coincides with the second stage of labor. Not all investigators accept the existence of a separate descent phase.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The characteristics of the labor curve do not appear to differ among varying",
"    <span class=\"nowrap\">",
"     racial/ethnic",
"    </span>",
"    groups [",
"    <a class=\"abstract\" href=\"UTD.htm?26/7/26742/abstract/11\">",
"     11",
"    </a>",
"    ], but there are significant differences between the labor curves of nulliparous and multiparous women. In classic studies, Friedman determined the average duration for each stage of labor in these two groups of parturients and calculated the maximum duration of each stage, defined as two standard deviations (SD) from the mean (",
"    <a class=\"graphic graphic_table graphicRef76118 \" href=\"UTD.htm?8/47/8956\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?26/7/26742/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. As an example, the minimum rate of cervical dilatation of 1.2 cm per hour for a nulliparous patient represents two SD",
"    <strong>",
"     below",
"    </strong>",
"    the mean rate of cervical dilatation for nulliparas, not the average rate of dilatation among these women (which is 3",
"    <span class=\"nowrap\">",
"     cm/h).",
"    </span>",
"   </p>",
"   <p>",
"    By comparing a parturient's rate of cervical dilatation with the normal profile described by Friedman, it is possible to detect abnormal labor patterns and thus identify pregnancies at risk for adverse events. This task can be facilitated by use of a partogram (",
"    <a class=\"graphic graphic_figure graphicRef65542 \" href=\"UTD.htm?28/54/29551\">",
"     figure 4",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?26/7/26742/abstract/12\">",
"     12",
"    </a>",
"    ], which is a graphical representation of the labor curve against which a patient's progress in labor is plotted. In this way, abnormal labor patterns can easily be identified and appropriate measures taken. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/2/11306?source=see_link\">",
"     \"Abnormal labor: Protraction and arrest disorders\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Friedman's curves were derived from studying laboring women in the 1950s. The subject was revisited in a more recent study which measured the duration of active labor (first and second stages) in 2511 low-risk women at term whom received intrapartum care from certified nurse-midwives in nine hospital settings in the United States and did not receive",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/0/5125?source=see_link\">",
"     oxytocin",
"    </a>",
"    or epidurals [",
"    <a class=\"abstract\" href=\"UTD.htm?26/7/26742/abstract/13\">",
"     13",
"    </a>",
"    ]. The mean length of the active-phase, first stage was 7.7 hours for nulliparas and 5.6 hours for multiparas (statistical limits of 2 standard deviations from the mean were 17.5 and 13.8 hours, respectively). The mean length of second stage was 54 minutes for nulliparas and 18 minutes for multiparas (statistical limits 146 and 64 minutes, respectively). Variables associated with longer labors were electronic fetal monitoring, ambulation, maternal age over 30 years, and narcotic analgesia.",
"   </p>",
"   <p>",
"    Others have also noted that the pattern of labor progression in contemporary practice is slower than described by Friedman [",
"    <a class=\"abstract\" href=\"UTD.htm?26/7/26742/abstract/14-16\">",
"     14-16",
"    </a>",
"    ]. These studies suggest that current diagnostic criteria for protraction and arrest disorders of labor may be too stringent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Second stage",
"    </span>",
"    &nbsp;&mdash;&nbsp;The second stage of labor refers to the interval between full cervical dilatation (10 cm) and delivery of the infant. It is characterized by descent of the presenting part through the maternal pelvis and culminates with expulsion of the fetus. The second stage of labor has been demonstrated to differ both by",
"    <span class=\"nowrap\">",
"     race/ethnicity",
"    </span>",
"    and maternal parity, but not by maternal obesity [",
"    <a class=\"abstract\" href=\"UTD.htm?26/7/26742/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Indications that the second stage has started are an increase in bloody show, maternal desire to bear down with each contraction, a feeling of pressure on the rectum accompanied by the desire to defecate, and onset of nausea and vomiting [",
"    <a class=\"abstract\" href=\"UTD.htm?26/7/26742/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The mother typically assumes a more active role in the second stage than the first stage, as she \"pushes\" to aid descent of the fetus. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/21/33114?source=see_link\">",
"     \"Management of normal labor and delivery\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Third stage",
"    </span>",
"    &nbsp;&mdash;&nbsp;The third stage of labor refers to the time from delivery of the baby to separation and expulsion of the placenta. The major complication associated with this period is hemorrhage, which remains an important cause of maternal morbidity and mortality. There are no uniform criteria for the normal length of the third stage of labor. Retention of the placenta for longer than 30 minutes at term is a commonly used endpoint for intervention in the absence of complications (eg, hemorrhage). The World Health Organization defines a retained placenta as one that has not been expelled by 60 minutes after delivery [",
"    <a class=\"abstract\" href=\"UTD.htm?26/7/26742/abstract/19\">",
"     19",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/42/41639?source=see_link\">",
"     \"Uterotonic drugs for management of the third stage of labor\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Precipitate labor and delivery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Precipitate or precipitous labor and delivery refers to a rapid labor and delivery of the fetus, variously defined as expulsion of the fetus within two to three hours of commencement of contractions [",
"    <a class=\"abstract\" href=\"UTD.htm?26/7/26742/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. It is rare, and not well-studied.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     CARDINAL MOVEMENTS OF LABOR",
"    </span>",
"    &nbsp;&mdash;&nbsp;The cardinal movements of labor refer to changes in the position of the fetal head during its passage through the birth canal (",
"    <a class=\"graphic graphic_figure graphicRef52812 \" href=\"UTD.htm?25/17/25881\">",
"     figure 5",
"    </a>",
"    ). Because of asymmetry in both the shape of the fetal head and the maternal bony pelvis, such rotations are required if the fetus is to successfully negotiate the birth canal.",
"   </p>",
"   <p>",
"    Seven discrete cardinal movements of the fetus occur over the course of labor and delivery: engagement, descent, flexion, internal rotation, extension, external rotation or restitution, and expulsion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Engagement",
"    </span>",
"    &nbsp;&mdash;&nbsp;Engagement refers to the passage of the widest diameter of the presenting part to a level below the plane of the pelvic inlet. In the cephalic presentation with a well-flexed head, the largest transverse diameter of the fetal head is the biparietal diameter (9.5 cm) (",
"    <a class=\"graphic graphic_figure graphicRef81518 \" href=\"UTD.htm?16/32/16898\">",
"     figure 6",
"    </a>",
"    ). In the breech presentation, the widest diameter is the bitrochanteric diameter. Engagement can be confirmed clinically by palpation of the presenting part abdominally",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    vaginally. The head is assumed to be engaged if the leading edge has reached the ischial spines and there is no significant molding or scalp edema (",
"    <a class=\"graphic graphic_figure graphicRef50019 \" href=\"UTD.htm?27/16/27906\">",
"     figure 7",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Descent",
"    </span>",
"    &nbsp;&mdash;&nbsp;Descent refers to the downward passage of the presenting part through the pelvis. Descent of the fetus is not a steady, continuous process. The greatest rate of descent occurs during the deceleration phase of the first stage and during the second stage of labor.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Flexion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Flexion of the fetal head occurs passively as the head descends due to resistance related to the shape of the bony pelvis and by the soft tissues of the pelvic floor. Although flexion of the fetal head onto the chest is present to some degree in most fetuses antepartum, complete flexion usually only occurs during the course of labor. With the head completely flexed, the fetus presents the smallest diameter of its head (suboccipito-bregmatic diameter) (",
"    <a class=\"graphic graphic_figure graphicRef62883 \" href=\"UTD.htm?12/61/13267\">",
"     figure 8",
"    </a>",
"    ), thereby allowing optimal passage through the pelvis. A deflexed head presents a larger diameter, which may be too large to negotiate the pelvic bone (",
"    <a class=\"graphic graphic_figure graphicRef58159 \" href=\"UTD.htm?29/38/30305\">",
"     figure 9",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Internal rotation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Internal rotation is the rotation of the presenting part from its original position (usually transverse with regard to the birth canal) to the anteroposterior position as it passes through the pelvis. As with flexion, internal rotation is a passive movement resulting from the shape of the pelvis and the resistance of the pelvic floor musculature.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Extension",
"    </span>",
"    &nbsp;&mdash;&nbsp;Extension occurs once the fetus has descended to the level of the introitus. This descent brings the base of the occiput into contact with the inferior margin of the symphysis pubis. At this point, the birth canal curves upwards. The fetal head is delivered by extension and rotates around the symphysis pubis. The forces responsible for this motion are the downward force exerted on the fetus by uterine contractions and maternal expulsive efforts along with the upward forces exerted by the muscles of the pelvic floor.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     External rotation (restitution)",
"    </span>",
"    &nbsp;&mdash;&nbsp;After the fetal head deflexes (extends), it rotates to the correct anatomic position in relation to the fetal torso; left or right rotation depends on the orientation of the fetus. This is again a passive movement resulting from a release of the forces exerted on the fetal head by the maternal bony pelvis and its musculature and mediated by the basal tone of the fetal musculature.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Expulsion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Expulsion refers to delivery of the body of the fetus. After delivery of the head and external rotation, further descent brings the anterior shoulder to the level of the symphysis pubis. The anterior shoulder rotates under the symphysis pubis, after which the rest of the body usually delivers without difficulty.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?12/13/12499?source=see_link\">",
"       \"Patient information: Labor and delivery (childbirth) (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?4/2/4131?source=see_link\">",
"       \"Patient information: How to tell when labor starts (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Labor involves a sequential, integrated set of changes within the myometrium, decidua, and uterine cervix that occur sometimes gradually over a period of days to weeks and sometimes rapidly over minutes to hours and culminate in delivery of the fetus. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Physiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The three main factors which affect the mechanics of active labor are the powers, the passenger, and the passage. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Mechanics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The occurrence of three to five contractions in 10 minutes has been used to define adequate labor, and is seen in about 95 percent of women in spontaneous labor at term. Adequate labor can be defined as 200 to 250 Montevideo units when using an intrauterine pressure catheter. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Powers (uterine contractions)'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Fetal factors affecting the course of labor include size, lie, presentation, attitude, position, station, number, and presence of anomalies. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Passenger (fetus)'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Pelvimetry to assess the passage is of limited clinical value as no method is able to consistently predict women at risk for cephalopelvic disproportion. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Passage (pelvis)'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The first stage of labor can be described according to the rate of cervical dilatation (",
"      <a class=\"graphic graphic_figure graphicRef53413 \" href=\"UTD.htm?40/54/41837\">",
"       figure 3",
"      </a>",
"      ). The second stage refers to the interval between full cervical dilatation (10 cm) and delivery of the infant, and the third stage refers to the time from delivery of the baby to separation and expulsion of the placenta. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Stages'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The cardinal movements of labor refer to changes in the position of the fetal head during its passage through the birth canal (",
"      <a class=\"graphic graphic_figure graphicRef52812 \" href=\"UTD.htm?25/17/25881\">",
"       figure 5",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Cardinal movements of labor'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/7/26742/abstract/1\">",
"      Chua S, Kurup A, Arulkumaran S, Ratnam SS. Augmentation of labor: does internal tocography result in better obstetric outcome than external tocography? Obstet Gynecol 1990; 76:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/7/26742/abstract/2\">",
"      CALDEYRO-BARCIA R, SICA-BLANCO Y, POSEIRO JJ, et al. A quantitative study of the action of synthetic oxytocin on the pregnant human uterus. J Pharmacol Exp Ther 1957; 121:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/7/26742/abstract/3\">",
"      Hauth JC, Hankins GD, Gilstrap LC 3rd, et al. Uterine contraction pressures with oxytocin induction/augmentation. Obstet Gynecol 1986; 68:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/7/26742/abstract/4\">",
"      van Loon AJ, Mantingh A, Serlier EK, et al. Randomised controlled trial of magnetic-resonance pelvimetry in breech presentation at term. Lancet 1997; 350:1799.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/7/26742/abstract/5\">",
"      Raman S, Samuel D, Suresh K. A comparative study of X-ray pelvimetry and CT pelvimetry. Aust N Z J Obstet Gynaecol 1991; 31:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/7/26742/abstract/6\">",
"      Zaretsky MV, Alexander JM, McIntire DD, et al. Magnetic resonance imaging pelvimetry and the prediction of labor dystocia. Obstet Gynecol 2005; 106:919.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/7/26742/abstract/7\">",
"      Pattinson RC. Pelvimetry for fetal cephalic presentations at term. Cochrane Database Syst Rev 2000; :CD000161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/7/26742/abstract/8\">",
"      FRIEDMAN E. The graphic analysis of labor. Am J Obstet Gynecol 1954; 68:1568.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/7/26742/abstract/9\">",
"      FRIEDMAN EA. Primigravid labor; a graphicostatistical analysis. Obstet Gynecol 1955; 6:567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/7/26742/abstract/10\">",
"      Peisner DB, Rosen MG. Transition from latent to active labor. Obstet Gynecol 1986; 68:448.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/7/26742/abstract/11\">",
"      Duignan NM, Studd JW, Hughes AO. Characteristics of normal labour in different racial groups. Br J Obstet Gynaecol 1975; 82:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/7/26742/abstract/12\">",
"      Studd J. Partograms and nomograms of cervical dilatation in management of primigravid labour. Br Med J 1973; 4:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/7/26742/abstract/13\">",
"      Albers LL. The duration of labor in healthy women. J Perinatol 1999; 19:114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/7/26742/abstract/14\">",
"      Zhang J, Troendle JF, Yancey MK. Reassessing the labor curve in nulliparous women. Am J Obstet Gynecol 2002; 187:824.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/7/26742/abstract/15\">",
"      Cesario SK. Reevaluation of Friedman's Labor Curve: a pilot study. J Obstet Gynecol Neonatal Nurs 2004; 33:713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/7/26742/abstract/16\">",
"      Zhang J, Troendle J, Mikolajczyk R, et al. The natural history of the normal first stage of labor. Obstet Gynecol 2010; 115:705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/7/26742/abstract/17\">",
"      Greenberg, M, Caughey, AB, Hopkins, LM, Stotland, NE, et al. Does the length of labor vary by ethnicity? Am J Obstet Gynecol 2005; 193:S41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/7/26742/abstract/18\">",
"      Diegmann EK, Andrews CM, Niemczura CA. The length of the second stage of labor in uncomplicated, nulliparous African American and Puerto Rican women. J Midwifery Womens Health 2000; 45:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/7/26742/abstract/19\">",
"      World Health Organization. Maternal and Child Health and Family Planning. The prevention and management of postpartum haemorrhage. Report of a technical working group. WHO/MCH 1990; 90.7:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/7/26742/abstract/20\">",
"      Sheiner E, Levy A, Mazor M. Precipitate labor: higher rates of maternal complications. Eur J Obstet Gynecol Reprod Biol 2004; 116:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/7/26742/abstract/21\">",
"      Erkkola R, Nikkanen V. Precipitate labour. Ann Chir Gynaecol 1978; 67:150.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4448 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-122.72.76.133-906C751B57-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_7_26742=[""].join("\n");
var outline_f26_7_26742=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H20\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      MECHANICS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Powers (uterine contractions)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Passenger (fetus)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Passage (pelvis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      STAGES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      First stage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Second stage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Third stage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Precipitate labor and delivery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      CARDINAL MOVEMENTS OF LABOR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Engagement",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Descent",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Flexion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Internal rotation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Extension",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      External rotation (restitution)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Expulsion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/4448\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/4448|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?33/45/34513\" title=\"figure 1A\">",
"      Female pelvic bones",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?14/8/14468\" title=\"figure 1B\">",
"      Pelvic shapes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?19/11/19637\" title=\"figure 2A\">",
"      Pelvimetry 1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?23/54/24421\" title=\"figure 2B\">",
"      Pelvimetry 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?40/54/41837\" title=\"figure 3\">",
"      Labor curve",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?28/54/29551\" title=\"figure 4\">",
"      Partogram form",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?25/17/25881\" title=\"figure 5\">",
"      Cardinal movements labor",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?16/32/16898\" title=\"figure 6\">",
"      Fontanelles and suture lines",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?27/16/27906\" title=\"figure 7\">",
"      Engaged vertex",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?12/61/13267\" title=\"figure 8\">",
"      Diameters of the fetal head at term",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?29/38/30305\" title=\"figure 9\">",
"      Flexion deflexion vertex",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/4448|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?8/47/8956\" title=\"table 1\">",
"      Criteria for normal labor",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/2/11306?source=related_link\">",
"      Abnormal labor: Protraction and arrest disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/21/33114?source=related_link\">",
"      Management of normal labor and delivery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?4/2/4131?source=related_link\">",
"      Patient information: How to tell when labor starts (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?12/13/12499?source=related_link\">",
"      Patient information: Labor and delivery (childbirth) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/0/6153?source=related_link\">",
"      Physiology of parturition",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/11/29882?source=related_link\">",
"      The impact of obesity on fertility and pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/42/41639?source=related_link\">",
"      Uterotonic drugs for management of the third stage of labor",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_7_26743="Tramadol: Pediatric drug information";
var content_f26_7_26743=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Tramadol: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?41/50/42792?source=see_link\">",
"    see \"Tramadol: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?30/5/30805?source=see_link\">",
"    see \"Tramadol: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F229623\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      ConZip&trade;;",
"     </li>",
"     <li>",
"      Rybix&trade; ODT;",
"     </li>",
"     <li>",
"      Ryzolt&trade;;",
"     </li>",
"     <li>",
"      Ultram&reg;;",
"     </li>",
"     <li>",
"      Ultram&reg; ER",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F229624\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Durela&trade;;",
"     </li>",
"     <li>",
"      Ralivia&trade;;",
"     </li>",
"     <li>",
"      Tridural&trade;;",
"     </li>",
"     <li>",
"      Ultram&reg;;",
"     </li>",
"     <li>",
"      Zytram&reg; XL",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F2102599\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Analgesic, Opioid",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F2103111\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?41/50/42792?source=see_link\">",
"      see \"Tramadol: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Moderate to severe pain:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children and Adolescents 4-16 years: Immediate release tablet or liquid: 1-2 mg/kg/dose every 4-6 hours; maximum single dose: 100 mg; maximum total daily dose is the lesser of: 8 mg/kg/day",
"     <b>",
"      or",
"     </b>",
"     400 mg/day (Finkel, 2002; Payne, 2002; Rose, 2003)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adolescents &ge;16 years and Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Immediate release formulations:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Tablet: 50-100 mg every 4-6 hours; maximum total daily dose: 400 mg/day. For patients not requiring rapid onset of effect, tolerability to adverse effects may be improved by initiating therapy at 25 mg/day and titrating dose by 25 mg every 3 days until 25 mg 4 times/day is reached. Dose may then be increased by 50 mg every 3 days as tolerated to reach 50 mg 4 times/day.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Orally-disintegrating tablet (Rybix&trade; ODT): 50-100 mg every 4-6 hours; maximum total daily dose: 400 mg/day. For patients not requiring rapid onset of effect, tolerability to adverse effects may be improved by initiating therapy at 50 mg/day and titrating dose by 50 mg every 3 days until 50 mg 4 times/day is reached; maximum total daily dose: 400 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Extended release formulations:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Ryzolt&trade;: Initial: 100 mg once daily; titrate by 100 mg increments every 2-3 days if needed for pain control; maximum total daily dose: 300 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Ultram&reg; ER: Adults &ge;18 years: 100 mg once daily; titrate by 100 mg increments every 5 days if needed for pain relief; maximum: 300 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosing adjustment in hepatic impairment:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Immediate release formulations: Adults: Cirrhosis: Recommended dose: 50 mg every 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Extended release formulations:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Ultram&reg; ER: Do not use in patients with severe (Child-Pugh Class C) hepatic impairment",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Ryzolt&trade;: Do not use in patients with any degree of hepatic impairment",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Dosing adjustment in renal impairment:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Immediate release formulations: Adults: Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute: Administer 50-100 mg dose every 12 hours (maximum: 200 mg/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Extended release formulations: Do not use in patients with Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F229595\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, variable release, oral, as hydrochloride: 150 mg [37.5 mg (immediate release) and 112.5 mg (extended release)]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     ConZip&trade;: 100 mg [25 mg (immediate release) and 75 mg (extended release)]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     ConZip&trade;: 200 mg [50 mg (immediate release) and 150 mg (extended release)]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     ConZip&trade;: 300 mg [50 mg (immediate release) and 250 mg (extended release)]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as hydrochloride: 50 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ultram&reg;: 50 mg [scored]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, extended release, oral, as hydrochloride: 100 mg, 200 mg, 300 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ryzolt&trade;: 100 mg, 200 mg, 300 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ultram&reg; ER: 100 mg, 200 mg, 300 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, orally disintegrating, oral, as hydrochloride:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Rybix&trade; ODT: 50 mg [contains aspartame; mint flavor]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F229580\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Excludes tablet (orally disintegrating)",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F2103999\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Immediate release tablet: May administer with or without food, but it is recommended that it be administered in a consistent manner.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Extended release tablet: Swallow whole with a sufficient amount of liquid. Do not crush, cut, dissolve, or chew extended release tablet; tablet should be taken once daily at approximately the same time each day.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Orally disintegrating tablet: Remove from foil blister by peeling back (do not push tablet through the foil). Place tablet on tongue and allow to dissolve (may take ~1 minute); water is not needed but may be administered with water. Do not chew, break, or split tablet.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F2103108\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store at 25&deg;C (77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F); protect from light; dispense in a tight container.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F2103101\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Immediate release formulations: Relief of moderate to moderately-severe pain (Ultram&reg;: FDA approved in ages &ge;17 years and adults; Rybix&trade; ODT: FDA approved in ages &ge;16 years and adults), including postoperative, cancer, neuropathic, low back pain, and pain associated with orthopedic disorders)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Extended release formulations: For patients requiring around-the-clock management of moderate to moderately-severe pain for an extended period of time (Ryzolt&trade;: FDA approved in ages &ge;16 years and adults; Ultram&reg; ER: FDA approved in ages &ge;18 years and adults)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F229681\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       TraMADol may be confused with tapentadol, Toradol&reg;, Trandate&reg;, traZODone, Voltaren&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Ultram&reg; may be confused with Ultane&reg;, Ultracet&reg;, Voltaren&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      International issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Theradol [Netherlands] may be confused with Foradil brand name for formoterol [U.S., Canada, and multiple international markets], Terazol brand name for terconazole [U.S. and Canada], and Toradol brand name for ketorolac [Canada and multiple international markets]",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Trexol [Mexico] may be confused with Trexall brand name for methotrexate [U.S.]; Truxal brand name for chlorprothixene [multiple international markets]",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F229679\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Chest pain, flushing, hypertension, peripheral edema, orthostatic hypotension, vasodilation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Agitation, anxiety, apathy, chills, confusion, coordination impaired, depersonalization, depression, dizziness, euphoria, fatigue, fever, headache, hypoesthesia, insomnia, lethargy, malaise, nervousness, pain, pyrexia, restlessness, somnolence, vertigo",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Dermatitis, pruritus, rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hot flashes, hyperglycemia, menopausal symptoms",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, anorexia, appetite decreased, constipation, diarrhea, dyspepsia, flatulence, nausea, vomiting, weight loss, xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Pelvic pain, prostatic disorder, urinary frequency, urinary retention, urinary tract infection, urine abnormalities",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthralgia, back pain, creatine phosphokinase increased, hypertonia, myalgia, neck pain, paresthesia, rigors, tremor, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Blurred vision, miosis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Bronchitis, congestion (nasal/sinus), cough, dyspnea, nasopharyngitis, pharyngitis, rhinitis, rhinorrhea, sinusitis, sneezing, sore throat, upper respiratory infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Diaphoresis, flu-like syndrome, shivering, withdrawal syndrome",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Abnormal gait, allergic reaction, amnesia, anaphylactoid reactions, anaphylaxis, anemia, angioedema, appendicitis, ALT increased/decreased, AST increased/decreased, bradycardia, bronchospasm, BUN increased, cataracts, cellulitis, cholecystitis, cholelithiasis, clamminess, cognitive dysfunction, concentration difficulty, creatinine increased, deafness, disorientation, diverticulitis, dreams abnormal, dysphagia, dysuria, ear infection, ECG abnormalities, edema, fecal impaction, gastroenteritis, gastrointestinal bleeding, GGT increased, gout, hallucination, hematuria, hemoglobin decreased, hepatitis, hypotension, hypersensitivity, irritability, joint stiffness, libido decreased, liver enzymes increased, liver failure, menstrual disorder, MI, migraine, muscle cramps, muscle spasms, muscle twitching, myocardial ischemia, night sweats, palpitation, pancreatitis, peripheral edema, peripheral ischemia, pneumonia, proteinuria, pulmonary edema, pulmonary embolism, sedation, seizure, serotonin syndrome, sleep disorder, speech disorder, Stevens-Johnson syndrome, stomatitis, suicidal tendency, syncope, taste perversion, tachycardia, thrombocytopenia, tinnitus, toxic epidermal necrolysis, urticaria, vesicles, visual disturbance",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     A withdrawal syndrome may include anxiety, diarrhea, hallucinations (rare), nausea, pain, piloerection, rigors, sweating, and tremor. Uncommon discontinuation symptoms may include severe anxiety, panic attacks, or paresthesia.",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F2103103\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to tramadol, opioids, or any component; opioid-dependent patients; acute intoxication with alcohol, hypnotics, centrally-acting analgesics, opioids, or psychotropic drugs",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tramadol extended release tablets: Patients with severe renal impairment (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute) or severe hepatic impairment (Child-Pugh Class C) since the extended release dosage form does not permit dosing flexibility required in this patient population; patients with severe/acute bronchial asthma, hypercapnia, or significant respiratory depression in the absence of an appropriately monitored setting and resuscitation equipment",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F2103117\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution and reduce dosage when administered to patients receiving other CNS depressants (may cause CNS depression and/or respiratory depression when combined with other CNS depressants). Use with caution and reduce dosage in patients with liver disease, renal impairment, myxedema, hypothyroidism, or hypoadrenalism. Orally disintegrating tablet (Rybix&trade; ODT) contains aspartame which is metabolized to phenylalanine and must be used with caution in patients with phenylketonuria. Use may complicate clinical assessment of patients with acute abdominal conditions.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F2103104\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Tramadol should only be used with",
"     <b>",
"      EXTREME",
"     </b>",
"     caution in patients receiving MAO inhibitors due to increased risk of seizures and serotonin syndrome. Serotonin syndrome (eg, agitation, hallucinations, coma, tachycardia, labile blood pressure, hyperthermia, hyper-reflexia, incoordination, nausea, vomiting, diarrhea) may occur with concomitant use of tramadol and SSRIs, tricyclic antidepressants, MAOIs, triptans, linezolid, SNRIs, or drugs which impair tramadol metabolism (CYP2D6 and CYP3A4 inhibitors). An increased risk of seizures has been reported; the risk of seizures increases with doses above the recommended range or if naloxone administration is used to treat tramadol overdose; use with caution in patients with a history or an increased risk of seizures (eg, head trauma, increased intracranial pressure, metabolic disorders, CNS infection, malignancy, drug withdrawal).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Use associated with increased risk of suicide in patients already prone to addiction and/or taking tranquilizers or antidepressant drugs. Avoid use in patients who are suicidal or addiction prone. Tramadol interacts with alcohol and drugs of abuse and is subject to overdose, misuse, abuse, and diversion. Tolerance or drug dependence may result from extended use (withdrawal symptoms have been reported); abrupt discontinuation should be avoided. Tapering of dose at the time of discontinuation reduces the risk of withdrawal symptoms.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Not recommended for use during pregnancy or in nursing mothers; neonatal seizures, neonatal withdrawal syndrome, and fetal death have been reported.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F229665\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP2B6 (minor), CYP2D6 (major), CYP3A4 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F229589\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alvimopan: Analgesics (Opioid) may enhance the adverse/toxic effect of Alvimopan. This is most notable for patients receiving long-term (i.e., more than 7 days) opiates prior to alvimopan initiation.  Management: Alvimopan is contraindicated in patients receiving therapeutic doses of opioids for more than 7 consecutive days immediately prior to alvimopan initiation.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ammonium Chloride: May increase the excretion of Analgesics (Opioid).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphetamines: May enhance the analgesic effect of Analgesics (Opioid).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antiemetics (5HT3 Antagonists): May diminish the analgesic effect of TraMADol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotic Agents (Phenothiazines): May enhance the hypotensive effect of Analgesics (Opioid).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotics: May enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: TraMADol may enhance the CNS depressant effect of CarBAMazepine. TraMADol may diminish the therapeutic effect of CarBAMazepine. CarBAMazepine may decrease the serum concentration of TraMADol.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Conivaptan: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cyclobenzaprine: May enhance the neuroexcitatory and/or seizure-potentiating effect of TraMADol. Cyclobenzaprine may enhance the serotonergic effect of TraMADol. This could result in serotonin syndrome. Management: Seek alternatives.  If these agents are given in combination, monitor for seizure activity and signs and symptoms of serotonin toxicity/serotonin syndrome.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Inhibitors (Moderate): May diminish the therapeutic effect of TraMADol. These CYP2D6 inhibitors may prevent the metabolic conversion of tramadol to its active metabolite that accounts for much of its opioid-like effects.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Inhibitors (Strong): May diminish the therapeutic effect of TraMADol. These CYP2D6 inhibitors may prevent the metabolic conversion of tramadol to its active metabolite that accounts for much of its opioid-like effects.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Desmopressin: Analgesics (Opioid) may enhance the adverse/toxic effect of Desmopressin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: TraMADol may enhance the neuroexcitatory and/or seizure-potentiating effect of MAO Inhibitors. TraMADol may enhance the serotonergic effect of MAO Inhibitors.  Management: Consider alternatives to combined treatment with tramadol and monoamine oxidase inhibitors due to an increased risk of serotonin syndrome and seizures. Avoid transdermal selegiline.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metoclopramide: Serotonin Modulators may enhance the adverse/toxic effect of Metoclopramide. This may be manifest as symptoms consistent with serotonin syndrome or neuroleptic malignant syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: CNS Depressants may enhance the sedative effect of Metyrosine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of CYP3A4 Substrates. Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mixed Agonist / Antagonist Opioids: May diminish the analgesic effect of Analgesics (Opioid). Management: Seek alternatives to mixed agonist/antagonist opioids in patients receiving pure opioid agonists, and monitor for symptoms of therapeutic failure/high dose requirements (or withdrawal in opioid-dependent patients) if patients receive these combinations.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pegvisomant: Analgesics (Opioid) may diminish the therapeutic effect of Pegvisomant.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: May enhance the neuroexcitatory and/or seizure-potentiating effect of TraMADol. TraMADol may enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This may cause serotonin syndrome.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: Analgesics (Opioid) may enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This may cause serotonin syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin Modulators: May enhance the adverse/toxic effect of other Serotonin Modulators. The development of serotonin syndrome may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Succinylcholine: May enhance the bradycardic effect of Analgesics (Opioid).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: Analgesics (Opioid) may enhance the orthostatic hypotensive effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tricyclic Antidepressants: May enhance the neuroexcitatory and/or seizure-potentiating effect of TraMADol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): TraMADol may enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F13162047\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Orally disintegrating tablet: Food delays the time to peak serum concentration by 30 minutes",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F229591\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F229604\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were observed in animal studies. Tramadol has been shown to cross the human placenta when administered during labor. Postmarketing reports following tramadol use during pregnancy include neonatal seizures, withdrawal syndrome, fetal death, and stillbirth. Not recommended for use during labor and delivery.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F2103112\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Pain relief, respiratory rate, blood pressure, and pulse; signs of tolerance, oversedation, withdrawal, abuse or suicidal ideation; renal and hepatic function",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F2103109\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Tramadol and its O-desmethyl metabolite bind to &mu;-opiate receptors in the CNS causing inhibition of ascending pain pathways, altering the perception of and response to pain; inhibits the reuptake of norepinephrine and serotonin which also modifies the ascending pain pathway",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F2103998\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Immediate release formulations:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: ~1 hour",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Maximum effect: 2-4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: 3-6 hours",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F2103110\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Immediate release formulation: Rapid and complete; extended release formulation: Delayed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 2.5-3 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 20%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Primarily hepatic via demethylation, glucuronidation, and sulfation; N-demethylation via CYP3A4; active O-desmethyltramadol metabolite formed by CYP2D6",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: Immediate release: 75%; extended release: 85% to 95% as compared to the immediate-release dosage form",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Tramadol: &sim;6-8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Active metabolite: 7-9 hours (prolonged in hepatic or renal impairment)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration: Immediate release formulations: 2 hours; extended release (formulation specific):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ultram&reg; ER: ~12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ryzolt&trade;: ~4-5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: Excreted in urine as unchanged drug (30%) and metabolites (60%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dialysis: &lt;7% removed in a 4-hour hemodialysis period",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F2103114\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?30/5/30805?source=see_link\">",
"      see \"Tramadol: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     While using this medication, avoid alcohol and other prescription or OTC medications (especially pain medications, sedatives, antihistamines, cough preparations or other narcotic-containing preparations) without consulting prescriber; may cause drowsiness and impair ability to perform activities requiring mental alertness or physical coordination. May be habit-forming; avoid abrupt discontinuation after prolonged use. Extended release tablet must be swallowed whole; do not break, chew, or crush.",
"    </p>",
"   </div>",
"   <div class=\"block exp drugH1Div\" id=\"F11509824\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Extemporaneous Preparations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     A 5 mg/mL oral suspension may be made with tablets and either Ora-Sweet&reg; SF or a mixture of 30 mL Ora-Plus&reg; and 30 mL strawberry syrup. Crush six 50 mg tramadol tablets in a mortar and reduce to a fine powder. Add small portions of the chosen vehicle and mix to a uniform paste; mix while adding vehicle in incremental proportions to",
"     <b>",
"      almost",
"     </b>",
"     60 mL; transfer to a calibrated bottle, rinse mortar with vehicle, and add quantity of vehicle sufficient to make 60 mL. Label \"shake well before use\". Stable for 90 days refrigerated or at room temperature.",
"    </p>",
"    <div class=\"reference\">",
"     Wagner DS, Johnson CE, Cichon-Hensley BK, et al, \"Stability of Oral Liquid Preparations of Tramadol in Strawberry Syrup and a Sugar-Free Vehicle,\"",
"     <i>",
"      Am J Health Syst Pharm",
"     </i>",
"     , 2003, 60(12):1268-70.",
"     <span class=\"pubmed-id\">",
"      12845924",
"     </span>",
"    </div>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Finkel JC, Rose JB, Schmitz ML, et al, \"An Evaluation of the Efficacy and Tolerability of Oral Tramadol Hydrochloride Tablets for the Treatment of Postsurgical Pain in Children,\"",
"      <i>",
"       Anesth Analg",
"      </i>",
"      , 2002, 94(6):1469-73.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/7/26743/abstract-text/12032009/pubmed\" id=\"12032009\" target=\"_blank\">",
"        12032009",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Payne KA, Roelofse JA, and Shipton EA, \"Pharmacokinetics of Oral Tramadol Drops for Postoperative Pain Relief in Children Aged 4 to 7 Years &minus; A Pilot Study,\"",
"      <i>",
"       Anesth Prog",
"      </i>",
"      , 2002, 49(4):109-12.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/7/26743/abstract-text/12779111/pubmed\" id=\"12779111\" target=\"_blank\">",
"        12779111",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rose JB, Finkel JC, Arquedas-Mohs A, et al, \"Oral Tramadol for the Treatment of Pain of 7-30 Days' Duration in Children,\"",
"      <i>",
"       Anesth Analg",
"      </i>",
"      , 2003, 96(1):78-81.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/7/26743/abstract-text/12505927/pubmed\" id=\"12505927\" target=\"_blank\">",
"        12505927",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12892 Version 41.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-58.240.98.179-6A22C7A760-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_7_26743=[""].join("\n");
var outline_f26_7_26743=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F229623\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F229624\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2102599\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2103111\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F229595\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F229580\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2103999\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2103108\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2103101\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F229681\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F229679\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2103103\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2103117\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2103104\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F229665\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F229589\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13162047\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F229591\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F229604\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2103112\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2103109\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2103998\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2103110\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2103114\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11509824\">",
"      Extemporaneous Preparations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12892\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12892|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?41/50/42792?source=related_link\">",
"      Tramadol: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?30/5/30805?source=related_link\">",
"      Tramadol: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_7_26744="Diagnosis of and screening for hypothyroidism";
var content_f26_7_26744=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Diagnosis of and screening for hypothyroidism",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/7/26744/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/7/26744/contributors\">",
"     Douglas S Ross, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/7/26744/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/7/26744/contributors\">",
"     David S Cooper, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/7/26744/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/7/26744/contributors\">",
"     Jean E Mulder, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?26/7/26744/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 6, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of hypothyroidism relies heavily upon laboratory tests because of the lack of specificity of the typical clinical manifestations. Primary hypothyroidism is characterized by a high serum thyrotropin (TSH) concentration and a low serum free thyroxine (T4) concentration, whereas subclinical hypothyroidism is defined biochemically as a normal free T4 concentration in the presence of an elevated TSH concentration. Secondary (central) hypothyroidism is characterized by a low serum T4 concentration and a serum TSH concentration that is not appropriately elevated.",
"   </p>",
"   <p>",
"    This topic will review diagnosis of and screening for hypothyroidism. The major clinical manifestations, causes, and treatment of hypothyroidism, and the diagnosis and management of subclinical hypothyroidism are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/10/14503?source=see_link\">",
"     \"Clinical manifestations of hypothyroidism\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/47/42744?source=see_link\">",
"     \"Disorders that cause hypothyroidism\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/53/43865?source=see_link\">",
"     \"Treatment of hypothyroidism\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/48/3850?source=see_link\">",
"     \"Subclinical hypothyroidism\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;In community surveys, the prevalence of overt hypothyroidism varies from 0.1 to 2 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?26/7/26744/abstract/1-5\">",
"     1-5",
"    </a>",
"    ]. The prevalence of subclinical hypothyroidism is higher, ranging from 4 to 10 percent of adults, with possibly a higher frequency in elderly women [",
"    <a class=\"abstract\" href=\"UTD.htm?26/7/26744/abstract/1,2,6,7\">",
"     1,2,6,7",
"    </a>",
"    ]. However, there is an age-related shift towards higher TSH concentrations in older patients and, therefore, if age-adjusted normal ranges are used, the prevalence may not increase with old age. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/33/3608?source=see_link&amp;anchor=H3#H3\">",
"     \"Laboratory assessment of thyroid function\", section on 'Serum TSH concentration'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Hypothyroidism is five to eight times more common in women than men, and more common in women with small body size at birth and during childhood [",
"    <a class=\"abstract\" href=\"UTD.htm?26/7/26744/abstract/5,8\">",
"     5,8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the United States National Health and Nutrition Examination Survey (NHANES III), 13,344 people without known thyroid disease or a family history of thyroid disease had measurements of serum TSH, T4, thyroglobulin antibodies, and thyroid peroxidase antibodies with the following results [",
"    <a class=\"abstract\" href=\"UTD.htm?26/7/26744/abstract/6\">",
"     6",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hypothyroidism was found in 4.6 percent (0.3 percent overt and 4.3 percent subclinical).",
"     </li>",
"     <li>",
"      Hyperthyroidism was found in 1.3 percent (0.5 percent overt and 0.7 percent subclinical).",
"     </li>",
"     <li>",
"      Serum thyroid peroxidase antibody concentrations were high in 11 percent.",
"     </li>",
"     <li>",
"      Mean serum TSH concentrations were significantly lower in blacks than in whites or Mexican-Americans.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, a significant proportion of the US population has laboratory evidence of thyroid disease, suggesting that routine screening could be useful. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Screening'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical manifestations of hypothyroidism are highly variable, depending upon the age at onset and the duration and severity of thyroid hormone deficiency. Common symptoms of thyroid hormone deficiency include fatigue, cold intolerance, weight gain, constipation, dry skin, myalgia, and menstrual irregularities (",
"    <a class=\"graphic graphic_table graphicRef62676 \" href=\"UTD.htm?41/41/42651\">",
"     table 1",
"    </a>",
"    ). Physical examination findings may include goiter (particularly in patients with iodine deficiency or goitrous chronic autoimmune thyroiditis [Hashimoto&rsquo;s thyroiditis]), bradycardia, hypertension, and a delayed relaxation phase of the deep tendon reflexes. In the majority of patients with chronic autoimmune thyroiditis, thyroid peroxidase antibodies are elevated. A variety of metabolic abnormalities may be present including hypercholesterolemia, macrocytic anemia, elevated creatine kinase, and hyponatremia [",
"    <a class=\"abstract\" href=\"UTD.htm?26/7/26744/abstract/9\">",
"     9",
"    </a>",
"    ]. The symptoms, signs, and metabolic abnormalities of hypothyroidism are discussed in more detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/10/14503?source=see_link\">",
"     \"Clinical manifestations of hypothyroidism\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because of the lack of specificity of the typical clinical manifestations, the diagnosis of hypothyroidism is based primarily upon laboratory testing.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Primary hypothyroidism is characterized by a high serum TSH concentration and a low serum free T4 concentration. Patients with a high serum TSH concentration and a normal serum free T4 concentration may have subclinical hypothyroidism. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/48/3850?source=see_link&amp;anchor=H5#H5\">",
"       \"Subclinical hypothyroidism\", section on 'Diagnosis'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/48/3850?source=see_link&amp;anchor=H6#H6\">",
"       \"Subclinical hypothyroidism\", section on 'Differential diagnosis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Central hypothyroidism is characterized by a low serum T4 concentration and a serum TSH concentration that is not appropriately elevated. In this setting, differentiation must be made between pituitary (secondary hypothyroidism) and hypothalamic (tertiary hypothyroidism) disorders. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/6/18536?source=see_link&amp;anchor=H22447146#H22447146\">",
"       \"Central hypothyroidism\", section on 'Diagnosis'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Primary hypothyroidism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary thyroid disease accounts for over 95 percent of cases of hypothyroidism.",
"   </p>",
"   <p>",
"    In most patients with symptoms or signs suggestive of hypothyroidism (",
"    <a class=\"graphic graphic_table graphicRef53510 \" href=\"UTD.htm?6/30/6638\">",
"     table 2",
"    </a>",
"    ), the serum TSH should be the initial test. If the serum TSH concentration is elevated, the TSH measurement should be repeated along with a serum free T4 to make the diagnosis of hypothyroidism (",
"    <a class=\"graphic graphic_table graphicRef67935 \" href=\"UTD.htm?26/20/26956\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If the repeat serum TSH value is still high and the serum free T4 is low, consistent with primary hypothyroidism, replacement therapy with T4 should be initiated. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/53/43865?source=see_link\">",
"       \"Treatment of hypothyroidism\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      If the repeat serum TSH value is still high but the serum free T4 value is within the normal range, indicating subclinical hypothyroidism, the decision about T4 replacement is made on a case by case basis and depends partly upon the degree of TSH elevation. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/48/3850?source=see_link\">",
"       \"Subclinical hypothyroidism\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      If the TSH is normal, but the patient has convincing symptoms of hypothyroidism, we measure a repeat serum TSH and a free T4 to assess for central hypothyroidism. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Secondary and tertiary (central) hypothyroidism'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    We define an elevated serum TSH as a TSH concentration above the upper limit of the normal TSH reference range, which is typically 4 to 5",
"    <span class=\"nowrap\">",
"     mU/L",
"    </span>",
"    in most laboratories. Presently there is considerable controversy over the appropriate upper limit of normal for serum TSH. Some experts have suggested that the true upper limit is only 2.5 or 3",
"    <span class=\"nowrap\">",
"     mU/L",
"    </span>",
"    in healthy individuals without thyroid disease, while others argue that the serum TSH distribution shifts towards higher values with age, independent of the presence of antithyroid antibodies [",
"    <a class=\"abstract\" href=\"UTD.htm?26/7/26744/abstract/10\">",
"     10",
"    </a>",
"    ]. In this case, the upper limit of normal could be as high as 6 to 8",
"    <span class=\"nowrap\">",
"     mU/L",
"    </span>",
"    in healthy octogenarians. This topic is reviewed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/33/3608?source=see_link&amp;anchor=H3#H3\">",
"     \"Laboratory assessment of thyroid function\", section on 'Serum TSH concentration'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Secondary and tertiary (central) hypothyroidism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thyrotropin releasing hormone (TRH) and TSH are required for normal thyroid hormone secretion. Central hypothyroidism is due to insufficient stimulation of the thyroid gland by TSH, and it is caused by either hypothalamic (tertiary hypothyroidism) or pituitary (secondary hypothyroidism) disease [",
"    <a class=\"abstract\" href=\"UTD.htm?26/7/26744/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. Central hypothyroidism is much less common than primary hypothyroidism.",
"   </p>",
"   <p>",
"    Secondary and tertiary hypothyroidism should be suspected in the following circumstances:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      There is known hypothalamic or pituitary disease",
"     </li>",
"     <li>",
"      A mass lesion is present in the pituitary",
"     </li>",
"     <li>",
"      When symptoms and signs of hypothyroidism are associated with other hormonal deficiencies",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In hypothyroidism caused by hypothalamic or pituitary disease, TSH secretion does not increase appropriately as T4 secretion falls. As a result, the symptoms and the serum free T4 value must be used to make the diagnosis. Thus, we measure both serum TSH and free T4 if pituitary or hypothalamic disease is suspected (eg, a young woman with amenorrhea and fatigue). We also measure free T4 if the patient has convincing symptoms of hypothyroidism despite a normal TSH result. In patients with central hypothyroidism, the serum free T4 value is low-normal to low and serum TSH may be frankly low, inappropriately normal (for the low T4), or slightly high (7 to 15",
"    <span class=\"nowrap\">",
"     mU/L)",
"    </span>",
"    due to secretion of biologically inactive TSH (",
"    <a class=\"graphic graphic_table graphicRef67935 \" href=\"UTD.htm?26/20/26956\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/7/26744/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The clinical manifestations, diagnosis, differential diagnosis, and treatment of central hypothyroidism are reviewed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/6/18536?source=see_link\">",
"     \"Central hypothyroidism\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5173977\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of an elevated serum TSH level includes resistance to TSH or thyroid hormone, recovery from nonthyroidal illness, and thyrotropin-secreting pituitary adenomas (",
"    <a class=\"graphic graphic_table graphicRef68907 \" href=\"UTD.htm?23/55/24443\">",
"     table 4",
"    </a>",
"    ). High serum TSH concentrations may also occur in primary adrenal insufficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?26/7/26744/abstract/14\">",
"     14",
"    </a>",
"    ] and factitiously in rare patients who have antibodies to the murine immunoglobulins used in the assay [",
"    <a class=\"abstract\" href=\"UTD.htm?26/7/26744/abstract/15\">",
"     15",
"    </a>",
"    ], or complexes of TSH bound to IgG [",
"    <a class=\"abstract\" href=\"UTD.htm?26/7/26744/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2107145\">",
"    <span class=\"h2\">",
"     Resistance to TSH or thyroid hormone",
"    </span>",
"    &nbsp;&mdash;&nbsp;An elevated TSH concentration may rarely be due to resistance to TSH (thyrotropin) secondary to alterations in the TSH receptor [",
"    <a class=\"abstract\" href=\"UTD.htm?26/7/26744/abstract/17\">",
"     17",
"    </a>",
"    ], failure of the cell to express the receptor at the cell surface, or to receptor-independent mechanisms. Many of these patients are euthyroid, while others are hypothyroid. Serum free T4 and T3 concentrations are typically normal or low. The thyroid gland is not enlarged. It may be difficult to distinguish subclinical hypothyroidism (common) from resistance to TSH (rare). The presence of other family members expressing the same phenotype and ultimately a defect in the TSH receptor confirms the diagnosis of resistance to TSH. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/8/16518?source=see_link\">",
"     \"Resistance to thyrotropin and thyrotropin-releasing hormone\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with mutations in the T3 receptor (generalized thyroid hormone resistance) have a normal or elevated TSH, but serum free T4 and T3 are also elevated. Some patients have manifestations of hypothyroidism; however, most such patients are euthyroid. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/37/1626?source=see_link\">",
"     \"Reduced sensitivity to thyroid hormone\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/47/42744?source=see_link\">",
"     \"Disorders that cause hypothyroidism\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5174009\">",
"    <span class=\"h2\">",
"     Nonthyroidal illness",
"    </span>",
"    &nbsp;&mdash;&nbsp;Euthyroid patients with nonthyroidal illness may have transient elevations in serum TSH concentrations (up to 20",
"    <span class=\"nowrap\">",
"     mU/L)",
"    </span>",
"    during recovery from nonthyroidal illness. In patients with a recent illness, TSH and free T4 should be repeated four to six weeks after recovery. Few of these patients prove to have hypothyroidism when reevaluated after recovery from their illness. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/39/44663?source=see_link\">",
"     \"Thyroid function in nonthyroidal illness\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5174041\">",
"    <span class=\"h2\">",
"     Thyrotropin-secreting pituitary adenomas",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thyrotropin (TSH)-secreting pituitary adenomas are a rare cause of hyperthyroidism. TSH-secreting adenomas secrete biologically active thyrotropin (TSH) in a more or less autonomous fashion. The characteristic biochemical abnormalities in patients with hyperthyroidism caused by a TSH-secreting adenoma are normal or high serum TSH concentrations and high serum total and free thyroxine (T4) and triiodothyronine (T3) concentrations. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/20/327?source=see_link\">",
"     \"Thyrotropin (TSH)-secreting pituitary adenomas\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical evaluation of a patient with primary hypothyroidism should be directed toward confirming the presence and identifying the cause of the hormone deficiency (",
"    <a class=\"graphic graphic_table graphicRef67769 \" href=\"UTD.htm?2/8/2188\">",
"     table 5",
"    </a>",
"    ). The history, for example, may uncover past treatment of hyperthyroidism with radioiodine or thyroidectomy, the use of drugs that affect thyroid hormone synthesis, or history of iodine deficiency or excess. Physical examination may, in some cases, reveal thyroid enlargement (goiter) or an old thyroidectomy scar. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/47/42744?source=see_link\">",
"     \"Disorders that cause hypothyroidism\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Chronic autoimmune hypothyroidism (Hashimoto&rsquo;s thyroiditis) is the most common cause of primary hypothyroidism in iodine sufficient areas of the world. The two major forms of the disorder are goitrous autoimmune thyroiditis and atrophic autoimmune thyroiditis, with the common pathologic feature being lymphocytic infiltration and the common serological feature being the presence of high serum concentrations of antibodies to thyroid peroxidase and thyroglobulin. Serum concentrations of thyroid peroxidase autoantibodies are elevated in more than 90 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?26/7/26744/abstract/18\">",
"     18",
"    </a>",
"    ]. We do not routinely measure thyroid peroxidase antibodies in patients with primary overt hypothyroidism, because almost all have chronic autoimmune thyroiditis. However, many thyroid experts measure serum thyroid peroxidase (TPO) antibodies in patients with goiter, especially in the absence of hypothyroidism, to identify immunologically mediated goiter. In addition, a test for antithyroid peroxidase antibodies may be useful to predict the likelihood of progression to permanent overt hypothyroidism in patients with subclinical hypothyroidism or those with painless (silent) thyroiditis or postpartum thyroiditis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/27/32185?source=see_link&amp;anchor=H62289336#H62289336\">",
"     \"Diagnostic approach to and treatment of goiter in adults\", section on 'Diagnostic testing'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/48/3850?source=see_link&amp;anchor=H7#H7\">",
"     \"Subclinical hypothyroidism\", section on 'Evaluation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Sometimes TPO antibodies are measured concomitantly with TSH in patients who have symptoms of hypothyroidism",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    a goiter on physical examination, and TPO antibodies are found to be elevated in patients with normal thyroid function tests. These patients have chronic autoimmune thyroiditis but do not have hypothyroidism. They are more likely to develop hypothyroidism than antibody negative individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?26/7/26744/abstract/7\">",
"     7",
"    </a>",
"    ]. Such patients should have serum TSH measured annually.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     SCREENING",
"    </span>",
"    &nbsp;&mdash;&nbsp;\"Screening\" refers to the measurement of thyroid function tests in asymptomatic patients at risk of having thyroid disease who are presently not known to have thyroid disease. The primary benefit of screening for hypothyroidism is the detection of hypothyroidism before the occurrence of symptoms. Subclinical thyroid dysfunction is common in the adult population [",
"    <a class=\"abstract\" href=\"UTD.htm?26/7/26744/abstract/6\">",
"     6",
"    </a>",
"    ]. However, there is no evidence that early detection and treatment with thyroxine (T4) improves clinically important outcomes in individuals with hypothyroidism detected by screening. Although T4 replacement therapy has few side effects when properly dosed, over-treatment with thyroid hormone is common and may be associated with adverse skeletal and cardiovascular effects, particularly in elderly patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/22/23913?source=see_link&amp;anchor=H3#H3\">",
"     \"Subclinical hyperthyroidism\", section on 'Exogenous subclinical hyperthyroidism'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are two strategies for screening asymptomatic individuals: screening all individuals over a certain age (when risk of hypothyroidism increases) or screening only those individuals with clinical risk factors for hypothyroidism. In the absence of data supporting any screening strategy, we suggest screening patients at increased risk for hypothyroidism, including but not limited to patients with goiter, history of autoimmune disease, previous radioactive iodine therapy,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    head and neck irradiation, family history of thyroid disease, and use of medications that may impair thyroid function (",
"    <a class=\"graphic graphic_table graphicRef53510 \" href=\"UTD.htm?6/30/6638\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    We recommend measurement of serum TSH as a screening test for hypothyroidism.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Effectiveness",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no clinical trials evaluating the effectiveness of screening for hypothyroidism. A computer decision model that evaluated a hypothetical cohort of women and men screened every five years beginning at age 35 years showed that screening for hypothyroidism was similarly cost-effective as other accepted preventive practices (eg, breast cancer or hypertension screening) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/7/26744/abstract/19\">",
"     19",
"    </a>",
"    ]. Benefit accrued mainly from the avoidance of symptoms of hypothyroidism when diagnosed and treated early, and from the decrease in adverse cardiovascular outcomes associated with the lower serum cholesterol concentrations in treated hypothyroid patients. The cost-effectiveness of screening was most favorable in elderly women.",
"   </p>",
"   <p>",
"    Although hypothyroidism is common in the elderly (eg, 5 to 15 percent in women over the age of 65), there is no evidence that it is associated with adverse outcomes in the oldest individuals when detected by screening alone. This was illustrated in a population-based, prospective study of 558 individuals in the Netherlands who were screened for hypothyroidism during the month of their 85",
"    <sup>",
"     th",
"    </sup>",
"    birthday and again three years later [",
"    <a class=\"abstract\" href=\"UTD.htm?26/7/26744/abstract/20\">",
"     20",
"    </a>",
"    ]. Annual follow-up (for four years) was also performed to assess activities of daily living (ADLs), cognitive performance, and depressive mood with the following results:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Twelve percent had hypothyroidism at baseline (7 percent overt and 5 percent subclinical). Those with overt hypothyroidism were referred to their primary care physician for further evaluation (although none were started on",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/43/41656?source=see_link\">",
"       levothyroxine",
"      </a>",
"      , as clinicians in the area do not routinely start treatment for disorders identified by screening only). None of the patients with subclinical hypothyroidism had progressed to overt hypothyroidism when retested at age 88 years.",
"     </li>",
"     <li>",
"      At baseline, there was no association between baseline serum TSH concentration and cognitive function, depressive symptoms, or disability in ADLs.",
"     </li>",
"     <li>",
"      All of the above measures of performance declined over time, but the decline was not accelerated in those with either subclinical or overt hypothyroidism. In fact, increasing serum TSH at baseline was associated with a slower decline in ability to perform \"instrumental\" ADLs (such as preparing one's own meals, shopping for groceries and personal items, managing one's money, using the telephone, and doing housework).",
"     </li>",
"     <li>",
"      Higher baseline TSH was also associated with lower all-cause and cardiovascular mortality, in spite of higher baseline serum cholesterol concentrations.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Candidates for screening",
"    </span>",
"    &nbsp;&mdash;&nbsp;All patients with symptoms of hypothyroidism (",
"    <a class=\"graphic graphic_table graphicRef62676 \" href=\"UTD.htm?41/41/42651\">",
"     table 1",
"    </a>",
"    ) should be evaluated for hypothyroidism. Screening of asymptomatic individuals is controversial [",
"    <a class=\"abstract\" href=\"UTD.htm?26/7/26744/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. In the absence of data showing any benefit of population-based screening, we suggest not routinely measuring thyroid function in asymptomatic nonpregnant individuals.",
"   </p>",
"   <p>",
"    As an alternative, we suggest screening for hypothyroidism in patients with laboratory or radiologic abnormalities that could be caused by hypothyroidism, patients with risk factors for hypothyroidism, and patients taking drugs that may impair thyroid function (",
"    <a class=\"graphic graphic_table graphicRef53510 \" href=\"UTD.htm?6/30/6638\">",
"     table 2",
"    </a>",
"    ). As examples, thyroid function should be measured in patients with the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Substantial hyperlipidemia or a change in lipid pattern, which occurs with increased frequency in hypothyroidism. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/56/28550?source=see_link\">",
"       \"Lipid abnormalities in thyroid disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Hyponatremia, often resulting from inappropriate production of antidiuretic hormone, which is another laboratory manifestation of hypothyroidism. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/30/3562?source=see_link&amp;anchor=H88313973#H88313973\">",
"       \"Causes of hyponatremia\", section on 'Hypothyroidism'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      High serum muscle enzyme concentrations. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/26/29093?source=see_link&amp;anchor=H5#H5\">",
"       \"Hypothyroid myopathy\", section on 'Elevation in serum creatine kinase'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Macrocytic anemia (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/46/29418?source=see_link&amp;anchor=H21#H21\">",
"       \"Approach to the adult patient with anemia\", section on 'Macrocytic anemia'",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Pericardial or pleural effusions (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/36/2632?source=see_link&amp;anchor=H2#H2\">",
"       \"Diagnostic evaluation of pleural effusion in adults: Additional tests for undetermined etiology\", section on 'History'",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Previous thyroid injury (eg, radioiodine therapy, thyroid or neck surgery, external radiation therapy).",
"     </li>",
"     <li>",
"      Pituitary or hypothalamic disorders (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/6/18536?source=see_link\">",
"       \"Central hypothyroidism\"",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      History of autoimmune diseases.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The universal screening of asymptomatic pregnant women for hypothyroidism during the first trimester of pregnancy is controversial. This topic is reviewed in detail elsewhere. In brief, we suggest a targeted approach to screening pregnant women. We favor screening pregnant women if they are from an area of moderate to severe iodine insufficiency, have symptoms of hypothyroidism, a family or personal history of thyroid disease, or a personal history of thyroid peroxidase antibodies, type 1 diabetes, head and neck radiation, recurrent miscarriage, morbid obesity, or infertility. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/47/14073?source=see_link&amp;anchor=H57693652#H57693652\">",
"     \"Hypothyroidism during pregnancy: Clinical manifestations, diagnosis, and treatment\", section on 'Screening'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Screening tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;Second and third generation serum TSH assays are both more sensitive and specific than serum free T4 measurements for detecting primary hypothyroidism in ambulatory patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/33/3608?source=see_link\">",
"     \"Laboratory assessment of thyroid function\"",
"    </a>",
"    .) Although the normal range for serum free T4 concentrations is wide (approximately 0.8 to 1.8",
"    <span class=\"nowrap\">",
"     ng/dL",
"    </span>",
"    [10 to 36",
"    <span class=\"nowrap\">",
"     pmol/L]),",
"    </span>",
"    each person has an endogenous set point dictating the optimum concentration for that individual. TSH secretion increases when the serum free T4 concentration falls below that level. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/34/33320?source=see_link&amp;anchor=H25#H25\">",
"     \"Thyroid hormone synthesis and physiology\", section on 'Regulation of thyroid hormone production'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Primary thyroid disease accounts for over 95 percent of cases of hypothyroidism. As a result, measurement of serum TSH (rather than free T4 or total T4) is an excellent screening test for hypothyroidism in ambulatory patients [",
"    <a class=\"abstract\" href=\"UTD.htm?26/7/26744/abstract/23\">",
"     23",
"    </a>",
"    ]. There are, however, three settings in which measurement of serum TSH may",
"    <strong>",
"     not",
"    </strong>",
"    be a useful tool for the diagnosis of hypothyroidism:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If pituitary or hypothalamic disease is known or suspected.",
"     </li>",
"     <li>",
"      In hospitalized patients, since there are many other factors in acutely or chronically ill euthyroid patients that influence TSH secretion. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/39/44663?source=see_link\">",
"       \"Thyroid function in nonthyroidal illness\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In patients receiving drugs or with underlying diseases that affect TSH secretion (",
"      <a class=\"graphic graphic_table graphicRef68907 \" href=\"UTD.htm?23/55/24443\">",
"       table 4",
"      </a>",
"      ). Drugs that can decrease TSH secretion include dopamine, high doses of glucocorticoids, and somatostatin analogues (such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/7/43128?source=see_link\">",
"       octreotide",
"      </a>",
"      ). Drugs that increase TSH secretion include dopamine antagonists (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/13/216?source=see_link\">",
"       metoclopramide",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/43/1717?source=see_link\">",
"       domperidone",
"      </a>",
"      ),",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"       amiodarone",
"      </a>",
"      , and oral cholecystographic dyes (eg, sodium ipodate).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Because errors may be made when only TSH is measured in patients with secondary or central hypothyroidism or TSH-mediated hyperthyroidism, some experts recommend that both serum TSH and free T4 be measured in all patients for screening purposes.",
"   </p>",
"   <p>",
"    This approach adds considerable cost to screening, and is likely to pick up few cases of unsuspected pituitary disease. As a result, many laboratories are using strategies such as the following to limit unnecessary laboratory testing:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Serum TSH normal &mdash; no further testing performed",
"     </li>",
"     <li>",
"      Serum TSH high &mdash; free T4 added to determine the degree of hypothyroidism",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Screening inpatients is a more difficult problem and is not recommended unless thyroid disease is strongly suspected since changes in thyroid hormones, binding proteins, and TSH concentrations occur in severe nonthyroidal illness. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/39/44663?source=see_link\">",
"     \"Thyroid function in nonthyroidal illness\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Recommendations by expert groups",
"    </span>",
"    &nbsp;&mdash;&nbsp;Screening recommendations from major groups have been conflicting. The American Academy of Family Physicians (AAFP) recommends periodic assessment of thyroid function in older women [",
"    <a class=\"abstract\" href=\"UTD.htm?26/7/26744/abstract/24\">",
"     24",
"    </a>",
"    ], and the American College of Physicians (ACP) suggests that office screening of women older than 50 years may be indicated [",
"    <a class=\"abstract\" href=\"UTD.htm?26/7/26744/abstract/25\">",
"     25",
"    </a>",
"    ]. The American Thyroid Association (ATA) and the American Association of Clinical Endocrinologists (AACE) have issued guidelines that recommend measurement of TSH in any individual at risk for hypothyroidism (eg, personal history of type 1 diabetes or other autoimmune disease, family history of thyroid disease, history of neck radiation to the thyroid, history of thyroid surgery) and consideration of measurement of TSH in patients over the age of 60 years [",
"    <a class=\"abstract\" href=\"UTD.htm?26/7/26744/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contrast, the United States Preventive Services Task Force does not recommend routine screening for thyroid disease in children or adults [",
"    <a class=\"abstract\" href=\"UTD.htm?26/7/26744/abstract/27,28\">",
"     27,28",
"    </a>",
"    ], and the Institute of Medicine has issued a statement that screening is not cost-effective in the (elderly) Medicare population [",
"    <a class=\"abstract\" href=\"UTD.htm?26/7/26744/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Recommendations for screening pregnant women are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/47/14073?source=see_link&amp;anchor=H57693652#H57693652\">",
"     \"Hypothyroidism during pregnancy: Clinical manifestations, diagnosis, and treatment\", section on 'Screening'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?3/54/3938?source=see_link\">",
"       \"Patient information: Hypothyroidism (underactive thyroid) (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?14/54/15203?source=see_link\">",
"       \"Patient information: Hypothyroidism (underactive thyroid) (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The clinical manifestations of hypothyroidism are highly variable, depending upon the age at onset and the duration and severity of thyroid hormone deficiency. Common symptoms of thyroid hormone deficiency include fatigue, cold intolerance, weight gain, constipation, dry skin, myalgia, and menstrual irregularities (",
"      <a class=\"graphic graphic_table graphicRef62676 \" href=\"UTD.htm?41/41/42651\">",
"       table 1",
"      </a>",
"      ). Physical examination findings may include goiter (particularly in patients with iodine deficiency or goitrous chronic autoimmune thyroiditis [Hashimoto&rsquo;s thyroiditis]), bradycardia, hypertension, and a delayed relaxation phase of the deep tendon reflexes. Serum concentrations of thyroid peroxidase autoantibodies are elevated in more than 90 percent of patients with hypothyroidism due to chronic autoimmune hypothyroidism (Hashimoto&rsquo;s thyroiditis). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Clinical features'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/10/14503?source=see_link\">",
"       \"Clinical manifestations of hypothyroidism\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The diagnosis of hypothyroidism is based primarily upon laboratory testing. In most patients with symptoms suggestive of hypothyroidism, the serum TSH should be the initial test. If the serum TSH concentration is elevated, the TSH measurement should be repeated along with a serum free T4 to make the diagnosis of hypothyroidism (",
"      <a class=\"graphic graphic_table graphicRef67935 \" href=\"UTD.htm?26/20/26956\">",
"       table 3",
"      </a>",
"      ). If the repeat serum TSH value is still high and the serum free T4 is low, suggesting primary hypothyroidism, replacement therapy with T4 should be initiated. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Diagnosis'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/53/43865?source=see_link\">",
"       \"Treatment of hypothyroidism\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Patients with a high serum TSH concentration and a normal serum free T4 concentration may have subclinical hypothyroidism. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Diagnosis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H5\">",
"       'Primary hypothyroidism'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If central hypothyroidism is suspected (eg, presence of pituitary or hypothalamic disease), or if the patient has convincing symptoms of hypothyroidism despite a normal TSH result, we measure serum TSH and free T4. In patients with central hypothyroidism, the serum free T4 value is low-normal or low and serum TSH may be frankly low, inappropriately normal (for the low T4), or slightly high (5 to 10",
"      <span class=\"nowrap\">",
"       mU/L)",
"      </span>",
"      due to secretion of biologically inactive TSH (",
"      <a class=\"graphic graphic_table graphicRef67935 \" href=\"UTD.htm?26/20/26956\">",
"       table 3",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Diagnosis'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/6/18536?source=see_link\">",
"       \"Central hypothyroidism\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The differential diagnosis of an elevated serum TSH concentration includes resistance to TSH, recovery from nonthyroidal illness, and a thyrotropin-secreting pituitary adenoma. (See",
"      <a class=\"local\" href=\"#H5173977\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The clinical evaluation of a patient with primary hypothyroidism should be directed toward confirming the presence and identifying the cause of the hormone deficiency (",
"      <a class=\"graphic graphic_table graphicRef67769 \" href=\"UTD.htm?2/8/2188\">",
"       table 5",
"      </a>",
"      ). The history, for example, may uncover past treatment of hyperthyroidism with radioiodine or thyroidectomy, the use of drugs that affect thyroid hormone synthesis, or history of iodine deficiency or excess. We do not routinely measure thyroid peroxidase antibodies in patients with primary overt hypothyroidism, because almost all have chronic autoimmune thyroiditis. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest",
"      <strong>",
"       not",
"      </strong>",
"      performing population-based screening for hypothyroidism (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). As an alternative, we prefer to screen individuals who are at increased risk for hypothyroidism (",
"      <a class=\"graphic graphic_table graphicRef53510 \" href=\"UTD.htm?6/30/6638\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Candidates for screening'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      TSH is the most sensitive test for detecting primary hypothyroidism in ambulatory patients. However, TSH alone may",
"      <strong>",
"       not",
"      </strong>",
"      be a useful tool for the diagnosis of hypothyroidism if pituitary or hypothalamic disease is known or suspected, in hospitalized patients, since there are many other factors in acutely or chronically ill euthyroid patients that influence TSH secretion, and in patients receiving drugs or with underlying diseases that affect TSH secretion (",
"      <a class=\"graphic graphic_table graphicRef68907 \" href=\"UTD.htm?23/55/24443\">",
"       table 4",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/39/44663?source=see_link\">",
"       \"Thyroid function in nonthyroidal illness\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The universal screening of asymptomatic pregnant women for hypothyroidism during the first trimester of pregnancy is controversial. We suggest a targeted approach rather than universal screening (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). We favor screening pregnant women if they are from an area of moderate to severe iodine insufficiency, have symptoms of hypothyroidism, a family or personal history of thyroid disease, or a personal history of thyroid peroxidase antibodies, type 1 diabetes, morbid obesity, head and neck radiation, recurrent miscarriage, or infertility. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/47/14073?source=see_link&amp;anchor=H57693652#H57693652\">",
"       \"Hypothyroidism during pregnancy: Clinical manifestations, diagnosis, and treatment\", section on 'Screening'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/7/26744/abstract/1\">",
"      Tunbridge WM, Evered DC, Hall R, et al. The spectrum of thyroid disease in a community: the Whickham survey. Clin Endocrinol (Oxf) 1977; 7:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/7/26744/abstract/2\">",
"      Vanderpump MP, Tunbridge WM, French JM, et al. The incidence of thyroid disorders in the community: a twenty-year follow-up of the Whickham Survey. Clin Endocrinol (Oxf) 1995; 43:55.",
"     </a>",
"    </li>",
"    <li>",
"     Vanderpump MP, Tunbridge WM. The epidemiology of thyroid diseases. In: The thyroid: A fundamental and clinical text, 8th, Braverman LE, Utiger RD (Eds), Lippincott Williams and Wilkins, Philadelphia 2000. p.467.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/7/26744/abstract/4\">",
"      Canaris GJ, Manowitz NR, Mayor G, Ridgway EC. The Colorado thyroid disease prevalence study. Arch Intern Med 2000; 160:526.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/7/26744/abstract/5\">",
"      Aoki Y, Belin RM, Clickner R, et al. Serum TSH and total T4 in the United States population and their association with participant characteristics: National Health and Nutrition Examination Survey (NHANES 1999-2002). Thyroid 2007; 17:1211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/7/26744/abstract/6\">",
"      Hollowell JG, Staehling NW, Flanders WD, et al. Serum TSH, T(4), and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III). J Clin Endocrinol Metab 2002; 87:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/7/26744/abstract/7\">",
"      Walsh JP, Bremner AP, Feddema P, et al. Thyrotropin and thyroid antibodies as predictors of hypothyroidism: a 13-year, longitudinal study of a community-based cohort using current immunoassay techniques. J Clin Endocrinol Metab 2010; 95:1095.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/7/26744/abstract/8\">",
"      Kajantie E, Phillips DI, Osmond C, et al. Spontaneous hypothyroidism in adult women is predicted by small body size at birth and during childhood. J Clin Endocrinol Metab 2006; 91:4953.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/7/26744/abstract/9\">",
"      McDermott MT. In the clinic. Hypothyroidism. Ann Intern Med 2009; 151:ITC61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/7/26744/abstract/10\">",
"      Surks MI, Hollowell JG. Age-specific distribution of serum thyrotropin and antithyroid antibodies in the US population: implications for the prevalence of subclinical hypothyroidism. J Clin Endocrinol Metab 2007; 92:4575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/7/26744/abstract/11\">",
"      Samuels MH, Ridgway EC. Central hypothyroidism. Endocrinol Metab Clin North Am 1992; 21:903.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/7/26744/abstract/12\">",
"      Lania A, Persani L, Beck-Peccoz P. Central hypothyroidism. Pituitary 2008; 11:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/7/26744/abstract/13\">",
"      Beck-Peccoz P, Amr S, Menezes-Ferreira MM, et al. Decreased receptor binding of biologically inactive thyrotropin in central hypothyroidism. Effect of treatment with thyrotropin-releasing hormone. N Engl J Med 1985; 312:1085.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/7/26744/abstract/14\">",
"      Topliss DJ, White EL, Stockigt JR. Significance of thyrotropin excess in untreated primary adrenal insufficiency. J Clin Endocrinol Metab 1980; 50:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/7/26744/abstract/15\">",
"      Kahn BB, Weintraub BD, Csako G, Zweig MH. Factitious elevation of thyrotropin in a new ultrasensitive assay: implications for the use of monoclonal antibodies in \"sandwich\" immunoassay. J Clin Endocrinol Metab 1988; 66:526.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/7/26744/abstract/16\">",
"      Loh TP, Kao SL, Halsall DJ, et al. Macro-thyrotropin: a case report and review of literature. J Clin Endocrinol Metab 2012; 97:1823.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/7/26744/abstract/17\">",
"      Tonacchera M, Di Cosmo C, De Marco G, et al. Identification of TSH receptor mutations in three families with resistance to TSH. Clin Endocrinol (Oxf) 2007; 67:712.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/7/26744/abstract/18\">",
"      Mariotti S, Caturegli P, Piccolo P, et al. Antithyroid peroxidase autoantibodies in thyroid diseases. J Clin Endocrinol Metab 1990; 71:661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/7/26744/abstract/19\">",
"      Danese MD, Powe NR, Sawin CT, Ladenson PW. Screening for mild thyroid failure at the periodic health examination: a decision and cost-effectiveness analysis. JAMA 1996; 276:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/7/26744/abstract/20\">",
"      Gussekloo J, van Exel E, de Craen AJ, et al. Thyroid status, disability and cognitive function, and survival in old age. JAMA 2004; 292:2591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/7/26744/abstract/21\">",
"      Surks MI, Ortiz E, Daniels GH, et al. Subclinical thyroid disease: scientific review and guidelines for diagnosis and management. JAMA 2004; 291:228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/7/26744/abstract/22\">",
"      Gharib H, Tuttle RM, Baskin HJ, et al. Subclinical thyroid dysfunction: a joint statement on management from the American Association of Clinical Endocrinologists, the American Thyroid Association, and the Endocrine Society. J Clin Endocrinol Metab 2005; 90:581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/7/26744/abstract/23\">",
"      Spencer CA. Clinical utility and cost-effectiveness of sensitive thyrotropin assays in ambulatory and hospitalized patients. Mayo Clin Proc 1988; 63:1214.",
"     </a>",
"    </li>",
"    <li>",
"     American Academy of Family Physicians. Summary of policy recommendations for periodic health examinations. Leawood, KS: American Academy of Family Physicians, 2002.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/7/26744/abstract/25\">",
"      Clinical guideline, part 1. Screening for thyroid disease. American College of Physicians. Ann Intern Med 1998; 129:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/7/26744/abstract/26\">",
"      Garber JR, Cobin RH, Gharib H, et al. Clinical practice guidelines for hypothyroidism in adults: cosponsored by the American Association of Clinical Endocrinologists and the American Thyroid Association. Thyroid 2012; 22:1200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/7/26744/abstract/27\">",
"      U.S. Preventive Services Task Force. Screening for thyroid disease: recommendation statement. Ann Intern Med 2004; 140:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/7/26744/abstract/28\">",
"      Helfand M, U.S. Preventive Services Task Force. Screening for subclinical thyroid dysfunction in nonpregnant adults: a summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2004; 140:128.",
"     </a>",
"    </li>",
"    <li>",
"     Committee on Medicare Coverage of Routine Thyroid Screening. Board on Health Care Services. Medicare Coverage of Routine Screening for Thyroid Dysfunction, Stone MB, Wallace RB (Eds), National Academies Press, Washington, DC 2003.",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7893 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-122.72.76.133-B89E15691A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_7_26744=[""].join("\n");
var outline_f26_7_26744=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H14\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Primary hypothyroidism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Secondary and tertiary (central) hypothyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5173977\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2107145\">",
"      Resistance to TSH or thyroid hormone",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5174009\">",
"      Nonthyroidal illness",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5174041\">",
"      Thyrotropin-secreting pituitary adenomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      SCREENING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Effectiveness",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Candidates for screening",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Screening tests",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Recommendations by expert groups",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ENDO/7893\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/7893|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?41/41/42651\" title=\"table 1\">",
"      Symptoms and signs of hypothyroidism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?6/30/6638\" title=\"table 2\">",
"      Indications test hypothyroidism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?26/20/26956\" title=\"table 3\">",
"      Assessment of thyroid function",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/55/24443\" title=\"table 4\">",
"      Disorders that affect TSH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?2/8/2188\" title=\"table 5\">",
"      Causes of hypothyroidism",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/46/29418?source=related_link\">",
"      Approach to the adult patient with anemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/30/3562?source=related_link\">",
"      Causes of hyponatremia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/6/18536?source=related_link\">",
"      Central hypothyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/10/14503?source=related_link\">",
"      Clinical manifestations of hypothyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/27/32185?source=related_link\">",
"      Diagnostic approach to and treatment of goiter in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/36/2632?source=related_link\">",
"      Diagnostic evaluation of pleural effusion in adults: Additional tests for undetermined etiology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/47/42744?source=related_link\">",
"      Disorders that cause hypothyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/26/29093?source=related_link\">",
"      Hypothyroid myopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/47/14073?source=related_link\">",
"      Hypothyroidism during pregnancy: Clinical manifestations, diagnosis, and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/33/3608?source=related_link\">",
"      Laboratory assessment of thyroid function",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/56/28550?source=related_link\">",
"      Lipid abnormalities in thyroid disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?14/54/15203?source=related_link\">",
"      Patient information: Hypothyroidism (underactive thyroid) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?3/54/3938?source=related_link\">",
"      Patient information: Hypothyroidism (underactive thyroid) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/37/1626?source=related_link\">",
"      Reduced sensitivity to thyroid hormone",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/8/16518?source=related_link\">",
"      Resistance to thyrotropin and thyrotropin-releasing hormone",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/22/23913?source=related_link\">",
"      Subclinical hyperthyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/48/3850?source=related_link\">",
"      Subclinical hypothyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/39/44663?source=related_link\">",
"      Thyroid function in nonthyroidal illness",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/34/33320?source=related_link\">",
"      Thyroid hormone synthesis and physiology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/20/327?source=related_link\">",
"      Thyrotropin (TSH)-secreting pituitary adenomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/53/43865?source=related_link\">",
"      Treatment of hypothyroidism",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_7_26745="Treatment of moderate persistent asthma in adolescents and adults";
var content_f26_7_26745=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of moderate persistent asthma in adolescents and adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/7/26745/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/7/26745/contributors\">",
"     Stephen Peters, MD, PhD, FACP, FCCP, FAAAAI, FCPP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/7/26745/contributors\">",
"     Jennifer W McCallister, MD, FACP, FCCP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/7/26745/contributors\">",
"     Rodolfo Pascual, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/7/26745/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/7/26745/contributors\">",
"     Bruce S Bochner, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/7/26745/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/7/26745/contributors\">",
"     Helen Hollingsworth, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?26/7/26745/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 4, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The principal goals of treatment of moderate persistent asthma are to minimize symptoms, normalize pulmonary function, prevent exacerbations, and improve health-related quality of life. A theoretical goal is to prevent the putative long-term consequences of airway inflammation, particularly airway remodeling and chronic persistent airway obstruction. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/52/4937?source=see_link\">",
"     \"Pathogenesis of asthma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The standard pharmacologic approaches to moderate persistent asthma in adolescents (children over the age of 12 years) and adults will be reviewed here. This information is consistent with the &ldquo;National Asthma Education and Prevention Program (NAEPP): Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma &ndash; Full Report 2007\" [",
"    <a class=\"abstract\" href=\"UTD.htm?26/7/26745/abstract/1\">",
"     1",
"    </a>",
"    ]. Similar guidelines have been published by the Global Initiative for Asthma (GINA) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/7/26745/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An overview of asthma management, including trigger control and the use of controller medications for asthma in children younger than 12 years of age, is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/37/8794?source=see_link\">",
"     \"An overview of asthma management\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/9/44184?source=see_link\">",
"     \"Trigger control to enhance asthma management\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/30/37354?source=see_link\">",
"     \"Chronic asthma in children younger than 12 years: Controller medications\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Expert Panel Report 3 of the NAEPP describes moderate persistent asthma as being characterized by any of the following (",
"    <a class=\"graphic graphic_table graphicRef58247 \" href=\"UTD.htm?32/48/33549\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?26/7/26745/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Daily symptoms of asthma",
"     </li>",
"     <li>",
"      Nocturnal awakenings more than once per week (although not every night)",
"     </li>",
"     <li>",
"      Daily need for inhaled short-acting beta agonists (SABAs) for symptom relief",
"     </li>",
"     <li>",
"      Some limitation in normal activity",
"     </li>",
"     <li>",
"      Forced expiratory flow in 1 second (FEV",
"      <sub>",
"       1",
"      </sub>",
"      ) between 60 and 80 percent of predicted",
"     </li>",
"     <li>",
"      Forced expiratory flow in 1",
"      <span class=\"nowrap\">",
"       second/forced",
"      </span>",
"      vital capacity",
"      <span class=\"nowrap\">",
"       (FEV",
"       <sub>",
"        1",
"       </sub>",
"       /FVC)",
"      </span>",
"      1 to 5 percent below normal range for age",
"     </li>",
"     <li>",
"      Two or more exacerbations requiring oral glucocorticoids per year",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    NAEPP definitions of severity apply best to patients in the untreated state. For patients already receiving therapy, the focus should shift to assessing control and adjusting medications accordingly. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Assessing control'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     GENERAL PRINCIPLES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The NAEPP recommends a stepwise approach to therapy, with aggressive attempts to control symptoms quickly and subsequent adjustment of therapy in a stepwise fashion as symptoms require. Adherence to guideline-based therapy has been shown in a randomized controlled trial to result in well-controlled or completely-controlled asthma in the majority of patients, regardless of initial asthma severity [",
"    <a class=\"abstract\" href=\"UTD.htm?26/7/26745/abstract/3\">",
"     3",
"    </a>",
"    ]. This approach is presented here, with some additional suggestions based on the authors' experience.",
"   </p>",
"   <p>",
"    An estimate of severity is used to determine the initial treatment in patients who are not receiving treatment at the time of evaluation. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Initiating controller therapy'",
"    </a>",
"    below.) The 2007 NAEPP guidelines prefer one of two long-term controller regimens for patients with moderate persistent asthma initially (Step 3 therapy): either medium-dose inhaled glucocorticoids alone, or the combination of low-dose inhaled glucocorticoids, plus a long-acting beta agonist (LABA) (",
"    <a class=\"graphic graphic_figure graphicRef56729 \" href=\"UTD.htm?43/33/44563\">",
"     figure 1",
"    </a>",
"    ). Several alternative agents are suggested.",
"   </p>",
"   <p>",
"    Once the patient is receiving treatment, the focus shifts to assessing the patient's asthma control and adjusting medications based upon the patients current level of symptoms. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Assessing control'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The NAEPP guidelines consider patients whose asthma is controlled with either Step 3 or Step 4 therapy over time, to have moderate persistent asthma, although Step 3 is the recommended initial treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?26/7/26745/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Patient education",
"    </span>",
"    &nbsp;&mdash;&nbsp;All patients should be provided with a personalized \"asthma action plan,\" which describes how and when their medications should be used, as well as how to recognize an exacerbation and make appropriate adjustments in medications (",
"    <a class=\"graphic graphic_form graphicRef55900 \" href=\"UTD.htm?36/39/37498\">",
"     figure 2",
"    </a>",
"    ). Teaching patients about asthma and formulating asthma action plans are reviewed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/15/31991?source=see_link\">",
"     \"What do patients need to know about their asthma?\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Immunotherapy for allergic asthma",
"    </span>",
"    &nbsp;&mdash;&nbsp;The 2007 NAEPP guidelines suggest consideration of subcutaneous allergen immunotherapy for patients with moderate persistent asthma who have allergic triggers [",
"    <a class=\"abstract\" href=\"UTD.htm?26/7/26745/abstract/1\">",
"     1",
"    </a>",
"    ]. Allergy is believed to play a greater pathogenic role in pediatric asthma, compared to asthma in adults. The use of immunotherapy in asthma treatment is reviewed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/8/39049?source=see_link\">",
"     \"Subcutaneous immunotherapy for allergic disease: Indications and efficacy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     SHORT-ACTING BETA AGONISTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inhaled SABAs should be prescribed to all patients with asthma (concomitantly with inhaled glucocorticoids) for the relief of acute symptoms.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/61/16344?source=see_link\">",
"     Albuterol",
"    </a>",
"    , at a dose of 2 to 4 puffs, is commonly prescribed, although other equivalent agents are available (",
"    <a class=\"graphic graphic_table graphicRef72467 \" href=\"UTD.htm?15/34/15917\">",
"     table 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/26/8618?source=see_link\">",
"     \"Beta agonists in asthma: Acute administration and prophylactic use\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Important issues regarding beta agonists include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      SABA do not treat the airway inflammation underlying asthma and are useful in the treatment of symptoms only. These agents should NOT be used as monotherapy for persistent asthma of any severity.",
"     </li>",
"     <li>",
"      The optimal use of these agents (ie, as needed versus at regularly scheduled intervals) in patients with moderate asthma has been an issue of some debate. Evidence for an association between overuse of short-acting beta agonists and increased asthma mortality, beta agonist tolerance, or worsened airways hyperreactivity has been conflicting and difficult to interpret. However, scheduled use of these agents has not been shown to confer additional benefit beyond as needed dosing, and we therefore suggest that these agents be used on an as-needed basis only [",
"      <a class=\"abstract\" href=\"UTD.htm?26/7/26745/abstract/4\">",
"       4",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/19/16698?source=see_link\">",
"       \"Beta agonists in asthma: Controversy regarding chronic use\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     INITIATING CONTROLLER THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inhaled glucocorticoids (GCs) (called inhaled corticosteroids (ICS) in the guidelines) are recommended as the initial and primary therapy in all patients with moderate persistent asthma. Several randomized, prospective studies demonstrate that inhaled GCs improve lung function, diminish symptoms, decrease need for SABAs, and improve airway responsiveness to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/32/10756?source=see_link\">",
"     methacholine",
"    </a>",
"    in patients with all levels of asthma severity [",
"    <a class=\"abstract\" href=\"UTD.htm?26/7/26745/abstract/5-9\">",
"     5-9",
"    </a>",
"    ]. Observational data also suggest that inhaled GCs diminish hospitalizations and mortality from asthma [",
"    <a class=\"abstract\" href=\"UTD.htm?26/7/26745/abstract/10-12\">",
"     10-12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Preferred options",
"    </span>",
"    &nbsp;&mdash;&nbsp;When starting therapy for patients with moderate persistent asthma, either of two approaches is recommended by the NAEPP guidelines, corresponding to Step 3 therapy (",
"    <a class=\"graphic graphic_figure graphicRef56729 \" href=\"UTD.htm?43/33/44563\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?26/7/26745/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Medium-dose inhaled GCs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Initiation of medium-dose inhaled glucocorticoids is appropriate for patients whose symptoms have been stable, although not well-controlled, in the preceding weeks (",
"    <a class=\"graphic graphic_table graphicRef78011 \" href=\"UTD.htm?15/35/15934\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The combination of a LABA plus an inhaled GC is more effective than higher doses of inhaled GCs in most patients, as demonstrated in several randomized trials [",
"    <a class=\"abstract\" href=\"UTD.htm?26/7/26745/abstract/3,13-17\">",
"     3,13-17",
"    </a>",
"    ]. As an example, in a double-blind study, 429 patients who were symptomatic on low-dose inhaled",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/7/33904?source=see_link\">",
"     beclomethasone",
"    </a>",
"    (200 mcg BID) were randomly assigned to receive either increased beclomethasone (500 mcg BID) or the combination of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/63/34806?source=see_link\">",
"     salmeterol",
"    </a>",
"    (50 mcg BID) plus beclomethasone (200 mcg BID) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/7/26745/abstract/13\">",
"     13",
"    </a>",
"    ]. Although both treatments resulted in improvement over baseline, the addition of salmeterol yielded a greater decrease in symptoms and beta-agonist use, improvement in morning peak flow, and reduction in peak flow variability. Furthermore, the addition of LABAs may allow for lowering of the inhaled GCs dose.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Low-dose inhaled GCs plus a LABA",
"    </span>",
"    &nbsp;&mdash;&nbsp;The combination of low-dose inhaled GCs plus a LABA is appropriate for previously untreated patients whose symptoms have been stable in the preceding weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?26/7/26745/abstract/1,18\">",
"     1,18",
"    </a>",
"    ]. The table provides a summary of currently available formulations of inhaled GCs and comparative dosing regimens (",
"    <a class=\"graphic graphic_table graphicRef78011 \" href=\"UTD.htm?15/35/15934\">",
"     table 3",
"    </a>",
"    )&nbsp;(",
"    <a class=\"graphic graphic_table graphicRef68143 \" href=\"UTD.htm?37/48/38668\">",
"     table 4",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The NAEPP guidelines give equal preference to the two options above. However, the United States Federal Drug Administration (FDA) issued an advisory regarding LABAs, recommending that they not be used alone as initial therapy for asthma of any severity, that they not be added when asthma control is actively deteriorating, that they only be used long-term in patients whose asthma cannot be adequately controlled with other asthma controller medications (eg, low or medium dose inhaled glucocorticoid), and that the LABA be discontinued, if possible, once asthma control is achieved [",
"    <a class=\"abstract\" href=\"UTD.htm?26/7/26745/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/19/16698?source=see_link\">",
"     \"Beta agonists in asthma: Controversy regarding chronic use\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Combination inhalers &ndash; There is widespread agreement that LABAs should ONLY be used IN COMBINATION with inhaled GCs [",
"      <a class=\"abstract\" href=\"UTD.htm?26/7/26745/abstract/21,22\">",
"       21,22",
"      </a>",
"      ]. The use of combination",
"      <span class=\"nowrap\">",
"       glucocorticoid/LABA",
"      </span>",
"      inhalers (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/21/8536?source=see_link\">",
"       budesonide-formoterol",
"      </a>",
"      , mometasone-formoterol,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/33/26136?source=see_link\">",
"       fluticasone-salmeterol",
"      </a>",
"      ) is a practical way to ensure that patients do not omit the inhaled glucocorticoid, leaving them on LABA monotherapy [",
"      <a class=\"abstract\" href=\"UTD.htm?26/7/26745/abstract/23-26\">",
"       23-26",
"      </a>",
"      ]. Each combination is available in several strengths which contain differing amount of inhaled GCs (",
"      <a class=\"graphic graphic_table graphicRef68143 \" href=\"UTD.htm?37/48/38668\">",
"       table 4",
"      </a>",
"      ). The use of these combination inhalers eliminates the possibility of using the LABA as monotherapy and therefore improves patient safety, although precise titration of the glucocorticoid dose is somewhat limited with these devices. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/20/18762?source=see_link\">",
"       \"Delivery of inhaled medication in adults\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      The combination of the",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/7/32880?source=see_link\">",
"       budesonide",
"      </a>",
"      -formoterol has also been shown to be useful as a reliever medication as well as a controller medication in persistent asthma [",
"      <a class=\"abstract\" href=\"UTD.htm?26/7/26745/abstract/27,28\">",
"       27,28",
"      </a>",
"      ]. When compared to budesonide-formoterol plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/61/16344?source=see_link\">",
"       albuterol",
"      </a>",
"      or budesonide alone plus albuterol, budesonide-formoterol for both maintenance therapy and symptom relief resulted in fewer asthma exacerbations, fewer courses of oral glucocorticoids, and improved asthma control [",
"      <a class=\"abstract\" href=\"UTD.htm?26/7/26745/abstract/27\">",
"       27",
"      </a>",
"      ]. Although this is an interesting finding, more studies examining this treatment strategy need to be done before it can be routinely recommended.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     A course of oral GCs in addition",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to one of the options above, a short course of oral glucocorticoids may be necessary to achieve symptom control in patients experiencing a significant exacerbation. We typically administer a one to two week tapering course beginning at 0.5 mg per kg body weight.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Alternate options",
"    </span>",
"    &nbsp;&mdash;&nbsp;Alternate approaches to treating patients with moderate persistent asthma include low-dose inhaled GCs plus either a leukotriene modifying agent or slow-release",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/31/30200?source=see_link\">",
"     theophylline",
"    </a>",
"    (",
"    <a class=\"graphic graphic_figure graphicRef56729 \" href=\"UTD.htm?43/33/44563\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/7/26745/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In our experience, the addition of these other agents will benefit some patients, although not all. Response to a given medication class cannot be predicted and must be determined empirically. When adding a second agent, we administer a one month trial and continue the new medication only if there is significant improvement in symptoms or lung function on the follow-up visit.",
"   </p>",
"   <p>",
"    Unfortunately, there is a tendency for medications to be continued even when benefit is not clear. If a second agent provides some but not full symptom control, then a third agent may be added. Alternatively, the partially effective agent could be discontinued if a better alternative is subsequently found.",
"   </p>",
"   <p>",
"    <strong>",
"     Leukotriene-modifying agents",
"    </strong>",
"    &mdash; Currently available agents include the leukotriene D4 (LTD4) receptor antagonists,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/54/20325?source=see_link\">",
"     zafirlukast",
"    </a>",
"    (Accolate) and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/49/37654?source=see_link\">",
"     montelukast",
"    </a>",
"    (Singulair), and the 5-lipoxygenase inhibitor,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/33/17940?source=see_link\">",
"     zileuton",
"    </a>",
"    (Zyflo) (",
"    <a class=\"graphic graphic_table graphicRef77367 \" href=\"UTD.htm?20/12/20683\">",
"     table 5",
"    </a>",
"    ). The mechanisms of action and safety of these agents and the need for monitoring with the use of zileuton are discussed elsewhere. The agents may be particularly helpful for patients who smoke (who may be less sensitive to inhaled GCs), and those with exercise or aspirin-induced asthma symptoms. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/1/30746?source=see_link\">",
"     \"Agents affecting the 5-lipoxygenase pathway in the treatment of asthma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Anti-leukotriene agents can improve symptoms and prevent exacerbations in some patients with moderate asthma and suboptimal control on inhaled GCs [",
"    <a class=\"abstract\" href=\"UTD.htm?26/7/26745/abstract/29-33\">",
"     29-33",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Two randomized trials showed a beneficial effect of adding",
"      <a class=\"drug drug_general\" href=\"UTD.htm?36/49/37654?source=see_link\">",
"       montelukast",
"      </a>",
"      to inhaled",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/7/32880?source=see_link\">",
"       budesonide",
"      </a>",
"      in patients with moderate asthma [",
"      <a class=\"abstract\" href=\"UTD.htm?26/7/26745/abstract/29,30\">",
"       29,30",
"      </a>",
"      ]. In one, the addition of montelukast (10 mg once daily) to inhaled budesonide (800 mcg once daily) was clinically equivalent to doubling the dose of inhaled glucocorticoid [",
"      <a class=\"abstract\" href=\"UTD.htm?26/7/26745/abstract/30\">",
"       30",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A &ldquo;pragmatic&rdquo; open-label trial compared use of leukotriene modifying agents with inhaled GCs for two years in a diverse primary care population [",
"      <a class=\"abstract\" href=\"UTD.htm?26/7/26745/abstract/34\">",
"       34",
"      </a>",
"      ]. The leukotriene receptor antagonists,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?36/49/37654?source=see_link\">",
"       montelukast",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/54/20325?source=see_link\">",
"       zafirlukast",
"      </a>",
"      , were equivalent to inhaled GCs as first-line controllers. It is possible that improved adherence to the oral leukotriene modifying agents in comparison to the inhaled GCs contributed to these findings. However, the study design limits the wide applicability of the results.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition to improving asthma control, anti-leukotriene agents may facilitate reduction of inhaled GCs dosage in patients on low or medium doses of inhaled GCs. In one study, for example, patients taking more than 1500",
"    <span class=\"nowrap\">",
"     mcg/day",
"    </span>",
"    of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/7/33904?source=see_link\">",
"     beclomethasone",
"    </a>",
"    withstood a 50 percent reduction in steroid dose while on the experimental LTD4 receptor antagonist, pranlukast, without a decrease in lung function or an increase in either symptoms or rescue beta-agonist use [",
"    <a class=\"abstract\" href=\"UTD.htm?26/7/26745/abstract/35\">",
"     35",
"    </a>",
"    ]. In contrast, patients receiving placebo sustained a 10 percent fall in FEV",
"    <sub>",
"     1",
"    </sub>",
"    and a 47",
"    <span class=\"nowrap\">",
"     L/min",
"    </span>",
"    decrease in morning peak flow rate, and had an increase in symptoms and rescue beta-agonist use.",
"   </p>",
"   <p>",
"    The relative efficacy of adding a leukotriene modifying agent to inhaled GCs, compared with adding an LABA, has not been studied extensively. However, in a large, multinational non-inferiority trial of 1490 subjects with persistent asthma symptoms despite inhaled GCs,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/49/37654?source=see_link\">",
"     montelukast",
"    </a>",
"    was at least as effective as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/63/34806?source=see_link\">",
"     salmeterol",
"    </a>",
"    in preventing asthma exacerbations [",
"    <a class=\"abstract\" href=\"UTD.htm?26/7/26745/abstract/36\">",
"     36",
"    </a>",
"    ]. Patients on stable doses of inhaled GCs were randomly assigned to either salmeterol or montelukast, and exacerbation rates were similar in both groups (20.1 percent versus 19.1 percent, respectively). In the &ldquo;pragmatic&rdquo; trial mentioned above, the leukotriene receptor antagonists (montelukast,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/54/20325?source=see_link\">",
"     zafirlukast",
"    </a>",
"    ) were equivalent to LABAs as add-on therapy at two months, but not at two years [",
"    <a class=\"abstract\" href=\"UTD.htm?26/7/26745/abstract/34\">",
"     34",
"    </a>",
"    ]. Further study is needed to clarify whether leukotriene antagonists and LABAs provide comparable benefit when used in combination with inhaled GCs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Theophylline",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sustained-release",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/31/30200?source=see_link\">",
"     theophylline",
"    </a>",
"    has been shown to be useful in patients with incomplete control of asthma symptoms while on inhaled GCs, as illustrated by the following studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/31/30200?source=see_link\">",
"       Theophylline",
"      </a>",
"      was shown to be a helpful addition to inhaled GCs and superior to regularly administered",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/61/16344?source=see_link\">",
"       albuterol",
"      </a>",
"      . In a randomized, placebo-controlled, crossover study, 32 patients received inhaled GCs and either placebo, inhaled albuterol four times per day, theophylline once daily, or the combination of theophylline and albuterol [",
"      <a class=\"abstract\" href=\"UTD.htm?26/7/26745/abstract/37\">",
"       37",
"      </a>",
"      ]. Both theophylline-containing regimens were superior in terms of pulmonary function and symptom control.",
"     </li>",
"     <li>",
"      A randomized, double-blind, placebo-controlled trial of 62 patients with moderate asthma and persistent symptoms despite inhaled GCs revealed that the addition of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/31/30200?source=see_link\">",
"       theophylline",
"      </a>",
"      to low-dose inhaled GCs was equally as effective as doubling the dose of the inhaled GCs [",
"      <a class=\"abstract\" href=\"UTD.htm?26/7/26745/abstract/38\">",
"       38",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/31/30200?source=see_link\">",
"     Theophylline",
"    </a>",
"    is inexpensive and available in an oral formulation. It is a reasonable alternative for patients who are intolerant of LABAs or who are unable to use a metered dose inhaler properly. Similarly, the addition of theophylline to inhaled GCs may allow better symptom control at lower doses of inhaled GCs. Attention to theophylline pharmacokinetics is essential in order to avoid toxicity. Notably, when added to inhaled GCs, the benefits from theophylline therapy typically were seen at a median concentration of 8.7",
"    <span class=\"nowrap\">",
"     mcg/mL,",
"    </span>",
"    below the often stated therapeutic range (10 to 20",
"    <span class=\"nowrap\">",
"     mcg/mL)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?26/7/26745/abstract/38\">",
"     38",
"    </a>",
"    ]. Theophylline dosing and monitoring is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/57/11161?source=see_link\">",
"     \"Theophylline use in asthma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Direct comparisons of sustained-released",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/31/30200?source=see_link\">",
"     theophylline",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/63/34806?source=see_link\">",
"     salmeterol",
"    </a>",
"    as added therapy in patients poorly controlled on inhaled GCs are lacking. However, as monotherapy (which is not recommended), salmeterol has been shown to be superior to theophylline in symptom control, peak flow, rescue beta-agonist use, and drug tolerance [",
"    <a class=\"abstract\" href=\"UTD.htm?26/7/26745/abstract/39,40\">",
"     39,40",
"    </a>",
"    ]. A meta-analysis including 1330 patients confirmed these findings [",
"    <a class=\"abstract\" href=\"UTD.htm?26/7/26745/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     ADJUSTING THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients should be reevaluated within two to six weeks of initiating therapy. Although the beneficial effects of inhaled GCs can be observed after a single dose, optimal therapeutic effects are achieved with chronic administration. Most of the improvement in lung function observed during inhaled GC therapy occurs within the first several weeks of treatment, although airway responsiveness may continue to improve (although not necessarily normalize) for over one year [",
"    <a class=\"abstract\" href=\"UTD.htm?26/7/26745/abstract/6,8,9,42\">",
"     6,8,9,42",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Assessing control",
"    </span>",
"    &nbsp;&mdash;&nbsp;Assessment of \"control,\" rather than severity, is used to adjust therapy in returning patients, or to alter therapy in patients evaluated for the first time while already taking a long-term controller medication. Control is based on impairment over the past two to four weeks (based on history or a validated questionnaire), current FEV",
"    <sub>",
"     1",
"    </sub>",
"    or peak flow, and estimates of risk, as shown in the figure (",
"    <a class=\"graphic graphic_table graphicRef53233 \" href=\"UTD.htm?38/33/39453\">",
"     table 6",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?26/7/26745/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Using the information gathered, the clinician should determine if the patient's asthma is well-controlled or not. If asthma is not well-controlled, therapy should be \"stepped-up.\" If the asthma is well-controlled, therapy can be continued or possibly \"stepped-down\" to minimize medication side effects. Most patients who are compliant with therapy achieve control of their asthma within a few weeks or months. Achieving control is emphasized because patients with poor control of asthma symptoms are more likely to require urgent care for asthma than those whose asthma is well-controlled [",
"    <a class=\"abstract\" href=\"UTD.htm?26/7/26745/abstract/43,44\">",
"     43,44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This adjustment of therapy should be repeated at each visit, because asthma is an inherently variable condition, and the management of asthma is a dynamic process that changes in accordance with the patient's needs over time.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Increasing therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Before increasing therapy, the clinician should assess the patient's understanding of and compliance with the current regimen as well as inhaler technique, and consider the possibility of contributing conditions, such as current cigarette smoking, chronic rhinosinusitis, and gastroesophageal reflux disease (GERD) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/7/26745/abstract/45,46\">",
"     45,46",
"    </a>",
"    ]. Although there is no evidence that treating minimally symptomatic or silent GERD improves asthma outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?26/7/26745/abstract/47\">",
"     47",
"    </a>",
"    ], treatment of symptomatic GERD may confer modest benefit in some patients [",
"    <a class=\"abstract\" href=\"UTD.htm?26/7/26745/abstract/48\">",
"     48",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/9/44184?source=see_link\">",
"     \"Trigger control to enhance asthma management\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/56/39816?source=see_link\">",
"     \"Gastroesophageal reflux and asthma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Medium-dose inhaled GCs plus a LABA",
"    </span>",
"    &nbsp;&mdash;&nbsp;The preferred option for increasing therapy in a patient with moderate persistent asthma is the combination of medium-dose inhaled GCs plus a LABA (Step 4 therapy) (",
"    <a class=\"graphic graphic_figure graphicRef56729 \" href=\"UTD.htm?43/33/44563\">",
"     figure 1",
"    </a>",
"    )&nbsp;(",
"    <a class=\"graphic graphic_table graphicRef68143 \" href=\"UTD.htm?37/48/38668\">",
"     table 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/7/26745/abstract/49\">",
"     49",
"    </a>",
"    ]. There does not appear to be a significant difference in outcomes (both efficacy and safety) between",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/33/26136?source=see_link\">",
"     fluticasone-salmeterol",
"    </a>",
"    versus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/21/8536?source=see_link\">",
"     budesonide-formoterol",
"    </a>",
"    , when used in the moderate dose range [",
"    <a class=\"abstract\" href=\"UTD.htm?26/7/26745/abstract/50-52\">",
"     50-52",
"    </a>",
"    ]. Mometasone-formoterol has been shown to have a similar effect on pulmonary function and a similar safety profile when compared with fluticasone-",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/63/34806?source=see_link\">",
"     salmeterol",
"    </a>",
"    , but was noted to have a more rapid onset of action [",
"    <a class=\"abstract\" href=\"UTD.htm?26/7/26745/abstract/53\">",
"     53",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H85264189\">",
"    <span class=\"h3\">",
"     Medium-dose inhaled GCs plus tiotropium",
"    </span>",
"    &nbsp;&mdash;&nbsp;Preliminary evidence suggests that adding the anticholinergic agent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/34/27173?source=see_link\">",
"     tiotropium",
"    </a>",
"    to medium dose inhaled GC may be another option [",
"    <a class=\"abstract\" href=\"UTD.htm?26/7/26745/abstract/54\">",
"     54",
"    </a>",
"    ], but this is not recommended by the NAEPP and further study of this option is needed before implementation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/36/33354?source=see_link&amp;anchor=H77146118#H77146118\">",
"     \"Alternative and experimental agents for the treatment of asthma\", section on 'Tiotropium'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Combining multiple therapies",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of other combinations of long-term controllers, such as inhaled GCs plus leukotriene modifiers plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/31/30200?source=see_link\">",
"     theophylline",
"    </a>",
"    , has not been specifically studied to determine which combinations are most effective. All combinations should include inhaled GCs because regimens that do not include an inhaled GC (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/63/34806?source=see_link\">",
"     salmeterol",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/49/37654?source=see_link\">",
"     montelukast",
"    </a>",
"    ) have been shown to be inferior [",
"    <a class=\"abstract\" href=\"UTD.htm?26/7/26745/abstract/55\">",
"     55",
"    </a>",
"    ]. Patients who fail to achieve symptom control despite two daily medications are likely to require the addition of high-dose inhaled GCs or oral glucocorticoids; they are thus classified as having severe asthma. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/49/14105?source=see_link\">",
"     \"Evaluation of severe asthma in adolescents and adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/17/3354?source=see_link\">",
"     \"Treatment of severe asthma in adolescents and adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Decreasing therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients whose asthma has been well-controlled over a period of three to six months on a stable medication regimen can have their therapy stepped down. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Assessing control'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    If the patient is on a medium dose inhaled glucocorticoid with a LABA, the LABA is usually discontinued first [",
"    <a class=\"abstract\" href=\"UTD.htm?26/7/26745/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. If the patient's asthma remains well-controlled at the next visit, the inhaled glucocorticoid dose is tapered by 25 to 50 percent to avoid the potential long-term side effects of inhaled GCs.",
"   </p>",
"   <p>",
"    A meta-analysis examined the effect of discontinuing the LABA in patients whose asthma was well-controlled for at least three months on a combination LABA plus GC inhaler [",
"    <a class=\"abstract\" href=\"UTD.htm?26/7/26745/abstract/56\">",
"     56",
"    </a>",
"    ]. Five randomized trials with a total of 1352 patients were included. Discontinuation of LABA resulted in loss of asthma control, fewer symptom free days, and increased rescue bronchodilator use. Increases in emergency or unscheduled visits and use of systemic glucocorticoids did not meet significance. The decision to discontinue a LABA after asthma control is attained should be made on a case by case basis, taking into consideration the patient&rsquo;s prior asthma history and estimated risk of deterioration in asthma control.",
"   </p>",
"   <p>",
"    The ability to reduce inhaled GC therapy without losing control of asthma was supported by the findings of a randomized trial of 259 patients with moderate persistent asthma assigned either to stable dose inhaled GCs, or a step-down approach to inhaled GCs dosing based on the patient's clinical condition [",
"    <a class=\"abstract\" href=\"UTD.htm?26/7/26745/abstract/57\">",
"     57",
"    </a>",
"    ]. Standard measures of asthma control were the same in both groups; however, patients in the dose reduction group maintained control with a lower cumulative dose of inhaled GCs over the course of the 12 month trial.",
"   </p>",
"   <p>",
"    In contrast to careful dose reduction, complete cessation of inhaled GCs is likely to lead to clinical deterioration in patients with persistent asthma. In a randomized, controlled trial of 175 patients with persistent asthma, the addition of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/63/34806?source=see_link\">",
"     salmeterol",
"    </a>",
"    to inhaled",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/38/39520?source=see_link\">",
"     triamcinolone",
"    </a>",
"    resulted in improved asthma symptom control [",
"    <a class=\"abstract\" href=\"UTD.htm?26/7/26745/abstract/58\">",
"     58",
"    </a>",
"    ]. After the introduction of salmeterol, inhaled GCs doses were successfully reduced by 50 percent in the majority of patients (90 percent) without a significant loss of asthma control. However, complete elimination of inhaled GCs resulted in significant deterioration of asthma control.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     ACUTE EXACERBATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The assessment and management of acute exacerbations, both at home and in the urgent care or emergency department setting, are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/56/5002?source=see_link\">",
"     \"Treatment of acute exacerbations of asthma in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     LONG-TERM MONITORING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with asthma should be re-evaluated periodically for a careful review of symptoms and for medication adjustment. We typically request that patients with moderate persistent asthma return to the office at three to four month intervals.",
"   </p>",
"   <p>",
"    We perform annual spirometry for stable moderate asthma. Spirometry should also be performed when there is a significant change in clinical status and may be considered to confirm that a step-down in medication has not caused a clinically-silent decline in lung function. Spirometry may have utility in comparing the efficacy of various add-on controller agents.",
"   </p>",
"   <p>",
"    Clinically significant bone loss is not likely to occur from the doses of inhaled glucocorticoids used to treat moderate asthma [",
"    <a class=\"abstract\" href=\"UTD.htm?26/7/26745/abstract/59\">",
"     59",
"    </a>",
"    ]. Additionally, there is little clinical data regarding subsequent bone fracture risk imposed by the use of either inhaled or oral GC in asthma. Thus, we do not routinely assess bone density, although it should be considered when other risk factors for osteoporosis are present.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?29/22/30052?source=see_link\">",
"       \"Patient information: Medicines for asthma (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?38/63/39925?source=see_link\">",
"       \"Patient information: Asthma treatment in adolescents and adults (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?30/25/31124?source=see_link\">",
"       \"Patient information: Trigger avoidance in asthma (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?31/6/31841?source=see_link\">",
"       \"Patient information: How to use a peak flow meter (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?28/25/29075?source=see_link\">",
"       \"Patient information: Asthma inhaler techniques in adults (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;All patients with moderate persistent asthma should be treated with the combination of daily inhaled glucocorticoids to reduce airway inflammation, plus a quick-acting bronchodilator to relieve acute symptoms. The NAEPP 2007 guidelines recommend initiating treatment at Step 3 for patients with moderate persistent asthma (",
"    <a class=\"graphic graphic_figure graphicRef56729 \" href=\"UTD.htm?43/33/44563\">",
"     figure 1",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H3\">",
"     'General principles'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We recommend an inhaled short-acting beta-agonist for relief of symptoms. We suggest that this be used on an as-needed basis, rather than at regularly scheduled intervals.",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/61/16344?source=see_link\">",
"       Albuterol",
"      </a>",
"      , at a dose of two to four puffs inhaled as needed every four to six hours, is widely used. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Short-acting beta agonists'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend inhaled glucocorticoids as the primary long-term controller therapy (",
"      <a class=\"graphic graphic_figure graphicRef56729 \" href=\"UTD.htm?43/33/44563\">",
"       figure 1",
"      </a>",
"      ). Inhaled GCs should be initiated at medium-doses when used without a long-acting beta agonist (LABA), or at low-doses in combination with a LABA (",
"      <a class=\"graphic graphic_table graphicRef78011 \" href=\"UTD.htm?15/35/15934\">",
"       table 3",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef68143 \" href=\"UTD.htm?37/48/38668\">",
"       table 4",
"      </a>",
"      ). Patients who are experiencing heightened symptoms when therapy is started may benefit from a one to two week course of oral glucocorticoids, in addition to long-term controller therapy. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Preferred options'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The patient's level of asthma control should be re-assessed at every subsequent visit for asthma care (",
"      <a class=\"graphic graphic_table graphicRef53233 \" href=\"UTD.htm?38/33/39453\">",
"       table 6",
"      </a>",
"      ). The possibility of medication non-compliance, poor inhaler technique, or exacerbating conditions (GERD, sinusitis, others) should be considered in patients whose asthma is not well-controlled, prior to increasing therapy. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Adjusting therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients requiring additional therapy to achieve symptom control, the preferred next option is the combination of medium-dose inhaled GCs and a LABA, or step 4 therapy (",
"      <a class=\"graphic graphic_figure graphicRef56729 \" href=\"UTD.htm?43/33/44563\">",
"       figure 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef68143 \" href=\"UTD.htm?37/48/38668\">",
"       table 4",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Increasing therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Alternative approaches to treating moderate persistent asthma include the combination of inhaled glucocorticoids and either leukotriene modifying agents or slow-release",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/31/30200?source=see_link\">",
"       theophylline",
"      </a>",
"      (",
"      <a class=\"graphic graphic_figure graphicRef56729 \" href=\"UTD.htm?43/33/44563\">",
"       figure 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef77367 \" href=\"UTD.htm?20/12/20683\">",
"       table 5",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Alternate options'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If asthma symptoms are well-controlled for a period of three to six months, we usually attempt to taper the medication regimen. The decision of which medication (LABA or inhaled GC) to taper or discontinue is made on a case by case basis taking into account the patient&rsquo;s past experience with asthma medications and likelihood of a deterioration in control. For patients on a combination LABA and medium dose inhaled GC, the LABA is usually discontinued first. When tapering inhaled GCs, we reduce the dose in increments of 25 to 50 percent at intervals of three months or longer, to the lowest dose that maintains the patient in a well-controlled state. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Decreasing therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     National Asthma Education and Prevention Program: Expert panel report III: Guidelines for the diagnosis and management of asthma. Bethesda, MD: National Heart, Lung, and Blood Institute, 2007. (NIH publication no. 08-4051) www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm (Accessed on January 05, 2012).",
"    </li>",
"    <li>",
"     Global Strategy for Asthma Management and Prevention, Global Initiative for Asthma (GINA) 2012. file://www.ginasthma.org/local/uploads/files/GINA_Report_2012Feb13.pdf (Accessed on March 12, 2013).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/7/26745/abstract/3\">",
"      Bateman ED, Boushey HA, Bousquet J, et al. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study. Am J Respir Crit Care Med 2004; 170:836.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/7/26745/abstract/4\">",
"      Drazen JM, Israel E, Boushey HA, et al. Comparison of regularly scheduled with as-needed use of albuterol in mild asthma. Asthma Clinical Research Network. N Engl J Med 1996; 335:841.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/7/26745/abstract/5\">",
"      Chervinsky P, van As A, Bronsky EA, et al. Fluticasone propionate aerosol for the treatment of adults with mild to moderate asthma. The Fluticasone Propionate Asthma Study Group. J Allergy Clin Immunol 1994; 94:676.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/7/26745/abstract/6\">",
"      Haahtela T, J&auml;rvinen M, Kava T, et al. Comparison of a beta 2-agonist, terbutaline, with an inhaled corticosteroid, budesonide, in newly detected asthma. N Engl J Med 1991; 325:388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/7/26745/abstract/7\">",
"      Juniper EF, Kline PA, Vanzieleghem MA, et al. Long-term effects of budesonide on airway responsiveness and clinical asthma severity in inhaled steroid-dependent asthmatics. Eur Respir J 1990; 3:1122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/7/26745/abstract/8\">",
"      Juniper EF, Kline PA, Vanzieleghem MA, et al. Effect of long-term treatment with an inhaled corticosteroid (budesonide) on airway hyperresponsiveness and clinical asthma in nonsteroid-dependent asthmatics. Am Rev Respir Dis 1990; 142:832.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/7/26745/abstract/9\">",
"      Salmeron S, Guerin JC, Godard P, et al. High doses of inhaled corticosteroids in unstable chronic asthma. A multicenter, double-blind, placebo-controlled study. Am Rev Respir Dis 1989; 140:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/7/26745/abstract/10\">",
"      Donahue JG, Weiss ST, Livingston JM, et al. Inhaled steroids and the risk of hospitalization for asthma. JAMA 1997; 277:887.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/7/26745/abstract/11\">",
"      Stempel DA, Meyer JW, Stanford RH, Yancey SW. One-year claims analysis comparing inhaled fluticasone propionate with zafirlukast for the treatment of asthma. J Allergy Clin Immunol 2001; 107:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/7/26745/abstract/12\">",
"      Suissa S, Ernst P, Benayoun S, et al. Low-dose inhaled corticosteroids and the prevention of death from asthma. N Engl J Med 2000; 343:332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/7/26745/abstract/13\">",
"      Greening AP, Ind PW, Northfield M, Shaw G. Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Allen &amp; Hanburys Limited UK Study Group. Lancet 1994; 344:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/7/26745/abstract/14\">",
"      Woolcock A, Lundback B, Ringdal N, Jacques LA. Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids. Am J Respir Crit Care Med 1996; 153:1481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/7/26745/abstract/15\">",
"      Pauwels RA, L&ouml;fdahl CG, Postma DS, et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. N Engl J Med 1997; 337:1405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/7/26745/abstract/16\">",
"      Greenstone IR, Ni Chroinin MN, Masse V, et al. Combination of inhaled long-acting beta2-agonists and inhaled steroids versus higher dose of inhaled steroids in children and adults with persistent asthma. Cochrane Database Syst Rev 2005; :CD005533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/7/26745/abstract/17\">",
"      O'Byrne PM, Naya IP, Kallen A, et al. Increasing doses of inhaled corticosteroids compared to adding long-acting inhaled beta2-agonists in achieving asthma control. Chest 2008; 134:1192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/7/26745/abstract/18\">",
"      Ni Chroinin M, Greenstone I, Lasserson TJ, Ducharme FM. Addition of inhaled long-acting beta2-agonists to inhaled steroids as first line therapy for persistent asthma in steroid-naive adults and children. Cochrane Database Syst Rev 2009; :CD005307.",
"     </a>",
"    </li>",
"    <li>",
"     FDA Alert for healthcare professionals Salmeterol xinofoate inhaltion powder (marketed as Serevent Diskus). www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm200776.htm.",
"    </li>",
"    <li>",
"     FDA Alert for healthcare professionals Fluticasone propionate and salmeterol inhalation powder (marketed as Advair Diskus). www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm200776.htm.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/7/26745/abstract/21\">",
"      Lazarus SC, Boushey HA, Fahy JV, et al. Long-acting beta2-agonist monotherapy vs continued therapy with inhaled corticosteroids in patients with persistent asthma: a randomized controlled trial. JAMA 2001; 285:2583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/7/26745/abstract/22\">",
"      Cates CJ, Cates MJ, Lasserson TJ. Regular treatment with formoterol for chronic asthma: serious adverse events. Cochrane Database Syst Rev 2008; :CD006923.",
"     </a>",
"    </li>",
"    <li>",
"     A combination of fluticasone and salmeterol for asthma. In: The Medical Letter on drugs and therapeutics, 43, New Rochelle, NY 2000. p.31.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/7/26745/abstract/24\">",
"      Kavuru M, Melamed J, Gross G, et al. Salmeterol and fluticasone propionate combined in a new powder inhalation device for the treatment of asthma: a randomized, double-blind, placebo-controlled trial. J Allergy Clin Immunol 2000; 105:1108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/7/26745/abstract/25\">",
"      Markham A, Jarvis B. Inhaled salmeterol/fluticasone propionate combination: a review of its use in persistent asthma. Drugs 2000; 60:1207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/7/26745/abstract/26\">",
"      Nathan RA, Nolte H, Pearlman DS, P04334 Study Investigators. Twenty-six-week efficacy and safety study of mometasone furoate/formoterol 200/10 microg combination treatment in patients with persistent asthma previously receiving medium-dose inhaled corticosteroids. Allergy Asthma Proc 2010; 31:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/7/26745/abstract/27\">",
"      O'Byrne PM, Bisgaard H, Godard PP, et al. Budesonide/formoterol combination therapy as both maintenance and reliever medication in asthma. Am J Respir Crit Care Med 2005; 171:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/7/26745/abstract/28\">",
"      Rabe KF, Atienza T, Magyar P, et al. Effect of budesonide in combination with formoterol for reliever therapy in asthma exacerbations: a randomised controlled, double-blind study. Lancet 2006; 368:744.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/7/26745/abstract/29\">",
"      Vaquerizo MJ, Casan P, Castillo J, et al. Effect of montelukast added to inhaled budesonide on control of mild to moderate asthma. Thorax 2003; 58:204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/7/26745/abstract/30\">",
"      Price DB, Hernandez D, Magyar P, et al. Randomised controlled trial of montelukast plus inhaled budesonide versus double dose inhaled budesonide in adult patients with asthma. Thorax 2003; 58:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/7/26745/abstract/31\">",
"      Virchow JC Jr, Prasse A, Naya I, et al. Zafirlukast improves asthma control in patients receiving high-dose inhaled corticosteroids. Am J Respir Crit Care Med 2000; 162:578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/7/26745/abstract/32\">",
"      Israel E, Cohn J, Dub&eacute; L, Drazen JM. Effect of treatment with zileuton, a 5-lipoxygenase inhibitor, in patients with asthma. A randomized controlled trial. Zileuton Clinical Trial Group. JAMA 1996; 275:931.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/7/26745/abstract/33\">",
"      Joos S, Miksch A, Szecsenyi J, et al. Montelukast as add-on therapy to inhaled corticosteroids in the treatment of mild to moderate asthma: a systematic review. Thorax 2008; 63:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/7/26745/abstract/34\">",
"      Price D, Musgrave SD, Shepstone L, et al. Leukotriene antagonists as first-line or add-on asthma-controller therapy. N Engl J Med 2011; 364:1695.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/7/26745/abstract/35\">",
"      Tamaoki J, Kondo M, Sakai N, et al. Leukotriene antagonist prevents exacerbation of asthma during reduction of high-dose inhaled corticosteroid. The Tokyo Joshi-Idai Asthma Research Group. Am J Respir Crit Care Med 1997; 155:1235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/7/26745/abstract/36\">",
"      Bjermer L, Bisgaard H, Bousquet J, et al. Montelukast and fluticasone compared with salmeterol and fluticasone in protecting against asthma exacerbation in adults: one year, double blind, randomised, comparative trial. BMJ 2003; 327:891.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/7/26745/abstract/37\">",
"      Rivington RN, Boulet LP, C&ocirc;t&eacute; J, et al. Efficacy of Uniphyl, salbutamol, and their combination in asthmatic patients on high-dose inhaled steroids. Am J Respir Crit Care Med 1995; 151:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/7/26745/abstract/38\">",
"      Evans DJ, Taylor DA, Zetterstrom O, et al. A comparison of low-dose inhaled budesonide plus theophylline and high-dose inhaled budesonide for moderate asthma. N Engl J Med 1997; 337:1412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/7/26745/abstract/39\">",
"      Fjellbirkeland L, Gulsvik A, Palmer JB. The efficacy and tolerability of inhaled salmeterol and individually dose-titrated, sustained-release theophylline in patients with reversible airways disease. Respir Med 1994; 88:599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/7/26745/abstract/40\">",
"      Tee AK, Koh MS, Gibson PG, et al. Long-acting beta2-agonists versus theophylline for maintenance treatment of asthma. Cochrane Database Syst Rev 2007; :CD001281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/7/26745/abstract/41\">",
"      Davies B, Brooks G, Devoy M. The efficacy and safety of salmeterol compared to theophylline: meta-analysis of nine controlled studies. Respir Med 1998; 92:256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/7/26745/abstract/42\">",
"      Engel T, Dirksen A, Heinig JH, et al. Single-dose inhaled budesonide in subjects with chronic asthma. Allergy 1991; 46:547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/7/26745/abstract/43\">",
"      Peters SP, Jones CA, Haselkorn T, et al. Real-world Evaluation of Asthma Control and Treatment (REACT): findings from a national Web-based survey. J Allergy Clin Immunol 2007; 119:1454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/7/26745/abstract/44\">",
"      Chapman KR, Boulet LP, Rea RM, Franssen E. Suboptimal asthma control: prevalence, detection and consequences in general practice. Eur Respir J 2008; 31:320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/7/26745/abstract/45\">",
"      Lazarus SC, Chinchilli VM, Rollings NJ, et al. Smoking affects response to inhaled corticosteroids or leukotriene receptor antagonists in asthma. Am J Respir Crit Care Med 2007; 175:783.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/7/26745/abstract/46\">",
"      Pedersen SE, Bateman ED, Bousquet J, et al. Determinants of response to fluticasone propionate and salmeterol/fluticasone propionate combination in the Gaining Optimal Asthma controL study. J Allergy Clin Immunol 2007; 120:1036.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/7/26745/abstract/47\">",
"      American Lung Association Asthma Clinical Research Centers, Mastronarde JG, Anthonisen NR, et al. Efficacy of esomeprazole for treatment of poorly controlled asthma. N Engl J Med 2009; 360:1487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/7/26745/abstract/48\">",
"      Kiljander TO, Junghard O, Beckman O, Lind T. Effect of esomeprazole 40 mg once or twice daily on asthma: a randomized, placebo-controlled study. Am J Respir Crit Care Med 2010; 181:1042.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/7/26745/abstract/49\">",
"      Ducharme FM, Ni Chroinin M, Greenstone I, Lasserson TJ. Addition of long-acting beta2-agonists to inhaled corticosteroids versus same dose inhaled corticosteroids for chronic asthma in adults and children. Cochrane Database Syst Rev 2010; :CD005535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/7/26745/abstract/50\">",
"      Busse WW, Shah SR, Somerville L, et al. Comparison of adjustable- and fixed-dose budesonide/formoterol pressurized metered-dose inhaler and fixed-dose fluticasone propionate/salmeterol dry powder inhaler in asthma patients. J Allergy Clin Immunol 2008; 121:1407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/7/26745/abstract/51\">",
"      Cates CJ, Lasserson TJ. Regular treatment with formoterol and an inhaled corticosteroid versus regular treatment with salmeterol and an inhaled corticosteroid for chronic asthma: serious adverse events. Cochrane Database Syst Rev 2010; :CD007694.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/7/26745/abstract/52\">",
"      Lasserson TJ, Ferrara G, Casali L. Combination fluticasone and salmeterol versus fixed dose combination budesonide and formoterol for chronic asthma in adults and children. Cochrane Database Syst Rev 2011; :CD004106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/7/26745/abstract/53\">",
"      Bernstein DI, H&eacute;bert J, Cheema A, et al. Efficacy and onset of action of mometasone furoate/formoterol and fluticasone propionate/salmeterol combination treatment in subjects with persistent asthma. Allergy Asthma Clin Immunol 2011; 7:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/7/26745/abstract/54\">",
"      Peters, SP, Kunselman, SJ, Icitovic, N. Tiotropium Bromide Step-Up Therapy for Adults with Uncontrolled Asthma. N Engl J Med 2010; 363:1291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/7/26745/abstract/55\">",
"      Deykin A, Wechsler ME, Boushey HA, et al. Combination therapy with a long-acting beta-agonist and a leukotriene antagonist in moderate asthma. Am J Respir Crit Care Med 2007; 175:228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/7/26745/abstract/56\">",
"      Brozek JL, Kraft M, Krishnan JA, et al. Long-acting &beta;2-agonist step-off in patients with controlled asthma. Arch Intern Med 2012; 172:1365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/7/26745/abstract/57\">",
"      Hawkins G, McMahon AD, Twaddle S, et al. Stepping down inhaled corticosteroids in asthma: randomised controlled trial. BMJ 2003; 326:1115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/7/26745/abstract/58\">",
"      Lemanske RF Jr, Sorkness CA, Mauger EA, et al. Inhaled corticosteroid reduction and elimination in patients with persistent asthma receiving salmeterol: a randomized controlled trial. JAMA 2001; 285:2594.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/7/26745/abstract/59\">",
"      Peters SP. Safety of inhaled corticosteroids in the treatment of persistent asthma. J Natl Med Assoc 2006; 98:851.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 532 Version 17.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-1.234.2.38-C3DAD56939-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_7_26745=[""].join("\n");
var outline_f26_7_26745=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H24\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      GENERAL PRINCIPLES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Patient education",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Immunotherapy for allergic asthma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      SHORT-ACTING BETA AGONISTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      INITIATING CONTROLLER THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Preferred options",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Medium-dose inhaled GCs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Low-dose inhaled GCs plus a LABA",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - A course of oral GCs in addition",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Alternate options",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Theophylline",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      ADJUSTING THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Assessing control",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Increasing therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Medium-dose inhaled GCs plus a LABA",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H85264189\">",
"      - Medium-dose inhaled GCs plus tiotropium",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Combining multiple therapies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Decreasing therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      ACUTE EXACERBATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      LONG-TERM MONITORING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/532\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/532|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?43/33/44563\" title=\"figure 1\">",
"      Stepwise asthma Rx 12 and up",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/532|Form\">",
"      <a href=\"#\" title=\"FORMS\">",
"       FORMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_form\" href=\"UTD.htm?36/39/37498\" title=\"figure 2\">",
"      Asthma action plan",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/532|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?32/48/33549\" title=\"table 1\">",
"      Initiating Rx 12 and up",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?15/34/15917\" title=\"table 2\">",
"      Doses beta agonist preparations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?15/35/15934\" title=\"table 3\">",
"      Inhaled GC doses for adults",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?37/48/38668\" title=\"table 4\">",
"      Usual doses inhaled GC-LABA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?20/12/20683\" title=\"table 5\">",
"      Usual doses antileukotriene",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?38/33/39453\" title=\"table 6\">",
"      Adjusting Rx 12 and up",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/1/30746?source=related_link\">",
"      Agents affecting the 5-lipoxygenase pathway in the treatment of asthma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/36/33354?source=related_link\">",
"      Alternative and experimental agents for the treatment of asthma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/37/8794?source=related_link\">",
"      An overview of asthma management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/26/8618?source=related_link\">",
"      Beta agonists in asthma: Acute administration and prophylactic use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/19/16698?source=related_link\">",
"      Beta agonists in asthma: Controversy regarding chronic use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/30/37354?source=related_link\">",
"      Chronic asthma in children younger than 12 years: Controller medications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/20/18762?source=related_link\">",
"      Delivery of inhaled medication in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/49/14105?source=related_link\">",
"      Evaluation of severe asthma in adolescents and adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/56/39816?source=related_link\">",
"      Gastroesophageal reflux and asthma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/52/4937?source=related_link\">",
"      Pathogenesis of asthma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?28/25/29075?source=related_link\">",
"      Patient information: Asthma inhaler techniques in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?38/63/39925?source=related_link\">",
"      Patient information: Asthma treatment in adolescents and adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?31/6/31841?source=related_link\">",
"      Patient information: How to use a peak flow meter (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?29/22/30052?source=related_link\">",
"      Patient information: Medicines for asthma (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?30/25/31124?source=related_link\">",
"      Patient information: Trigger avoidance in asthma (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/8/39049?source=related_link\">",
"      Subcutaneous immunotherapy for allergic disease: Indications and efficacy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/57/11161?source=related_link\">",
"      Theophylline use in asthma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/56/5002?source=related_link\">",
"      Treatment of acute exacerbations of asthma in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/17/3354?source=related_link\">",
"      Treatment of severe asthma in adolescents and adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/9/44184?source=related_link\">",
"      Trigger control to enhance asthma management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/15/31991?source=related_link\">",
"      What do patients need to know about their asthma?",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_7_26746="Antiviral drugs for the prevention and treatment of seasonal influenza in children";
var content_f26_7_26746=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Antiviral drugs for the prevention and treatment of seasonal influenza in children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/7/26746/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/7/26746/contributors\">",
"     Flor M Munoz, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/7/26746/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/7/26746/contributors\">",
"     George B Mallory, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/7/26746/contributors\">",
"     Morven S Edwards, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/7/26746/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/7/26746/contributors\">",
"     Mary M Torchia, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?26/7/26746/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 20, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Influenza is an acute respiratory illness caused by influenza A or B viruses, which occurs in outbreaks worldwide every year, mainly during the winter seasons in temperate climates.",
"   </p>",
"   <p>",
"    Certain groups of children are at increased risk of acquiring severe or complicated illness from influenza (",
"    <a class=\"graphic graphic_table graphicRef72029 \" href=\"UTD.htm?32/50/33579\">",
"     table 1",
"    </a>",
"    ). Among healthy children, influenza generally is an acute, self-limited, and uncomplicated disease [",
"    <a class=\"abstract\" href=\"UTD.htm?26/7/26746/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. However, it can be associated with severe morbidity and mortality. Influenza causes an appreciable disease burden (eg, school and work absence, increased frequency of outpatient medical visits), and children are important vectors for the spread of disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/49/24346?source=see_link&amp;anchor=H2#H2\">",
"     \"Clinical features and diagnosis of seasonal influenza in children\", section on 'Epidemiology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Immunization is the major public health measure for the prevention of influenza infection [",
"    <a class=\"abstract\" href=\"UTD.htm?26/7/26746/abstract/4-6\">",
"     4-6",
"    </a>",
"    ]. However, antiviral drugs also may be used for prevention in high-risk patients who have not been immunized or who may have a suboptimal response to vaccine, in patients in whom influenza vaccine is contraindicated, and for anyone who wants to reduce their risk of acquiring influenza in seasons when the vaccine is a poor match for circulating influenza.",
"   </p>",
"   <p>",
"    Antiviral drugs are an important treatment option for patients who develop influenza infection despite immunization. Families of infants and children who are susceptible to severe disease from influenza should be reminded that these children may develop influenza infection despite immunization. If so, they should be seen by their health care provider as soon as possible after symptom onset because treatment is most beneficial when started early in the course of influenza.",
"   </p>",
"   <p>",
"    The use of antiviral drugs in the prevention and treatment of influenza in children will be presented here. Influenza vaccination in children and the use of antiviral drugs in adults are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/18/27946?source=see_link\">",
"     \"Seasonal influenza vaccination in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/13/44249?source=see_link\">",
"     \"Prevention of seasonal influenza in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/46/22250?source=see_link\">",
"     \"Treatment of seasonal influenza in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     INFLUENZA ACTIVITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Centers for Disease Control and Prevention (CDC), in collaboration with the World Health Organization (WHO) and its reporting network, tracks influenza virus isolates throughout the world to monitor disease activity and to predict the appropriate components for the annual influenza vaccine. This information, which is updated weekly during influenza season, is available via the",
"    <a class=\"external\" href=\"file://www.cdc.gov/flu/weekly/\">",
"     CDC",
"    </a>",
"    . In addition, FluNet, a database for global influenza virus surveillance, is available via the",
"    <a class=\"external\" href=\"file://www.who.int/influenza/gisrs_laboratory/flunet/en/\">",
"     WHO",
"    </a>",
"    . Local hospital or clinic laboratories may also collect information to monitor influenza activity in a specific geographic area.",
"   </p>",
"   <p>",
"    Since July 2011, H3N2 influenza A variant viruses caused by reassortment of swine-origin H3N2 influenza A viruses and pandemic H1N1 influenza A viruses have been increasingly reported in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?26/7/26746/abstract/7-9\">",
"     7-9",
"    </a>",
"    ]. These viruses are susceptible to",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?17/59/18360?source=see_link\">",
"     oseltamivir",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?15/47/16117?source=see_link\">",
"     zanamivir",
"    </a>",
"    , but resistant to",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?16/62/17383?source=see_link\">",
"     amantadine",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/39/34420?source=see_link\">",
"     rimantadine",
"    </a>",
"    . Additional unexpected reassortment combinations may occur; updated information is available from the",
"    <a class=\"external\" href=\"file://www.cdc.gov/flu/weekly/fluactivitysurv.htm\">",
"     CDC",
"    </a>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/58/15272?source=see_link&amp;anchor=H104949276#H104949276\">",
"     \"Epidemiology of influenza\", section on 'H3N2 variant influenza'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     ANTIVIRAL DRUGS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two classes of antiviral drugs are available for the prevention and treatment of influenza in children: neuraminidase inhibitors and adamantanes (M2 inhibitors) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/7/26746/abstract/1,10\">",
"     1,10",
"    </a>",
"    ]. Neuraminidase inhibitors and adamantanes should not be used to treat illnesses caused by other respiratory viruses. The pharmacology of these drugs is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/11/19640?source=see_link\">",
"     \"Pharmacology of antiviral drugs for influenza\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Since September 2009, &gt;99 percent of circulating influenza virus strains have been susceptible to neuraminidase inhibitors [",
"    <a class=\"abstract\" href=\"UTD.htm?26/7/26746/abstract/11-13\">",
"     11-13",
"    </a>",
"    ]. However, high levels of resistance to adamantanes exist in the currently circulating strains and they should not be used for treatment of influenza. Information regarding antiviral resistance that emerges during the influenza season is available through the",
"    <a class=\"external\" href=\"file://www.cdc.gov/flu/professionals/\">",
"     Centers for Disease Control and Prevention",
"    </a>",
"    (CDC).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Neuraminidase inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?17/59/18360?source=see_link\">",
"     Oseltamivir",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?15/47/16117?source=see_link\">",
"     zanamivir",
"    </a>",
"    , laninamivir, and peramivir are neuraminidase inhibitors, which prevent the release of virions from the host cell [",
"    <a class=\"abstract\" href=\"UTD.htm?26/7/26746/abstract/14\">",
"     14",
"    </a>",
"    ]. Neuraminidase inhibitors are active against influenza A viruses (including the pandemic 2009-2010 H1N1 strain) and influenza B viruses [",
"    <a class=\"abstract\" href=\"UTD.htm?26/7/26746/abstract/10\">",
"     10",
"    </a>",
"    ]. Oseltamivir and zanamivir are available in the United States. Laninamivir and peramivir are available in Japan, but not yet licensed in the United States.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?17/59/18360?source=see_link\">",
"       Oseltamivir",
"      </a>",
"      &ndash; Oseltamivir is active against both influenza A and B viruses. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Antiviral resistance'",
"      </a>",
"      below.)",
"      <br/>",
"      <br/>",
"      Oseltamivir is approved in the United States for the prophylaxis of influenza A and B viruses in individuals &ge;1 year of age and the treatment of influenza A and B viruses in individuals &ge;2 weeks of age, but may be used for the prophylaxis and treatment of influenza infection in younger children when indicated [",
"      <a class=\"abstract\" href=\"UTD.htm?26/7/26746/abstract/10,15\">",
"       10,15",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Oseltamivir is administered orally. It is available as a capsule or as a powder for liquid suspension. The dose and duration of oseltamivir vary according to weight and indication (eg, prophylaxis or treatment) (",
"      <a class=\"graphic graphic_table graphicRef61888 \" href=\"UTD.htm?2/61/3037\">",
"       table 2",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef70571 \" href=\"UTD.htm?6/45/6877\">",
"       table 3",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?26/7/26746/abstract/10\">",
"       10",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Prophylaxis dosing'",
"      </a>",
"      below and",
"      <a class=\"local\" href=\"#H27\">",
"       'Treatment dosing'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?15/47/16117?source=see_link\">",
"       Zanamivir",
"      </a>",
"      &ndash; Zanamivir is active against both influenza A and B viruses. Zanamivir is approved in the United States for the prophylaxis of influenza in individuals &ge;5 years and the treatment of influenza in individuals &ge;7 years of age [",
"      <a class=\"abstract\" href=\"UTD.htm?26/7/26746/abstract/10\">",
"       10",
"      </a>",
"      ]. Zanamivir is a dry powder administered by oral inhalation; the dose and duration vary according to the indication (",
"      <a class=\"graphic graphic_table graphicRef61888 \" href=\"UTD.htm?2/61/3037\">",
"       table 2",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef70571 \" href=\"UTD.htm?6/45/6877\">",
"       table 3",
"      </a>",
"      ). Zanamivir inhalation powder should not be reconstituted in any liquid formulation and is not recommended for use in nebulizers or mechanical ventilators [",
"      <a class=\"abstract\" href=\"UTD.htm?26/7/26746/abstract/16\">",
"       16",
"      </a>",
"      ]. Zanamivir is not recommended for patients with a history of wheezing or underlying chronic respiratory disease [",
"      <a class=\"abstract\" href=\"UTD.htm?26/7/26746/abstract/10\">",
"       10",
"      </a>",
"      ]. These patients are at increased risk of developing bronchospasm and occasionally may have some decline in their respiratory function after administration of zanamivir.",
"     </li>",
"     <li>",
"      Laninamivir &ndash; Laninamivir is a long-acting neuraminidase inhibitor that is administered in a single inhalation [",
"      <a class=\"abstract\" href=\"UTD.htm?26/7/26746/abstract/17,18\">",
"       17,18",
"      </a>",
"      ]. In in vitro studies and clinical trials, it has shown activity against",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?17/59/18360?source=see_link\">",
"       oseltamivir",
"      </a>",
"      -resistant influenza viruses [",
"      <a class=\"abstract\" href=\"UTD.htm?26/7/26746/abstract/17,19,20\">",
"       17,19,20",
"      </a>",
"      ]. In randomized trials, the efficacy and safety of laninamivir in children with influenza infection were similar to those of oseltamivir and",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?15/47/16117?source=see_link\">",
"       zanamivir",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?26/7/26746/abstract/17,18\">",
"       17,18",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Peramivir &ndash; Peramivir is an intravenously administered neuraminidase inhibitor that is available in Japan. In the United States it is available through participation in clinical trials; during the 2009 influenza pandemic, it was used to treat potentially life-threatening influenza through Emergency Use Authorization (EUA), but the EUA is no longer in effect [",
"      <a class=\"abstract\" href=\"UTD.htm?26/7/26746/abstract/21-23\">",
"       21-23",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Adverse events",
"    </span>",
"    &nbsp;&mdash;&nbsp;In prelicensure studies,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?17/59/18360?source=see_link\">",
"     oseltamivir",
"    </a>",
"    was well tolerated, with few adverse effects [",
"    <a class=\"abstract\" href=\"UTD.htm?26/7/26746/abstract/24\">",
"     24",
"    </a>",
"    ]. Gastrointestinal complaints were most frequent, occurring in 14 percent of oseltamivir recipients, compared with 8.5 percent of placebo recipients. In postmarketing reports, gastrointestinal symptoms continue to predominate [",
"    <a class=\"abstract\" href=\"UTD.htm?26/7/26746/abstract/25-27\">",
"     25-27",
"    </a>",
"    ]. During a school outbreak of 2009 pandemic influenza A (H1N1), 14 percent of students and 20 percent of staff who were prescribed oseltamivir prophylaxis discontinued it because of adverse effects (predominantly nausea, vomiting, and rash) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/7/26746/abstract/25\">",
"     25",
"    </a>",
"    ]. In retrospective reviews, the use of oseltamivir for the treatment of influenza among infants younger than 12 months of age was not associated with increased risk of adverse neurologic events or mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?26/7/26746/abstract/28,29\">",
"     28,29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?15/47/16117?source=see_link\">",
"     Zanamivir",
"    </a>",
"    also is generally well tolerated [",
"    <a class=\"abstract\" href=\"UTD.htm?26/7/26746/abstract/10\">",
"     10",
"    </a>",
"    ]. In clinical trials, the frequencies of adverse events were similar for persons receiving inhaled zanamivir and placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?26/7/26746/abstract/10,30\">",
"     10,30",
"    </a>",
"    ]. The most common adverse events (reported in fewer than 5 percent of recipients) include diarrhea; nausea; sinusitis; nasal signs and symptoms; bronchitis; cough; headache; dizziness; and ear, nose, and throat infections [",
"    <a class=\"abstract\" href=\"UTD.htm?26/7/26746/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Rare adverse effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Postmarketing reports have identified rare but serious adverse events in patients with influenza who are taking neuraminidase inhibitors [",
"    <a class=\"abstract\" href=\"UTD.htm?26/7/26746/abstract/32-34\">",
"     32-34",
"    </a>",
"    ]. These events include neuropsychiatric effects (delirium, hallucinations, confusion, abnormal behavior, convulsions, and encephalitis), death, and severe skin reactions (including toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/7/26746/abstract/15\">",
"     15",
"    </a>",
"    ]. Most of the reports of neuropsychiatric events involved",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?17/59/18360?source=see_link\">",
"     oseltamivir",
"    </a>",
"    and occurred in children in Japan, where the use of neuraminidase inhibitors is widespread [",
"    <a class=\"abstract\" href=\"UTD.htm?26/7/26746/abstract/35\">",
"     35",
"    </a>",
"    ]. The events often had an abrupt onset and rapid resolution [",
"    <a class=\"abstract\" href=\"UTD.htm?26/7/26746/abstract/34\">",
"     34",
"    </a>",
"    ]. Severe skin reactions also have been reported in adults and non-Japanese children. A causal association between neuraminidase inhibitors and these events has not been established [",
"    <a class=\"abstract\" href=\"UTD.htm?26/7/26746/abstract/36-40\">",
"     36-40",
"    </a>",
"    ]. Some of the adverse events may have been related to influenza infection rather than treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?26/7/26746/abstract/41-45\">",
"     41-45",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/49/24346?source=see_link&amp;anchor=H9#H9\">",
"     \"Clinical features and diagnosis of seasonal influenza in children\", section on 'Complications'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Adverse events related to neuraminidase inhibitors should be reported to the",
"    <a class=\"external\" href=\"file://www.fda.gov/safety/medwatch/default.htm\">",
"     US Food and Drug Administration (FDA) MedWatch",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Adamantane drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?16/62/17383?source=see_link\">",
"     Amantadine",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/39/34420?source=see_link\">",
"     rimantadine",
"    </a>",
"    are adamantanes (also called M2 inhibitors). Adamantanes target the M2 protein of influenza A, which forms a protein channel in the viral membrane that is essential for efficient viral replication. Adamantanes are not active against influenza B viruses or against currently circulating strains of influenza A virus [",
"    <a class=\"abstract\" href=\"UTD.htm?26/7/26746/abstract/30,46\">",
"     30,46",
"    </a>",
"    ]. They are not recommended for the treatment or prophylaxis of influenza during the 2012-2013 season. However, they may have a role (in combination with a neuraminidase inhibitor) if an increase of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?17/59/18360?source=see_link\">",
"     oseltamivir",
"    </a>",
"    resistance occurs [",
"    <a class=\"abstract\" href=\"UTD.htm?26/7/26746/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Adamantanes are approved for prophylaxis against infection from influenza A viruses in children &ge;1 year of age.",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?16/62/17383?source=see_link\">",
"     Amantadine",
"    </a>",
"    is also approved for the treatment of influenza A viral infections in children &ge;1 year of age. Although",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/39/34420?source=see_link\">",
"     rimantadine",
"    </a>",
"    is not licensed by the FDA for the treatment of influenza in children younger than 13 years, published data suggest that it is safe and effective in children &ge;1 year of age [",
"    <a class=\"abstract\" href=\"UTD.htm?26/7/26746/abstract/48,49\">",
"     48,49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The pharmacology of adamantanes is discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/11/19640?source=see_link\">",
"     \"Pharmacology of antiviral drugs for influenza\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Ribavirin",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/59/12216?source=see_link\">",
"     Ribavirin",
"    </a>",
"    is a nucleoside analog that has in vitro activity against both influenza A and B viruses. Reports have suggested clinical benefits when ribavirin was administered by aerosol to treat influenza A or B infections [",
"    <a class=\"abstract\" href=\"UTD.htm?26/7/26746/abstract/50,51\">",
"     50,51",
"    </a>",
"    ]. When administered orally, ribavirin is poorly absorbed and thus has not been shown to be effective against influenza. Ribavirin is not approved by the FDA for the treatment or prevention of influenza.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     ANTIVIRAL RESISTANCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since September 2009, &gt;99 percent of circulating influenza virus isolates have been susceptible to neuraminidase inhibitors [",
"    <a class=\"abstract\" href=\"UTD.htm?26/7/26746/abstract/11-13,30,46,52\">",
"     11-13,30,46,52",
"    </a>",
"    ]. Information regarding antiviral resistance that emerges during the influenza season is available through the",
"    <a class=\"external\" href=\"file://www.cdc.gov/flu/professionals/\">",
"     Centers for Disease Control and Prevention",
"    </a>",
"    (CDC). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/60/39880?source=see_link\">",
"     \"Antiviral drug resistance among seasonal influenza viruses\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Testing influenza isolates for antiviral resistance is not available in clinical settings, and clinical features do not distinguish",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?17/59/18360?source=see_link\">",
"     oseltamivir",
"    </a>",
"    -resistant from oseltamivir-susceptible viruses [",
"    <a class=\"abstract\" href=\"UTD.htm?26/7/26746/abstract/30\">",
"     30",
"    </a>",
"    ]. Clinicians should review local surveillance data to know which types and subtypes of influenza viruses are circulating in their communities. Local surveillance data may be obtained through the",
"    <a class=\"external\" href=\"file://www.cdc.gov/flu/\">",
"     CDC",
"    </a>",
"    . Certain laboratory tests can distinguish between influenza A and B viruses, and between influenza subtypes (",
"    <a class=\"graphic graphic_table graphicRef69655 \" href=\"UTD.htm?31/2/31789\">",
"     table 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/7/26746/abstract/30\">",
"     30",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/49/24346?source=see_link&amp;anchor=H22#H22\">",
"     \"Clinical features and diagnosis of seasonal influenza in children\", section on 'Approach to testing'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     CHEMOPROPHYLAXIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immunization is the major means of prevention of influenza infection, and chemoprophylaxis should not be substituted for vaccination in high-risk individuals (",
"    <a class=\"graphic graphic_table graphicRef72029 \" href=\"UTD.htm?32/50/33579\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/7/26746/abstract/4,5\">",
"     4,5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Chemoprophylaxis can be used to prevent influenza infection in high-risk children who have not been fully immunized. Chemoprophylaxis can be administered simultaneously with the",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?20/21/20824?source=see_link\">",
"     inactivated influenza vaccine",
"    </a>",
"    (given as an intramuscular injection) to provide protection until an immune response develops. Individuals immunized with the live-attenuated influenza vaccine (given intranasally) should not receive chemoprophylaxis for 14 days after receipt of the vaccine because the vaccine strains are susceptible to antiviral drugs [",
"    <a class=\"abstract\" href=\"UTD.htm?26/7/26746/abstract/53\">",
"     53",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    Other preventive measures are integral to the management of all children, and particularly those who are high-risk. These measures include general infection control procedures, avoidance of ill contacts, administration of influenza vaccine unless specifically contraindicated, and immunization of household contacts and out-of-home caregivers. (See",
"    <a class=\"local\" href=\"#H32\">",
"     'Infection control'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/18/27946?source=see_link&amp;anchor=H7#H7\">",
"     \"Seasonal influenza vaccination in children\", section on 'Indications'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Target groups",
"    </span>",
"    &nbsp;&mdash;&nbsp;Decisions regarding the use of influenza chemoprophylaxis should be made on a case-by-case basis. Factors to consider in making this decision include the potential for severe or complicated infection occurring in the child or the child's contacts, the potential for adverse side effects, the possibility of development of antiviral resistance, the likelihood of completion of therapy (failure to complete therapy may contribute to the development of resistance), and the supply of chemoprophylactic drugs (which are the same agents used for influenza treatment) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/7/26746/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H41598329\">",
"    <span class=\"h3\">",
"     Pre-exposure prophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;To limit emergence of anti-viral resistant viruses, the Centers for Disease Control and Prevention (CDC) and American Academy of Pediatrics (AAP) recommend that pre-exposure chemoprophylaxis be reserved for persons who are at high risk for influenza-related complications who cannot otherwise be protected during times when they are at high risk for exposure to influenza [",
"    <a class=\"abstract\" href=\"UTD.htm?26/7/26746/abstract/6,10\">",
"     6,10",
"    </a>",
"    ]. Indiscriminant use of chemoprophylaxis may promote resistance to antiviral medications and reduce availability of antiviral medications for the treatment of individuals who are severely ill or at high risk of influenza complications.",
"   </p>",
"   <p>",
"    When an outbreak of seasonal influenza is present in the community, potential target groups for pre-exposure chemoprophylaxis may include [",
"    <a class=\"abstract\" href=\"UTD.htm?26/7/26746/abstract/6,10\">",
"     6,10",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Children at high risk for severe or complicated influenza (",
"      <a class=\"graphic graphic_table graphicRef72029 \" href=\"UTD.htm?32/50/33579\">",
"       table 1",
"      </a>",
"      ) for whom influenza vaccine is contraindicated",
"     </li>",
"     <li>",
"      Children at high risk for severe or complicated influenza during the two weeks after influenza immunization",
"     </li>",
"     <li>",
"      Family members or healthcare providers who are unimmunized and are likely to have ongoing, close exposure to children younger than 24 months and unimmunized children who are at high risk for severe or complicated influenza",
"     </li>",
"     <li>",
"      Unimmunized staff and children (to control influenza outbreaks in a closed institutional setting with pediatric residents at high risk for severe or complicated influenza)",
"     </li>",
"     <li>",
"      High-risk children who may not respond to influenza vaccine, including those who are immunocompromised (as a supplement to influenza immunization)",
"     </li>",
"     <li>",
"      Children at high risk and their family",
"      <span class=\"nowrap\">",
"       members/close",
"      </span>",
"      contacts and healthcare providers when circulating strains of influenza virus are not matched with seasonal influenza vaccine strains (based on data from the",
"      <a class=\"external\" href=\"file://www.cdc.gov/flu/\">",
"       CDC",
"      </a>",
"      and local health departments) [",
"      <a class=\"abstract\" href=\"UTD.htm?26/7/26746/abstract/10,30\">",
"       10,30",
"      </a>",
"      ] (see",
"      <a class=\"local\" href=\"#H3\">",
"       'Influenza activity'",
"      </a>",
"      above)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H41598336\">",
"    <span class=\"h3\">",
"     Post-exposure prophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The AAP suggests that post-exposure prophylaxis may be indicated for family",
"    <span class=\"nowrap\">",
"     members/contacts",
"    </span>",
"    of infected individuals (regardless of risk status) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/7/26746/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Postexposure prophylaxis is",
"    <strong>",
"     not",
"    </strong>",
"    indicated [",
"    <a class=\"abstract\" href=\"UTD.htm?26/7/26746/abstract/10\">",
"     10",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      For healthy children or adults based on potential exposures",
"     </li>",
"     <li>",
"      If more than 48 hours have elapsed since the last contact",
"     </li>",
"     <li>",
"      When contact did not occur during the ill person's infectious period (one day before until 24 hours after the fever ends)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Early treatment of exposed individuals is an alternative to postexposure prophylaxis [",
"    <a class=\"abstract\" href=\"UTD.htm?26/7/26746/abstract/10\">",
"     10",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H20\">",
"     'Antiviral therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?17/59/18360?source=see_link\">",
"     Oseltamivir",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?15/47/16117?source=see_link\">",
"     zanamivir",
"    </a>",
"    chemoprophylaxis significantly diminishes influenza illness among household and hospital contacts of patients with laboratory-confirmed influenza [",
"    <a class=\"abstract\" href=\"UTD.htm?26/7/26746/abstract/10,54,55\">",
"     10,54,55",
"    </a>",
"    ]. Nonetheless, patients should be informed that chemoprophylaxis lowers, but does not eliminate, the risk of influenza, that susceptibility to influenza returns once the antiviral medication is stopped, and that immunization remains the primary means of protection [",
"    <a class=\"abstract\" href=\"UTD.htm?26/7/26746/abstract/6\">",
"     6",
"    </a>",
"    ]. High-risk individuals should seek medical evaluation if they develop a febrile respiratory illness or moderate to severe illness despite chemoprophylaxis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/27/37305?source=see_link\">",
"     \"Clinical manifestations and diagnosis of pandemic H1N1 influenza ('swine influenza')\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/49/24346?source=see_link&amp;anchor=H7#H7\">",
"     \"Clinical features and diagnosis of seasonal influenza in children\", section on 'Clinical features'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Neuraminidase inhibitors &ndash; A systematic review of seven randomized controlled trials found that prophylactic use of neuraminidase inhibitors reduced the risk of developing seasonal influenza by 70 to 90 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?26/7/26746/abstract/56\">",
"       56",
"      </a>",
"      ]. The highest rates of protection are from studies examining the prevention of febrile laboratory-confirmed influenza infection (efficacy of",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?17/59/18360?source=see_link\">",
"       oseltamivir",
"      </a>",
"      : 82 percent; efficacy of",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?15/47/16117?source=see_link\">",
"       zanamivir",
"      </a>",
"      : 84 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?26/7/26746/abstract/56\">",
"       56",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Adamantanes &ndash;",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?16/62/17383?source=see_link\">",
"       Amantadine",
"      </a>",
"      and",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/39/34420?source=see_link\">",
"       rimantadine",
"      </a>",
"      are not active against influenza B viruses. When used prophylactically, amantadine and rimantadine have been reported to be 70 to 90 percent effective in preventing clinical illness with seasonal influenza A when circulating strains of influenza A are susceptible to adamantanes [",
"      <a class=\"abstract\" href=\"UTD.htm?26/7/26746/abstract/56-59\">",
"       56-59",
"      </a>",
"      ]. This level of effectiveness is similar to that afforded by immunization. The currently circulating influenza A viruses are not susceptible to adamantanes [",
"      <a class=\"abstract\" href=\"UTD.htm?26/7/26746/abstract/11-13\">",
"       11-13",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Choice of drug",
"    </span>",
"    &nbsp;&mdash;&nbsp;The choice of agent for prophylaxis is influenced by the age of the child and the susceptibility patterns of circulating strains (if known) (",
"    <a class=\"graphic graphic_table graphicRef61888 \" href=\"UTD.htm?2/61/3037\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/7/26746/abstract/6,10\">",
"     6,10",
"    </a>",
"    ]. Neuraminidase inhibitors are recommended for the 2012-2013 influenza season based on viral surveillance and resistance data indicating that &gt;99 percent of currently circulating influenza viruses are susceptible to neuraminidase inhibitors [",
"    <a class=\"abstract\" href=\"UTD.htm?26/7/26746/abstract/6,10,46\">",
"     6,10,46",
"    </a>",
"    ]. The",
"    <a class=\"external\" href=\"file://www.cdc.gov/flu/professionals/\">",
"     CDC",
"    </a>",
"    will provide updated recommendations for chemoprophylaxis as indicated throughout the 2012-2013 influenza season.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Prophylaxis dosing",
"    </span>",
"    &nbsp;&mdash;&nbsp;The doses of the neuraminidase inhibitors used for influenza prophylaxis for children &ge;1 year of age are listed in the table (",
"    <a class=\"graphic graphic_table graphicRef61888 \" href=\"UTD.htm?2/61/3037\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/7/26746/abstract/60\">",
"     60",
"    </a>",
"    ].",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?17/59/18360?source=see_link\">",
"     Oseltamivir",
"    </a>",
"    dosing for full-term infants &lt;1 year of age depends upon the weight of the infant [",
"    <a class=\"abstract\" href=\"UTD.htm?26/7/26746/abstract/30\">",
"     30",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Age &lt;3 months &ndash; Not recommended, except in critical situations",
"     </li>",
"     <li>",
"      Age 3 to 12 months &ndash; 3",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per dose once daily",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <strong>",
"     If weight is not known",
"    </strong>",
"    , dosing should be determined by age as follows [",
"    <a class=\"abstract\" href=\"UTD.htm?26/7/26746/abstract/61\">",
"     61",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Age four to five months &ndash; 17 mg once daily",
"     </li>",
"     <li>",
"      Age 6 to 11 months &ndash; 24 mg once daily",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The dosing regimens recommended above are not intended for premature infants, who may have slower clearance of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?17/59/18360?source=see_link\">",
"     oseltamivir",
"    </a>",
"    due to immature renal function; doses recommended for full-term infants may lead to very high drug concentrations in premature infants younger than one year [",
"    <a class=\"abstract\" href=\"UTD.htm?26/7/26746/abstract/30\">",
"     30",
"    </a>",
"    ]. Limited data from cohorts of premature infants who received treatment with oseltamivir are discussed below. (See",
"    <a class=\"local\" href=\"#H27\">",
"     'Treatment dosing'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    When dispensing the oral suspension of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?17/59/18360?source=see_link\">",
"     oseltamivir",
"    </a>",
"    to children &lt;1 year of age, providers and pharmacists must take care to provide a dosing device that matches the units of measure on the prescription [",
"    <a class=\"abstract\" href=\"UTD.htm?26/7/26746/abstract/62,63\">",
"     62,63",
"    </a>",
"    ]. Healthcare providers should write doses in milligrams (mg) if the dosing dispenser with the drug is in mg [",
"    <a class=\"abstract\" href=\"UTD.htm?26/7/26746/abstract/63\">",
"     63",
"    </a>",
"    ]. As an alternative, the oral dosing dispenser that is provided in the package (which has markings for 30 mg, 45 mg, and 60 mg) can be removed, and pharmacists or healthcare personnel should provide an oral syringe that can accurately measure the prescribed milliliter (mL) dose [",
"    <a class=\"abstract\" href=\"UTD.htm?26/7/26746/abstract/62\">",
"     62",
"    </a>",
"    ]. The caregiver should also be counseled regarding proper administration.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Duration",
"    </span>",
"    &nbsp;&mdash;&nbsp;The duration for pre-exposure prophylaxis depends upon the indication. For individuals receiving chemoprophylaxis while awaiting the development of an immune response to the vaccine, the duration is usually two weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?26/7/26746/abstract/64\">",
"     64",
"    </a>",
"    ]. Otherwise, pre-exposure chemoprophylaxis should be administered every day for the duration of potential exposure to a person with influenza.",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?15/47/16117?source=see_link\">",
"     Zanamivir",
"    </a>",
"    regimens as long as 28 days and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?17/59/18360?source=see_link\">",
"     oseltamivir",
"    </a>",
"    regimens as long as 42 days have been well tolerated, but currently no published data for regimens longer than 42 days are available [",
"    <a class=\"abstract\" href=\"UTD.htm?26/7/26746/abstract/65\">",
"     65",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Post-exposure chemoprophylaxis should be administered for seven days after the last known exposure [",
"    <a class=\"abstract\" href=\"UTD.htm?26/7/26746/abstract/10\">",
"     10",
"    </a>",
"    ]. For control of outbreaks in long-term care facilities and hospitals, chemoprophylaxis should be administered for a minimum of two weeks, and up to one week after the last known case was identified.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     ANTIVIRAL THERAPY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Treatment indications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Decisions regarding treatment of influenza in children must consider underlying conditions, disease severity, and duration of symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?26/7/26746/abstract/6,10\">",
"     6,10",
"    </a>",
"    ]. The Centers for Disease Control and Prevention (CDC) and American Academy of Pediatrics (AAP) provide the following indications for antiviral treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?26/7/26746/abstract/6,10\">",
"     6,10",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Any child hospitalized with presumed influenza",
"     </li>",
"     <li>",
"      Children with confirmed or suspected influenza who have severe, complicated, or progressive illness",
"     </li>",
"     <li>",
"      Influenza infection of any severity in children at high risk for complications (",
"      <a class=\"graphic graphic_table graphicRef72029 \" href=\"UTD.htm?32/50/33579\">",
"       table 1",
"      </a>",
"      ), regardless of influenza-immunization status",
"     </li>",
"     <li>",
"      Any otherwise-healthy child with influenza infection for whom a decrease in duration of clinical symptoms is felt to be warranted by his or her provider (if treatment can be initiated within 48 hours of illness onset)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For most previously healthy children, influenza is a mild and self-limiting infection [",
"    <a class=\"abstract\" href=\"UTD.htm?26/7/26746/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. Unnecessary treatment of such children, even when they present early in the course of illness, has the potential effect of resulting in a diminished supply of drugs for patients at risk for severe illness. In addition, indiscriminate treatment may contribute to the development of antiviral resistance. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Antiviral resistance'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22909985\">",
"    <span class=\"h2\">",
"     Timing of treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;When clinically indicated, antiviral therapy should be started as soon as possible after symptom onset, ideally within 48 hours [",
"    <a class=\"abstract\" href=\"UTD.htm?26/7/26746/abstract/10\">",
"     10",
"    </a>",
"    ]. Antiviral therapy may be administered after 48 hours of symptoms in hospitalized children, those with severe or progressive disease, and those at high risk of complications. Treatment should be initiated whether or not the patient received seasonal influenza vaccine. Laboratory confirmation with viral culture or polymerase chain reaction (PCR) tests should not delay the initiation of antiviral therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?26/7/26746/abstract/10\">",
"     10",
"    </a>",
"    ]. Negative rapid diagnostic tests do not exclude influenza. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/49/24346?source=see_link&amp;anchor=H19#H19\">",
"     \"Clinical features and diagnosis of seasonal influenza in children\", section on 'Laboratory diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Efficacy/effectiveness",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Clinical illness",
"    </span>",
"    &nbsp;&mdash;&nbsp;In randomized trials and meta-analyses, antiviral treatment of children and otherwise-healthy individuals within two days of seasonal influenza illness onset shortens the duration of illness by approximately one day and hastens the return to normal activity compared with placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?26/7/26746/abstract/54,66-68\">",
"     54,66-68",
"    </a>",
"    ]. If antiviral therapy is administered within 12 hours of symptom onset, the reduction of duration may be increased by as many as three days [",
"    <a class=\"abstract\" href=\"UTD.htm?26/7/26746/abstract/69,70\">",
"     69,70",
"    </a>",
"    ]. The benefits may be increased in young children. In a randomized trial, initiation of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?17/59/18360?source=see_link\">",
"     oseltamivir",
"    </a>",
"    within 24 hours of the onset of symptoms shortened the median time to resolution of illness by 3.5 days (3 versus 6.5 days) in children one to three years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?26/7/26746/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the largest randomized trial in children, treatment with",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?17/59/18360?source=see_link\">",
"     oseltamivir",
"    </a>",
"    shortened influenza-like illness by approximately one day [",
"    <a class=\"abstract\" href=\"UTD.htm?26/7/26746/abstract/24\">",
"     24",
"    </a>",
"    ]. Among 695 children with influenza symptoms (fever, cough, coryza), approximately two-thirds had laboratory-confirmed influenza. Compared with children with influenza-like illness who were treated with placebo, those treated with oseltamivir had significant reduction in:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The duration of illness (101 versus 137 hours, 95% CI 89-118 hours versus 125 to 150 hours)",
"     </li>",
"     <li>",
"      The incidence of otitis media (12 versus 21 percent)",
"     </li>",
"     <li>",
"      The incidence of clinician-prescribed antibiotics (31 versus 41 percent)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Data regarding the efficacy of antiviral treatment in high-risk children are limited. In a meta-analysis, treatment of high-risk individuals with neuraminidase inhibitors did not have a significant effect on the duration of symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?26/7/26746/abstract/71\">",
"     71",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Limited data from some randomized trials and observational studies suggest that antiviral treatment can reduce the risk of complications, severe illness, or death [",
"    <a class=\"abstract\" href=\"UTD.htm?26/7/26746/abstract/54,72-81\">",
"     54,72-81",
"    </a>",
"    ]. In a retrospective study, treatment with neuraminidase inhibitors within 24 hours of hospital admission was associated with decreased duration of hospitalization among critically ill children with seasonal influenza [",
"    <a class=\"abstract\" href=\"UTD.htm?26/7/26746/abstract/82\">",
"     82",
"    </a>",
"    ]. However, no decrease in duration of intensive care unit days, rates of readmission within seven days, or mortality were observed.",
"   </p>",
"   <p>",
"    The role of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?17/59/18360?source=see_link\">",
"     oseltamivir",
"    </a>",
"    in the prevention of lower respiratory tract infection complications in adolescents and adults is controversial. A meta-analysis of 10 trials, 8 of which were not published (all 10 of which were funded by the maker of oseltamivir) and pooled analysis of 2 published trials came to differing conclusions about prevention of lower respiratory tract complications [",
"    <a class=\"abstract\" href=\"UTD.htm?26/7/26746/abstract/83,84\">",
"     83,84",
"    </a>",
"    ]. An independent meta-analysis of the same ten trials and a subsequent randomized trial concluded that oseltamivir reduces the risk of lower respiratory tract infections in patients with influenza by 28 percent (95% CI 11 to 42 percent), but the diminished risk is limited to lower respiratory tract complications that are treated with antibiotics [",
"    <a class=\"abstract\" href=\"UTD.htm?26/7/26746/abstract/85\">",
"     85",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A subsequent meta-analysis of observational studies evaluated the effectiveness of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?17/59/18360?source=see_link\">",
"     oseltamivir",
"    </a>",
"    versus no treatment in the prevention of influenza hospitalization and mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?26/7/26746/abstract/80\">",
"     80",
"    </a>",
"    ]. Only observational studies that adjusted for potential confounding factors were included. In pooled analysis of four studies, oseltamivir appeared to reduce hospitalization among outpatients (odds ratio [OR] 0.75, 95% CI 0.66-0.89) and in pooled analysis of three studies, oseltamivir appeared to reduce mortality among hospitalized high-risk patients (OR 0.23, 95% CI 0.13-0.43). However, given the inherent limitations of observational studies, the overall quality of this evidence is low to very low.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Viral shedding",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although treatment of children with neuraminidase inhibitors reduces the amount of viral shedding, it does not appear to shorten the duration of shedding. In studies of children hospitalized with seasonal influenza, viral shedding (by antigen detection) continued for approximately four to seven days, regardless of whether children were treated with neuraminidase inhibitors [",
"    <a class=\"abstract\" href=\"UTD.htm?26/7/26746/abstract/73,86,87\">",
"     73,86,87",
"    </a>",
"    ]. In a study of children hospitalized with pandemic 2009 H1N1 influenza virus who were treated with",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?17/59/18360?source=see_link\">",
"     oseltamivir",
"    </a>",
"    , viral shedding persisted for a median of nine days after the onset of symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?26/7/26746/abstract/88\">",
"     88",
"    </a>",
"    ]. In an outpatient study of 384 patients with positive rapid tests for influenza, oseltamivir treatment within 24 hours of symptom onset did not reduce viral shedding or household transmission of influenza [",
"    <a class=\"abstract\" href=\"UTD.htm?26/7/26746/abstract/89\">",
"     89",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Choice of agent",
"    </span>",
"    &nbsp;&mdash;&nbsp;The choice of agent for treatment of influenza is influenced by the age of the child, the susceptibility patterns of circulating strains (if known), and the results of influenza testing (if testing is done) (",
"    <a class=\"graphic graphic_table graphicRef70571 \" href=\"UTD.htm?6/45/6877\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/7/26746/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Neuraminidase inhibitors are recommended for treatment during the 2012-2013 influenza season based on viral surveillance and resistance data indicating that &gt;99 percent of currently circulating influenza viruses are susceptible to neuraminidase inhibitors [",
"    <a class=\"abstract\" href=\"UTD.htm?26/7/26746/abstract/11-13,46\">",
"     11-13,46",
"    </a>",
"    ]. The",
"    <a class=\"external\" href=\"file://www.cdc.gov/flu/professionals/\">",
"     CDC",
"    </a>",
"    will provide updated treatment recommendations as indicated throughout the 2012-2013 influenza season. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Antiviral resistance'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Treatment dosing",
"    </span>",
"    &nbsp;&mdash;&nbsp;The doses of the neuraminidase inhibiting agents used for influenza treatment for children &ge;1 year of age are listed in the table (",
"    <a class=\"graphic graphic_table graphicRef70571 \" href=\"UTD.htm?6/45/6877\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/7/26746/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Weight-based dosing of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?17/59/18360?source=see_link\">",
"     oseltamivir",
"    </a>",
"    is recommended for infants &lt;1 year of age [",
"    <a class=\"abstract\" href=\"UTD.htm?26/7/26746/abstract/15,30\">",
"     15,30",
"    </a>",
"    ]. The CDC recommends oseltamivir 3",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per dose twice daily for full-term infants &lt;1 year of age [",
"    <a class=\"abstract\" href=\"UTD.htm?26/7/26746/abstract/15,30\">",
"     15,30",
"    </a>",
"    ]. In a pharmacokinetic study, infants &le;8 months of age who received a dose of 3",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    twice daily achieved the target exposure (an area under the curve selected to maximize effectiveness and minimize development of resistance) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/7/26746/abstract/90\">",
"     90",
"    </a>",
"    ]. However, a dose of 3.5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    twice daily was necessary to reliably achieve the target exposure in infants 9 through 11 months of age. Although the authors of the study suggest that the appropriate dose of oseltamivir for infants 9 through 11 months of age is 3.5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    twice daily, the CDC has not revised its recommendations for this age group.",
"   </p>",
"   <p>",
"    If the infant&rsquo;s weight is not known, dosing by age may be necessary [",
"    <a class=\"abstract\" href=\"UTD.htm?26/7/26746/abstract/61\">",
"     61",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Age zero to three months &ndash; 12 mg twice daily for five days",
"     </li>",
"     <li>",
"      Age four to five months &ndash; 17 mg twice daily for five days",
"     </li>",
"     <li>",
"      Age 6 to 11 months &ndash; 24 mg twice daily for five days",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The dosing regimens recommended above are not intended for premature infants, who may have slower clearance of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?17/59/18360?source=see_link\">",
"     oseltamivir",
"    </a>",
"    due to immature renal function; doses recommended for full-term infants may lead to very high drug concentrations in premature infants younger than one year [",
"    <a class=\"abstract\" href=\"UTD.htm?26/7/26746/abstract/30\">",
"     30",
"    </a>",
"    ]. Limited data from a cohort of 32 premature infants who were inadvertently exposed to 2009 pandemic H1N1 influenza by a healthcare worker suggest that 1.0",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    twice daily produces drug concentrations similar to those in older children receiving 3",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    twice daily [",
"    <a class=\"abstract\" href=\"UTD.htm?26/7/26746/abstract/91\">",
"     91",
"    </a>",
"    ]. Additional limited data support a dose of 1",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    twice daily for premature infants &lt;38 weeks postmenstrual age [",
"    <a class=\"abstract\" href=\"UTD.htm?26/7/26746/abstract/92\">",
"     92",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    When dispensing the oral suspension of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?17/59/18360?source=see_link\">",
"     oseltamivir",
"    </a>",
"    to children &lt;1 year of age, providers and pharmacists must take care to provide a dosing device that matches the units of measure on the prescription [",
"    <a class=\"abstract\" href=\"UTD.htm?26/7/26746/abstract/62,63\">",
"     62,63",
"    </a>",
"    ]. Healthcare providers should write doses in mg if the dosing dispenser with the drug is in mg [",
"    <a class=\"abstract\" href=\"UTD.htm?26/7/26746/abstract/63\">",
"     63",
"    </a>",
"    ]. As an alternative, the oral dosing dispenser that is provided in the package (which has markings for 30 mg, 45 mg, and 60 mg) can be removed, and pharmacists or healthcare personnel should provide an oral syringe that can accurately measure the prescribed milliliter (mL) dose [",
"    <a class=\"abstract\" href=\"UTD.htm?26/7/26746/abstract/62\">",
"     62",
"    </a>",
"    ]. The caregiver should also be counseled regarding proper administration.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Treatment duration",
"    </span>",
"    &nbsp;&mdash;&nbsp;The usual duration of antiviral therapy for influenza is five days. Patients in whom influenza treatment is initiated should receive a full course of therapy unless an alternative diagnosis is established [",
"    <a class=\"abstract\" href=\"UTD.htm?26/7/26746/abstract/30\">",
"     30",
"    </a>",
"    ]. Hospitalized patients with severe illness may require an extended course of therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7508114\">",
"    <span class=\"h2\">",
"     Treatment failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients receiving neuraminidase inhibitors who do not respond to treatment may have an infection with an antiviral resistant virus.",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?17/59/18360?source=see_link\">",
"     Oseltamivir",
"    </a>",
"    resistance has been reported among children and immunocompromised during treatment with oseltamivir, predominantly among immunocompromised patients with 2009 H1N1 virus infection [",
"    <a class=\"abstract\" href=\"UTD.htm?26/7/26746/abstract/93-96\">",
"     93-96",
"    </a>",
"    ]. Treatment options for patients with suspected oseltamivir-resistant influenza may include inhaled",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?15/47/16117?source=see_link\">",
"     zanamivir",
"    </a>",
"    (no cross resistance has been documented) or investigational parenteral neuraminidase inhibiting agents (eg, peramivir and zanamivir) available through clinical trials or single patient emergency Investigational New Drug protocols [",
"    <a class=\"abstract\" href=\"UTD.htm?26/7/26746/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     OTHER THERAPIES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Supportive care",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other measures for the treatment of influenza include symptomatic therapy for fever, headache, and myalgia with",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/15/19705?source=see_link\">",
"     acetaminophen",
"    </a>",
"    . The use of salicylates should be avoided in children younger than 18 years of age because of the association with Reye syndrome. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/62/22506?source=see_link&amp;anchor=H28202936#H28202936\">",
"     \"Acute toxic-metabolic encephalopathy in children\", section on 'Reye syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Over-the-counter cold medications have no proven benefit and have been associated with fatal overdose in young children. They are not recommended. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/53/13146?source=see_link&amp;anchor=H199065563#H199065563\">",
"     \"The common cold in children: Treatment and prevention\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Antibiotics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antibiotics should be reserved for proven or strongly suspected bacterial complications of acute influenza, such as bacterial pneumonia, otitis media, and sinusitis. The choice of antibiotics may be aided by examination and culture of appropriate specimens. However, if the etiology of the bacterial complication is not clear from the examination of such specimens, empiric antibiotics generally should be directed at the most common bacterial pathogens following influenza: primarily",
"    <em>",
"     Streptococcus pneumoniae",
"    </em>",
"    ,",
"    <em>",
"     Streptococcus pyogenes",
"    </em>",
"    ,",
"    <em>",
"     Staphylococcus aureus",
"    </em>",
"    ,",
"    <em>",
"     Haemophilus influenzae",
"    </em>",
"    type b, and nontypeable",
"    <em>",
"     H. influenzae",
"    </em>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/60/29642?source=see_link&amp;anchor=H17#H17\">",
"     \"Acute otitis media in children: Epidemiology, microbiology, clinical manifestations, and complications\", section on 'Bacteria'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/48/25354?source=see_link&amp;anchor=H12#H12\">",
"     \"Inpatient treatment of pneumonia in children\", section on 'Empiric therapy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/58/42921?source=see_link&amp;anchor=H3#H3\">",
"     \"Acute bacterial rhinosinusitis in children: Microbiology and treatment\", section on 'Empiric antibiotic therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h1\">",
"     INFECTION CONTROL",
"    </span>",
"    &nbsp;&mdash;&nbsp;When children are hospitalized with influenza or an influenza-like illness, standard precautions and droplet precautions are recommended for the duration of illness [",
"    <a class=\"abstract\" href=\"UTD.htm?26/7/26746/abstract/53\">",
"     53",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/34/2599?source=see_link&amp;anchor=H7867242#H7867242\">",
"     \"Infection control measures to prevent seasonal influenza in healthcare settings\", section on 'Isolation precautions'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Unless children require evaluation for influenza-like illness (eg, high-risk group, evidence of lower respiratory tract infection, severe illness, or rapid clinical deterioration), children with an influenza-like illness should stay away from healthcare settings and high-risk individuals until at least seven days after onset of symptoms or 24 hours after resolution of fever, whichever is longer [",
"    <a class=\"abstract\" href=\"UTD.htm?26/7/26746/abstract/97\">",
"     97",
"    </a>",
"    ]. Viral shedding, even with treatment, may exceed 10 days [",
"    <a class=\"abstract\" href=\"UTD.htm?26/7/26746/abstract/88,98\">",
"     88,98",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The Centers for Disease Control and Prevention (CDC) recommends that children with an influenza-like illness stay home from school or day care until 24 hours after their fever (temperature &gt;100&ordm;F (37.8&ordm;C)) has resolved without antipyretics [",
"    <a class=\"abstract\" href=\"UTD.htm?26/7/26746/abstract/97\">",
"     97",
"    </a>",
"    ]. This recommendation applies whether or not the child received antiviral therapy. It also applies to other settings in which the majority of people are not at increased risk of complications from influenza (eg, camp, stores, community gatherings).",
"   </p>",
"   <p>",
"    More stringent guidelines and longer exclusion periods may be made at the community level [",
"    <a class=\"abstract\" href=\"UTD.htm?26/7/26746/abstract/97\">",
"     97",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?32/47/33522?source=see_link\">",
"       \"Patient information: Flu (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?38/12/39105?source=see_link\">",
"       \"Patient information: Influenza prevention (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?34/12/35013?source=see_link\">",
"       \"Patient information: Influenza symptoms and treatment (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h2\">",
"     Resistance",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Influenza viruses circulating during the 2012-2013 season are susceptible to neuraminidase inhibitors (",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?17/59/18360?source=see_link\">",
"       oseltamivir",
"      </a>",
"      and",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?15/47/16117?source=see_link\">",
"       zanamivir",
"      </a>",
"      ), but the current strains exhibit high levels of resistance to adamantanes (",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?16/62/17383?source=see_link\">",
"       amantadine",
"      </a>",
"      and",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/39/34420?source=see_link\">",
"       rimantadine",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Antiviral resistance'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h2\">",
"     Prophylaxis",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Immunization is the major means of prevention of influenza infection. Chemoprophylaxis should not replace vaccination for individuals who are at high risk for severe or complicated influenza infection (",
"      <a class=\"graphic graphic_table graphicRef72029 \" href=\"UTD.htm?32/50/33579\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Chemoprophylaxis'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/18/27946?source=see_link&amp;anchor=H7#H7\">",
"       \"Seasonal influenza vaccination in children\", section on 'Indications'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Decisions regarding the use of chemoprophylaxis for influenza should be made on a case-by-case basis. Factors to be considered in the benefit-to-risk calculation include the potential for severe or complicated infection in the child or the child's contacts, the potential for adverse side effects, the possibility of development of antiviral resistance, the likelihood of completion of therapy, and the supply of chemoprophylactic drugs (which are the same agents used for influenza treatment). (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Target groups'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      When chemoprophylaxis is necessary during the 2012-2013 influenza season, neuraminidase inhibitors (",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?17/59/18360?source=see_link\">",
"       oseltamivir",
"      </a>",
"      or",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?15/47/16117?source=see_link\">",
"       zanamivir",
"      </a>",
"      ) are recommended. The choice of agent depends upon the age of the child (",
"      <a class=\"graphic graphic_table graphicRef61888 \" href=\"UTD.htm?2/61/3037\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Choice of drug'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The duration of pre-exposure chemoprophylaxis varies depending upon the indication. Post-exposure prophylaxis should be continued for seven days after the last known exposure. For control of outbreaks in long-term care facilities and hospitals, chemoprophylaxis should be administered for a minimum of two weeks, and up to one week after the last known case was identified. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Duration'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among individuals without risk factors for severe or complicated influenza (",
"      <a class=\"graphic graphic_table graphicRef72029 \" href=\"UTD.htm?32/50/33579\">",
"       table 1",
"      </a>",
"      ), treatment of influenza with antiviral therapy shortens the duration of illness by approximately one day if initiated within 48 hours of illness onset. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Efficacy/effectiveness'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Antiviral treatment of high-risk patients has not been shown to reduce the duration of illness, but may decrease the risk of complications or need for hospitalization. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Efficacy/effectiveness'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Treatment, when indicated, should be administered as early in the course of illness as possible, ideally within 48 hours of symptom onset. Laboratory confirmation should not delay the initiation of antiviral therapy in individuals in whom treatment is indicated. Negative rapid diagnostic tests do not exclude influenza. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Efficacy/effectiveness'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/49/24346?source=see_link&amp;anchor=H19#H19\">",
"       \"Clinical features and diagnosis of seasonal influenza in children\", section on 'Laboratory diagnosis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In accord with the Centers for Disease Control and Prevention (CDC) and the American Academy of Pediatrics (AAP), we recommend antiviral therapy for (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      )&nbsp;(see",
"      <a class=\"local\" href=\"#H21\">",
"       'Treatment indications'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Children hospitalized with confirmed or suspected influenza",
"     </li>",
"     <li>",
"      Children with an influenza-like illness who are at increased risk of severe or complicated influenza (",
"      <a class=\"graphic graphic_table graphicRef72029 \" href=\"UTD.htm?32/50/33579\">",
"       table 1",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Otherwise-healthy children with influenza infection for whom a decrease in duration of clinical symptoms is felt to be warranted by his or her provider",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Neuraminidase inhibitors (",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?17/59/18360?source=see_link\">",
"       oseltamivir",
"      </a>",
"      or",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?15/47/16117?source=see_link\">",
"       zanamivir",
"      </a>",
"      ) are recommended for the treatment of influenza virus during the 2012-2013 influenza season. The choice of agent depends upon the age of the child (",
"      <a class=\"graphic graphic_table graphicRef70571 \" href=\"UTD.htm?6/45/6877\">",
"       table 3",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H26\">",
"       'Choice of agent'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Dosing for",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?17/59/18360?source=see_link\">",
"       oseltamivir",
"      </a>",
"      treatment varies according to the child's weight (",
"      <a class=\"graphic graphic_table graphicRef70571 \" href=\"UTD.htm?6/45/6877\">",
"       table 3",
"      </a>",
"      ). The dose for",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?15/47/16117?source=see_link\">",
"       zanamivir",
"      </a>",
"      treatment is 10 mg (two inhalations) twice per day. (See",
"      <a class=\"local\" href=\"#H27\">",
"       'Treatment dosing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend NOT using salicylates for symptomatic therapy in children with influenza who are younger than 18 years of age (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H30\">",
"       'Supportive care'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29086714\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;We are saddened by the death of Caroline Breese Hall, MD, who passed away in December 2012. We wish to acknowledge Dr. Hall&rsquo;s many contributions to UpToDate, in particular her work as an author of this topic.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Guidance on the use of zanamivir, oseltamivir and amantadine for the treatment of influenza. Technology Appraisal No. 58. National Institute for Clinical Excellence London, 2003. www.nice.org.uk (Accessed on September 07, 2008).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/7/26746/abstract/2\">",
"      Kumar S, Havens PL, Chusid MJ, et al. Clinical and epidemiologic characteristics of children hospitalized with 2009 pandemic H1N1 influenza A infection. Pediatr Infect Dis J 2010; 29:591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/7/26746/abstract/3\">",
"      Poehling KA, Edwards KM, Weinberg GA, et al. The underrecognized burden of influenza in young children. N Engl J Med 2006; 355:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/7/26746/abstract/4\">",
"      Fiore AE, Uyeki TM, Broder K, et al. Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Recomm Rep 2010; 59:1.",
"     </a>",
"    </li>",
"    <li>",
"     Guidance on the use of oseltamivir and amantadine for the prophylaxis of influenza. Technology Appraisal No. 67. National Institute for Clinical Excellence London, 2003 www.nice.org.uk (Accessed on August 07, 2008).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/7/26746/abstract/6\">",
"      Committee on Infectious Diseases, American Academy of Pediatrics. Recommendations for prevention and control of influenza in children, 2012-2013. Pediatrics 2012; 130:780.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/7/26746/abstract/7\">",
"      Centers for Disease Control and Prevention (CDC). Update: Influenza A (H3N2)v transmission and guidelines - five states, 2011. MMWR Morb Mortal Wkly Rep 2012; 60:1741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/7/26746/abstract/8\">",
"      Centers for Disease Control and Prevention (CDC). Notes from the field: Outbreak of influenza A (H3N2) virus among persons and swine at a county fair--Indiana, July 2012. MMWR Morb Mortal Wkly Rep 2012; 61:561.",
"     </a>",
"    </li>",
"    <li>",
"     Centers for Disease Control and Prevention. CDC reports cases 18-29 of H3N2v virus infection; continues to recommend interim precautions when interacting with pigs. file://www.cdc.gov/flu/spotlights/h3n2v_us_cases.htm (Accessed on August 03, 2012).",
"    </li>",
"    <li>",
"     Centers for Disease Control and Prevention. 2011-2012 Influenza antiviral medications: Summary for clinicians. file://www.cdc.gov/flu/professionals/antivirals/summary-clinicians.htm (Accessed on September 05, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/7/26746/abstract/11\">",
"      Centers for Disease Control and Prevention (CDC). Update: influenza activity --- United States, October 3-December 11, 2010. MMWR Morb Mortal Wkly Rep 2010; 59:1651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/7/26746/abstract/12\">",
"      Centers for Disease Control and Prevention (CDC). Update: influenza activity - United States, 2009-10 season. MMWR Morb Mortal Wkly Rep 2010; 59:901.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/7/26746/abstract/13\">",
"      Centers for Disease Control and Prevention (CDC). Update: influenza activity--United States, October 3, 2010-February 5, 2011. MMWR Morb Mortal Wkly Rep 2011; 60:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/7/26746/abstract/14\">",
"      Couch RB. Prevention and treatment of influenza. N Engl J Med 2000; 343:1778.",
"     </a>",
"    </li>",
"    <li>",
"     Tamiflu (oseltamivir phosphate) prescribing information. www.gene.com/download/pdf/tamiflu_prescribing.pdf (Accessed on January 02, 2013).",
"    </li>",
"    <li>",
"     US Food and Drug Administration. MedWatch Safety Alert. Relenza (zanamivir) inhalation powder www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm186081.htm (Accessed on September 06, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/7/26746/abstract/17\">",
"      Sugaya N, Ohashi Y. Long-acting neuraminidase inhibitor laninamivir octanoate (CS-8958) versus oseltamivir as treatment for children with influenza virus infection. Antimicrob Agents Chemother 2010; 54:2575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/7/26746/abstract/18\">",
"      Katsumi Y, Otabe O, Matsui F, et al. Effect of a single inhalation of laninamivir octanoate in children with influenza. Pediatrics 2012; 129:e1431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/7/26746/abstract/19\">",
"      Watanabe A, Chang SC, Kim MJ, et al. Long-acting neuraminidase inhibitor laninamivir octanoate versus oseltamivir for treatment of influenza: A double-blind, randomized, noninferiority clinical trial. Clin Infect Dis 2010; 51:1167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/7/26746/abstract/20\">",
"      Gubareva LV, Trujillo AA, Okomo-Adhiambo M, et al. Comprehensive assessment of 2009 pandemic influenza A (H1N1) virus drug susceptibility in vitro. Antivir Ther 2010; 15:1151.",
"     </a>",
"    </li>",
"    <li>",
"     Centers for Disease Control and Prevention. Termination of the emergency use authorization (EUA) of medical products and devices. Available at file://www.cdc.gov/h1n1flu/eua/.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/7/26746/abstract/22\">",
"      Sorbello A, Jones SC, Carter W, et al. Emergency use authorization for intravenous peramivir: evaluation of safety in the treatment of hospitalized patients infected with 2009 H1N1 influenza A virus. Clin Infect Dis 2012; 55:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/7/26746/abstract/23\">",
"      Yu Y, Garg S, Yu PA, et al. Peramivir use for treatment of hospitalized patients with influenza A(H1N1)pdm09 under emergency use authorization, October 2009-June 2010. Clin Infect Dis 2012; 55:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/7/26746/abstract/24\">",
"      Whitley RJ, Hayden FG, Reisinger KS, et al. Oral oseltamivir treatment of influenza in children. Pediatr Infect Dis J 2001; 20:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/7/26746/abstract/25\">",
"      Strong M, Burrows J, Stedman E, Redgrave P. Adverse drug effects following oseltamivir mass treatment and prophylaxis in a school outbreak of 2009 pandemic influenza A(H1N1) in June 2009, Sheffield, United Kingdom. Euro Surveill 2010; 15:pii/19565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/7/26746/abstract/26\">",
"      Heinonen S, Silvennoinen H, Lehtinen P, et al. Early oseltamivir treatment of influenza in children 1-3 years of age: a randomized controlled trial. Clin Infect Dis 2010; 51:887.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/7/26746/abstract/27\">",
"      Siedler K, Skopnik H. Oseltamivir for treatment of influenza in infants less than one year: a retrospective analysis. Pediatr Infect Dis J 2010; 29:495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/7/26746/abstract/28\">",
"      Kimberlin DW, Shalabi M, Abzug MJ, et al. Safety of oseltamivir compared with the adamantanes in children less than 12 months of age. Pediatr Infect Dis J 2010; 29:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/7/26746/abstract/29\">",
"      Okamoto S, Kamiya I, Kishida K, et al. Experience with oseltamivir for infants younger than 1 year old in Japan. Pediatr Infect Dis J 2005; 24:575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/7/26746/abstract/30\">",
"      Fiore AE, Fry A, Shay D, et al. Antiviral agents for the treatment and chemoprophylaxis of influenza --- recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2011; 60:1.",
"     </a>",
"    </li>",
"    <li>",
"     Relenza (zanamivir) [package insert]. Research Triangle Park, NC: GlaxoSmithKline; 2008.",
"    </li>",
"    <li>",
"     U.S. Food and Drug Administration. Tamiflu pediatric adverse events: Questions and answers www.fda.gov/cder/drug/infopage/tamiflu/QA20051117.htm (Accessed on September 06, 2011).",
"    </li>",
"    <li>",
"     U.S. Food and Drug Administration. 2008 Safety alerts for drugs, biologics, medical devices, and dietary supplements. Tamiflu (oseltamivir phosphate). file://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm095044.htm (Accessed on September 06, 2011).",
"    </li>",
"    <li>",
"     U.S. Food and Drug Administration. 2008 Safety alerts for drugs, biologics, medical devices, and dietary supplements. Relenza (zanamivir). file://www.fda.gov/Safety/MedWatch/Safetyinformation/SafetyAlertsforHumanMedicalProducts/ucm094982.htm (Accessed on September 06, 2011).",
"    </li>",
"    <li>",
"     Pollack A. Childhood deaths in Japan bring new look at flu drug. New York Times, November 18, 2005.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/7/26746/abstract/36\">",
"      Casscells SW, Granger E, Kress AM, Linton A. The association between oseltamivir use and adverse neuropsychiatric outcomes among TRICARE beneficiaries, ages 1 through 21 years diagnosed with influenza. Int J Adolesc Med Health 2009; 21:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/7/26746/abstract/37\">",
"      Lindemann L, Jacobsen H, Schuhbauer D, et al. In vitro pharmacological selectivity profile of oseltamivir prodrug (Tamiflu) and active metabolite. Eur J Pharmacol 2010; 628:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/7/26746/abstract/38\">",
"      Hoffmann G, Funk C, Fowler S, et al. Nonclinical pharmacokinetics of oseltamivir and oseltamivir carboxylate in the central nervous system. Antimicrob Agents Chemother 2009; 53:4753.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/7/26746/abstract/39\">",
"      Smith JR, Sacks S. Incidence of neuropsychiatric adverse events in influenza patients treated with oseltamivir or no antiviral treatment. Int J Clin Pract 2009; 63:596.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/7/26746/abstract/40\">",
"      Toovey S, Rayner C, Prinssen E, et al. Assessment of neuropsychiatric adverse events in influenza patients treated with oseltamivir: a comprehensive review. Drug Saf 2008; 31:1097.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/7/26746/abstract/41\">",
"      Terada K, Kawai Y, Monju A, et al. Adolescent jump case in Japan associated with influenza but not oseltamivir. Pediatr Infect Dis J 2008; 27:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/7/26746/abstract/42\">",
"      Hara K, Tanabe T, Nakano R, et al. Clinical characteristics of children with abnormal behaviors associated with influenza infection. J Jpn Pediatr Soc 2007; 111:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/7/26746/abstract/43\">",
"      Wang YH, Huang YC, Chang LY, et al. Clinical characteristics of children with influenza A virus infection requiring hospitalization. J Microbiol Immunol Infect 2003; 36:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/7/26746/abstract/44\">",
"      Huang YC, Li WC, Tsao KC, et al. Influenza-associated central nervous system dysfunction in Taiwanese children: clinical characteristics and outcomes with and without administration of oseltamivir. Pediatr Infect Dis J 2009; 28:647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/7/26746/abstract/45\">",
"      Tanabe T, Hara K, Nakajima M, et al. Oseltamivir treatment for children showing abnormal behavior during influenza virus infection. Brain Dev 2010; 32:440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/7/26746/abstract/46\">",
"      Centers for Disease Control and Prevention (CDC). Update: influenza activity - United States, 2011-12 season and composition of the 2012-13 influenza vaccine. MMWR Morb Mortal Wkly Rep 2012; 61:414.",
"     </a>",
"    </li>",
"    <li>",
"     CDC issues interim recommendations for the use of influenza antiviral medications in the setting of oseltamivir resistance among circulating influenza A (H1N1) viruses, 2008-09 influenza season. file://emergency.cdc.gov/HAN/han00279.asp (Accessed on September 06, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/7/26746/abstract/48\">",
"      Hall CB, Dolin R, Gala CL, et al. Children with influenza A infection: treatment with rimantadine. Pediatrics 1987; 80:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/7/26746/abstract/49\">",
"      Harper SA, Bradley JS, Englund JA, et al. Seasonal influenza in adults and children--diagnosis, treatment, chemoprophylaxis, and institutional outbreak management: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2009; 48:1003.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/7/26746/abstract/50\">",
"      Gilbert BE, Wilson SZ, Knight V, et al. Ribavirin small-particle aerosol treatment of infections caused by influenza virus strains A/Victoria/7/83 (H1N1) and B/Texas/1/84. Antimicrob Agents Chemother 1985; 27:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/7/26746/abstract/51\">",
"      Chan-Tack KM, Murray JS, Birnkrant DB. Use of ribavirin to treat influenza. N Engl J Med 2009; 361:1713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/7/26746/abstract/52\">",
"      Centers for Disease Control and Prevention (CDC). Update: influenza activity--United States, September 30-November 24, 2012. MMWR Morb Mortal Wkly Rep 2012; 61:990.",
"     </a>",
"    </li>",
"    <li>",
"     American Academy of Pediatrics. Influenza. In: Red Book: 2012 Report of the Committee on Infectious Diseases, 29th, Pickering LK.  (Ed), American Academy of Pediatrics, Elk Grove Village, IL 2012. p.439.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/7/26746/abstract/54\">",
"      Wang K, Shun-Shin M, Gill P, et al. Neuraminidase inhibitors for preventing and treating influenza in children. Cochrane Database Syst Rev 2012; 1:CD002744.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/7/26746/abstract/55\">",
"      Shinjoh M, Takano Y, Takahashi T, et al. Postexposure prophylaxis for influenza in pediatric wards oseltamivir or zanamivir after rapid antigen detection. Pediatr Infect Dis J 2012; 31:1119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/7/26746/abstract/56\">",
"      Jackson RJ, Cooper KL, Tappenden P, et al. Oseltamivir, zanamivir and amantadine in the prevention of influenza: a systematic review. J Infect 2011; 62:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/7/26746/abstract/57\">",
"      Crawford SA, Clover RD, Abell TD, et al. Rimantadine prophylaxis in children: a follow-up study. Pediatr Infect Dis J 1988; 7:379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/7/26746/abstract/58\">",
"      Glezen WP. Modifying clinical practices to manage influenza in children effectively. Pediatr Infect Dis J 2008; 27:738.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/7/26746/abstract/59\">",
"      Clover RD, Crawford SA, Abell TD, et al. Effectiveness of rimantadine prophylaxis of children within families. Am J Dis Child 1986; 140:706.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/7/26746/abstract/60\">",
"      American Academy of Pediatrics Committee on Infectious Diseases. Antiviral therapy and prophylaxis for influenza in children. Pediatrics 2007; 119:852.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/7/26746/abstract/61\">",
"      American Academy of Pediatrics Committee on Infectious Diseases. Recommendations for prevention and control of influenza in children, 2011-2012. Pediatrics 2011; 128:813.",
"     </a>",
"    </li>",
"    <li>",
"     Tamiflu (oseltamivir) for oral suspension: potential medication errors. www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm183714.htm (Accessed on September 06, 2011).",
"    </li>",
"    <li>",
"     FDA Public Health Alert: Potential medication errors with Tamiflu for oral suspension. www.fda.gov/Drugs/DrugSafety/InformationbyDrugClass/ucm183649.htm (Accessed on September 06, 2011).",
"    </li>",
"    <li>",
"     Centers for Disease Control and Prevention. 2010-2011 influenza antiviral medications: Summary for clinicians. file://www.cdc.gov/flu/professionals/antivirals/summary-clinicians.htm (Accessed on November 24, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/7/26746/abstract/65\">",
"      Khazeni N, Bravata DM, Holty JE, et al. Systematic review: safety and efficacy of extended-duration antiviral chemoprophylaxis against pandemic and seasonal influenza. Ann Intern Med 2009; 151:464.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/7/26746/abstract/66\">",
"      Smieja M. ACP Journal Club. Review: oseltamivir relieves symptoms but does not reduce hospitalizations in influenza. Ann Intern Med 2012; 157:JC3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/7/26746/abstract/67\">",
"      Jefferson T, Jones MA, Doshi P, et al. Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children. Cochrane Database Syst Rev 2012; 1:CD008965.",
"     </a>",
"    </li>",
"    <li>",
"     Alves Galvao MG, Rocha Crispino Santos MA, Alves da Cunha AJ. Amantadine and rimantadine to prevent and treat influenza A in children and the elderly. file://onlinelibrary.wiley.com/doi/10.1002/14651858.CD002745.pub3/abstract.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/7/26746/abstract/69\">",
"      Aoki FY, Macleod MD, Paggiaro P, et al. Early administration of oral oseltamivir increases the benefits of influenza treatment. J Antimicrob Chemother 2003; 51:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/7/26746/abstract/70\">",
"      Kawai N, Ikematsu H, Iwaki N, et al. Factors influencing the effectiveness of oseltamivir and amantadine for the treatment of influenza: a multicenter study from Japan of the 2002-2003 influenza season. Clin Infect Dis 2005; 40:1309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/7/26746/abstract/71\">",
"      Cooper NJ, Sutton AJ, Abrams KR, et al. Effectiveness of neuraminidase inhibitors in treatment and prevention of influenza A and B: systematic review and meta-analyses of randomised controlled trials. BMJ 2003; 326:1235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/7/26746/abstract/72\">",
"      Piedra PA, Schulman KL, Blumentals WA. Effects of oseltamivir on influenza-related complications in children with chronic medical conditions. Pediatrics 2009; 124:170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/7/26746/abstract/73\">",
"      Yu H, Liao Q, Yuan Y, et al. Effectiveness of oseltamivir on disease progression and viral RNA shedding in patients with mild pandemic 2009 influenza A H1N1: opportunistic retrospective study of medical charts in China. BMJ 2010; 341:c4779.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/7/26746/abstract/74\">",
"      Jain S, Kamimoto L, Bramley AM, et al. Hospitalized patients with 2009 H1N1 influenza in the United States, April-June 2009. N Engl J Med 2009; 361:1935.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/7/26746/abstract/75\">",
"      Lee EH, Wu C, Lee EU, et al. Fatalities associated with the 2009 H1N1 influenza A virus in New York city. Clin Infect Dis 2010; 50:1498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/7/26746/abstract/76\">",
"      Farias JA, Fern&aacute;ndez A, Monteverde E, et al. Critically ill infants and children with influenza A (H1N1) in pediatric intensive care units in Argentina. Intensive Care Med 2010; 36:1015.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/7/26746/abstract/77\">",
"      Dom&iacute;nguez-Cherit G, Lapinsky SE, Macias AE, et al. Critically Ill patients with 2009 influenza A(H1N1) in Mexico. JAMA 2009; 302:1880.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/7/26746/abstract/78\">",
"      Creanga AA, Johnson TF, Graitcer SB, et al. Severity of 2009 pandemic influenza A (H1N1) virus infection in pregnant women. Obstet Gynecol 2010; 115:717.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/7/26746/abstract/79\">",
"      Louie JK, Acosta M, Jamieson DJ, et al. Severe 2009 H1N1 influenza in pregnant and postpartum women in California. N Engl J Med 2010; 362:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/7/26746/abstract/80\">",
"      Hsu J, Santesso N, Mustafa R, et al. Antivirals for treatment of influenza: a systematic review and meta-analysis of observational studies. Ann Intern Med 2012; 156:512.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/7/26746/abstract/81\">",
"      Falagas ME, Koletsi PK, Vouloumanou EK, et al. Effectiveness and safety of neuraminidase inhibitors in reducing influenza complications: a meta-analysis of randomized controlled trials. J Antimicrob Chemother 2010; 65:1330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/7/26746/abstract/82\">",
"      Coffin SE, Leckerman K, Keren R, et al. Oseltamivir shortens hospital stays of critically ill children hospitalized with seasonal influenza: a retrospective cohort study. Pediatr Infect Dis J 2011; 30:962.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/7/26746/abstract/83\">",
"      Kaiser L, Wat C, Mills T, et al. Impact of oseltamivir treatment on influenza-related lower respiratory tract complications and hospitalizations. Arch Intern Med 2003; 163:1667.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/7/26746/abstract/84\">",
"      Jefferson T, Jones M, Doshi P, Del Mar C. Neuraminidase inhibitors for preventing and treating influenza in healthy adults: systematic review and meta-analysis. BMJ 2009; 339:b5106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/7/26746/abstract/85\">",
"      Hern&aacute;n MA, Lipsitch M. Oseltamivir and risk of lower respiratory tract complications in patients with flu symptoms: a meta-analysis of eleven randomized clinical trials. Clin Infect Dis 2011; 53:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/7/26746/abstract/86\">",
"      Sato M, Hosoya M, Kato K, Suzuki H. Viral shedding in children with influenza virus infections treated with neuraminidase inhibitors. Pediatr Infect Dis J 2005; 24:931.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/7/26746/abstract/87\">",
"      Sugaya N, Tamura D, Yamazaki M, et al. Comparison of the clinical effectiveness of oseltamivir and zanamivir against influenza virus infection in children. Clin Infect Dis 2008; 47:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/7/26746/abstract/88\">",
"      Li CC, Wang L, Eng HL, et al. Correlation of pandemic (H1N1) 2009 viral load with disease severity and prolonged viral shedding in children. Emerg Infect Dis 2010; 16:1265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/7/26746/abstract/89\">",
"      Ng S, Cowling BJ, Fang VJ, et al. Effects of oseltamivir treatment on duration of clinical illness and viral shedding and household transmission of influenza virus. Clin Infect Dis 2010; 50:707.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/7/26746/abstract/90\">",
"      Kimberlin DW, Acosta EP, Prichard MN, et al. Oseltamivir pharmacokinetics, dosing, and resistance among children aged &lt;2 years with influenza. J Infect Dis 2013; 207:709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/7/26746/abstract/91\">",
"      Acosta EP, Jester P, Gal P, et al. Oseltamivir dosing for influenza infection in premature neonates. J Infect Dis 2010; 202:563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/7/26746/abstract/92\">",
"      McPherson C, Warner B, Hunstad DA, et al. Oseltamivir dosing in premature infants. J Infect Dis 2012; 206:847.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/7/26746/abstract/93\">",
"      Valinotto LE, Diez RA, Barrero PR, et al. Emergence of intratreatment resistance to oseltamivir in pandemic influenza A H1N1 2009 virus. Antivir Ther 2010; 15:923.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/7/26746/abstract/94\">",
"      Suhaila M, Tang JW, Lee HK, et al. Mixtures of oseltamivir-sensitive and -resistant pandemic influenza A/H1N1/2009 viruses in immunocompromised hospitalized children. Pediatr Infect Dis J 2011; 30:625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/7/26746/abstract/95\">",
"      Nguyen HT, Fry AM, Loveless PA, et al. Recovery of a multidrug-resistant strain of pandemic influenza A 2009 (H1N1) virus carrying a dual H275Y/I223R mutation from a child after prolonged treatment with oseltamivir. Clin Infect Dis 2010; 51:983.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/7/26746/abstract/96\">",
"      Whitley RJ, Boucher CA, Lina B, et al. Global Assessment of Resistance to Neuraminidase Inhibitors, 2008-2011: The Influenza Resistance Information Study (IRIS). Clin Infect Dis 2013.",
"     </a>",
"    </li>",
"    <li>",
"     CDC Recommendations for the amount of time persons with influenza-like illness should be away from others www.cdc.gov/h1n1flu/guidance/exclusion.htm (Accessed on September 06, 2011).",
"    </li>",
"    <li>",
"     De Serres G. 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) San Francisco, September 2009.",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5985 Version 21.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1002-222.190.118.195-4B2100FB5C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_7_26746=[""].join("\n");
var outline_f26_7_26746=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H34\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      INFLUENZA ACTIVITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      ANTIVIRAL DRUGS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Neuraminidase inhibitors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Adverse events",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Rare adverse effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Adamantane drugs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Ribavirin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      ANTIVIRAL RESISTANCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      CHEMOPROPHYLAXIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Target groups",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H41598329\">",
"      - Pre-exposure prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H41598336\">",
"      - Post-exposure prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Efficacy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Choice of drug",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Prophylaxis dosing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Duration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      ANTIVIRAL THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Treatment indications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22909985\">",
"      Timing of treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Efficacy/effectiveness",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Clinical illness",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Complications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Viral shedding",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Choice of agent",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Treatment dosing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Treatment duration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7508114\">",
"      Treatment failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      OTHER THERAPIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Supportive care",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Antibiotics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      INFECTION CONTROL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      Resistance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      Prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29086714\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/5985\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5985|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?32/50/33579\" title=\"table 1\">",
"      Groups at high risk for influenza complications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?2/61/3037\" title=\"table 2\">",
"      Neuraminidase inhibitor dosing for flu prophylaxis in children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?6/45/6877\" title=\"table 3\">",
"      Neuraminidase inhibitor dosing for flu treatment in children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?31/2/31789\" title=\"table 4\">",
"      Influenza testing methods",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/58/42921?source=related_link\">",
"      Acute bacterial rhinosinusitis in children: Microbiology and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/60/29642?source=related_link\">",
"      Acute otitis media in children: Epidemiology, microbiology, clinical manifestations, and complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/62/22506?source=related_link\">",
"      Acute toxic-metabolic encephalopathy in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/60/39880?source=related_link\">",
"      Antiviral drug resistance among seasonal influenza viruses",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/49/24346?source=related_link\">",
"      Clinical features and diagnosis of seasonal influenza in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/27/37305?source=related_link\">",
"      Clinical manifestations and diagnosis of pandemic H1N1 influenza ('swine influenza')",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/58/15272?source=related_link\">",
"      Epidemiology of influenza",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/34/2599?source=related_link\">",
"      Infection control measures to prevent seasonal influenza in healthcare settings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/48/25354?source=related_link\">",
"      Inpatient treatment of pneumonia in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?32/47/33522?source=related_link\">",
"      Patient information: Flu (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?38/12/39105?source=related_link\">",
"      Patient information: Influenza prevention (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?34/12/35013?source=related_link\">",
"      Patient information: Influenza symptoms and treatment (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/11/19640?source=related_link\">",
"      Pharmacology of antiviral drugs for influenza",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/13/44249?source=related_link\">",
"      Prevention of seasonal influenza in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/18/27946?source=related_link\">",
"      Seasonal influenza vaccination in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/53/13146?source=related_link\">",
"      The common cold in children: Treatment and prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/46/22250?source=related_link\">",
"      Treatment of seasonal influenza in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_7_26747="Risk of preterm birth with selected infections";
var content_f26_7_26747=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F63047&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F63047&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Risk of preterm birth with selected infections",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"2\" width=\"50%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Infection",
"       </td>",
"       <td class=\"subtitle1\">",
"        Odds ratio",
"        <br/>",
"        (95% confidence interval)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bacterial vaginosis before 16 weeks",
"       </td>",
"       <td class=\"centered\">",
"        7.55 (1.8-31.7)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        N. gonorrhoae",
"       </td>",
"       <td class=\"centered\">",
"        5.31 (1.57-17.9)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Asymptomatic bacteriuria",
"       </td>",
"       <td class=\"centered\">",
"        2.08 (1.45-3.03)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"2\">",
"        Chlamydia trachomatis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        at 24 weeks",
"       </td>",
"       <td class=\"sublist_other_centered\">",
"        2.2 (1.03-4.78)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        at 28 weeks",
"       </td>",
"       <td class=\"sublist_other_centered\">",
"        0.95 (0.36-2.47)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Trichomonas vaginalis",
"       </td>",
"       <td class=\"centered\">",
"        1.3 (1.1-1.4)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        U. urealyticum",
"       </td>",
"       <td class=\"centered\">",
"        1.0 (0.8-1.2)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adadpted from: Klein LL, Gibbs RS. Am J Obstet Gynecol 2004; 190:1493.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_7_26747=[""].join("\n");
var outline_f26_7_26747=null;
var title_f26_7_26748="Indications for the clinical use of esophageal pH recording";
var content_f26_7_26748=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F78947&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F78947&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Indications for the clinical use of esophageal pH recording",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Esophageal pH recording",
"        <strong>",
"         is indicated",
"        </strong>",
"        to document abnormal esophageal acid exposure in an endoscopy-negative patient being considered for surgical antireflux repair (pH study done after withholding antisecretory drug regimen for &ge;1 week).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Esophageal pH recording",
"        <strong>",
"         is indicated",
"        </strong>",
"        to evaluate patients after antireflux surgery who are suspected to have ongoing abnormal reflux (pH study done after withholding antisecretory drug regimen for &ge;1 week).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Esophageal pH recording",
"        <strong>",
"         is indicated",
"        </strong>",
"        to evaluate patients with either normal or equivocal endoscopic findings and reflux symptoms that are refractory to PPI therapy (pH study done after withholding antisecretory drug regimen for &ge;1 week.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Esophageal pH recording",
"        <strong>",
"         is possibly indicated",
"        </strong>",
"        to detect refractory reflux in chest pain patients&nbsp;after cardiac evaluation using a symptom reflux association scheme, preferably the symptom association probability calculation (pH study done withholding PPI therapy for at least&nbsp;1 week but after a trial of&nbsp;PPI therapy for at least 4 weeks).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Esophageal pH recording",
"        <strong>",
"         is possibly indicated",
"        </strong>",
"        to evaluate a patient with suspected otolaryngologic manifestations (laryngitis, pharyngitis, chronic cough) of GERD after symptoms have failed to respond to at least 4 weeks of PPI therapy (pH study done withholding PPI therapy if the intent is to verify the presence of reflux disease or while the patient continues taking their antisecretory drug regimen to document the adequacy of therapy).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Esophageal pH recording",
"        <strong>",
"         is possibly indicated",
"        </strong>",
"        to document concomitant GERD in an adult onset, non-allergic asthmatic suspected of having reflux induced asthma exacerbations&nbsp;(pH study done withholding PPI therapy if the intent is to verify the presence of reflux disease or while the patient continues taking their antisecretory drug regimen to document the adequacy of therapy).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Esophageal pH recording",
"        <strong>",
"         is not indicated",
"        </strong>",
"        to detect or verify reflux esophagitis (this is an endoscopic diagnosis).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Esophageal pH recording",
"        <strong>",
"         is not indicated",
"        </strong>",
"        to evaluate for \"alkaline reflux.\"",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     PPI: proton pump inhibitor; GERD: gastroesophageal reflux disease.",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Kahrilas PJ, Quigley EM. Clinical esophageal pH recording: A technical review for practice guideline development. Gastroenterology 1996; 110:1982.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_7_26748=[""].join("\n");
var outline_f26_7_26748=null;
var title_f26_7_26749="Management pancreatic injury";
var content_f26_7_26749=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F78626&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F78626&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 531px\">",
"   <div class=\"ttl\">",
"    Management pancreatic injury",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 511px; height: 290px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Patients with significant injury to the head of the pancreas involving the proximal ducts may require debridement, or rarely, more extensive surgery such as pancreaticoduodenectomy or pyloric exclusion.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Patton JH Jr, Lyden SP, Croce MA, et al. Pancreatic trauma: A simplified management guideline. J Trauma 1997; 43:234. Copyright &copy; 1997 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_7_26749=[""].join("\n");
var outline_f26_7_26749=null;
var title_f26_7_26750="BG in postprandial hypoglycemia";
var content_f26_7_26750=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F72850&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F72850&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Lack of correlation between symptoms and plasma glucose in postprandial hypoglycemia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 404px; height: 320px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Relation between plasma glucose concentrations and possible hypoglycemic symptoms in a patient with postprandial symptoms who was studied after oral glucose administration (blue curve) and a more physiologic mixed meal (red curve). After oral glucose, symptoms occurred at both the peak and nadir of the plasma glucose responses. Similar symptoms occurred after the mixed meal even though there were no episodes of hypoglycemia. These observations indicate that the postprandial symptoms were not due to hypoglycemia. To convert plasma glucose values to mmol/L multiply by 0.056.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Hogan MJ, Service FJ, Sharbrough FW, Gerich JE. Oral glucose tolerance test compared with a mixed meal in the diagnosis of reactive hypoglycemia. A caveat on stimulation.&nbsp;Mayo Clin Proc 1983; 58:491.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_7_26750=[""].join("\n");
var outline_f26_7_26750=null;
var title_f26_7_26751="Collagen synthesis and tenisle strength";
var content_f26_7_26751=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F69924&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F69924&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 628px\">",
"   <div class=\"ttl\">",
"    Collagen synthesis and tenisle strength",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 608px; height: 405px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Relation of the rate of collagen synthesis to the gain of tensile strength of rat skin wounds.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Madden JW, Peacock EE Jr. Studies on the biology of collagen during wound healing. 1. Rate of collagen synthesis and deposition in cutaneous wounds of the rat. Surgery 1968; 64:288. Illustration used with the permission of Elsevier Inc. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_7_26751=[""].join("\n");
var outline_f26_7_26751=null;
